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Abstract
Paradoxical Roles of Nanoparticles in Cancer Therapeutics and
Carcinogenesis
Emily Despeaux
Nanoparticles (NPs) are becoming increasingly common in consumer goods and are
under investigation for a variety of industrial and biomedical applications. However,
challenges in determining NP toxicity may prevent them from reaching their full potential.
NPs cannot be treated as single class for toxicity evaluations. Even among particles made
from the same material, particle-specific physical properties, including size, shape,
surface charge, agglomeration state, and surface modifications have a strong effect on
the toxicity. Even so, the obstacles to conclusively and reproducibly evaluating toxicity
span all NP classes. NP literature is riddled with confusing and often contradictory reports
regarding the biocompatibility of both engineered NPs, designed with biocompatibility as
a priority, and NPs from occupational or environmental exposures. Incomplete NP
characterization and sample inhomogeneity represent major confounding factors in
disparate results from seemingly comparable study setups. Additionally, NPs can
interfere with many conventional toxicity screening methods. Inappropriate doses,
exposure routes, and toxicity endpoints further diminish the utility of many published
studies.
Given the burgeoning interest in NP-based therapeutic agents, consistent, reliable
standards are needed to ensure the biocompatibility of new formulations. To those ends,
the synthesis, characterization, and in vitro toxicity of a multi-functional NP therapeutic
were investigated (Chapter 2). Specifically, superparamagnetic iron oxide nanoparticles
(SPIONs) were coated with amphiphilic polymer and functionalized with antisense
oligonucleotides targeting survivin, an anti-apoptotic protein that is highly overexpressed
in cancer. SPION physical properties, including particle size and composition, were
characterized at each step of synthesis. Our results showed that the SPION platform is
biocompatible and capable of delivering functional antisense oligonucleotides to regulate
survivin expression; however, significant refinement of the DNA-to-SPION coupling step
is needed. Applied clinically, antisense survivin coupled SPIONs can reduce the required
dose of, adverse effects from, and resistance to, current cancer chemotherapy regimens.
In contrast to engineered NPs for biomedical applications, where real-world exposures
would involve careful control of both exposure time- and dose, occupational NP
exposures are variable, chronic, and difficult to model in laboratory settings. Chapter 3
focuses on identifying the mechanisms behind carbon nanotube (CNT)-induced
malignant transformation of bronchial epithelial cells using a chronic in vitro exposure
model. We specifically investigated the role of mesothelin (MSLN), a cell-surface protein
that is highly overexpressed in many cancers, in the aggressive phenotype noted
following chronic, low-dose CNT exposure. MSLN knockdown resulted in significantly

decreased invasion, migration, colonies on soft agar, and tumor sphere formation. In vivo,
MSLN knockdown cells formed smaller primary tumors and less metastases. The
mechanism by which MSLN contributes to these more aggressive behaviors was
investigated using Ingenuity Pathway Analysis, which predicted that increased MSLN
could induce cyclin E, a cell cycle regulator known to be associated with human cancer.
We found that MSLN knockdown cells had decreased cyclin E, and their proliferation rate
was reverted to nearly that of untransformed cells. Cell cycle analysis results were
consistent with the decreased rate of proliferation. Together, our results indicate a novel
role of MSLN in the malignant transformation of bronchial epithelial cells following CNT
exposure, suggesting its utility as a potential biomarker and drug target for CNT-induced
malignancies.
As demonstrated by the two studies presented here, NPs have the potential to function
as both cancer therapeutics and carcinogens. Careful evaluation of toxicity, ensuring that
appropriate doses, assays, exposure routes, and endpoints are used, is imperative.
Elucidating the physical properties and functionalization that contribute to toxicity, and the
mechanisms of that toxicity, will allow NP benefits to be fully exploited while minimizing
the risk of widespread, detrimental public health effects
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Chapter 1: Introduction
1.0 Cancer Therapeutics
1.0.1 Cancer Development

Cancer develops as a result of the accumulation of multiple damaging mutations to
critical cell regulatory mechanisms.1 These changes typically occur in a step-wise fashion,
with initial damage overriding either cell death pathways or cell replication damage
checkpoints. Normally cells have a number of mechanisms in place to avoid propagating
damaging genetic errors. During replication there are a number of checkpoints to ensure
that only complete sets of intact genetic material are passed on and, if irreparable damage
is present, the replication process is halted. Similarly, cells exposed to toxic substances,
viral infections, or other damaging stimuli will often undergo apoptosis to prevent
spreading the problem. Escaping these normal control mechanisms allows the damaged
cell to replicate, and the propagation of these regulatory failures results allows mutations
to accumulate.
Although each cancer develops its own unique collection of mutations and aberrant
behaviors, there are several characteristic features of malignancies. 1,2 Cancerous cells
tend to proliferate faster than normal cells, even in the absence of normal growth signals.
They are also resistant to normal apoptotic stimuli, including chemotherapy drugs or
radiation, and their drug resistance generally increases throughout the course of
treatment due to selective pressure. Resistance to physiologic apoptotic stimuli allows
the malignant cells to continue to thrive even if they detach from their biological matrix,
1

leading to circulating tumor cells and metastases. 3 Additionally, rapidly growing tumors
can stimulate angiogenesis to ensure a supply of oxygen and nutrients to support their
increased metabolism.
Traditional cancer therapies attempt to exploit the characteristic behaviors of cancer
cells to kill the malignant cells at a greater rate than healthy cells. Many chemotherapeutic
agents interfere with cellular replication and metabolism. Drugs aiming to inhibit tumor
blood supply have also been developed. While these traditional therapies have greatly
improved cancer outcomes, they have a number of dose-limiting side effects because the
pathways they target are also present in normal cells. Improved targeting of cancer
therapies, where the drugs are able to accumulate in or mechanistically act only on tumor
cells, is expected to significantly increase drug efficacy while reducing off-target effects.

1.0.2 Conventional Cancer Therapeutics

Conventional cancer therapeutics interfere with cellular metabolism and replication.
Cancer cells grow and divide faster than healthy cells, meaning drugs targeting cellular
metabolic and reproductive functions should preferentially effect the cancer cells.
However, this preferential effect is minimal because these drugs act on pathways that are
present and functioning in all cells. These indiscriminate mechanisms of destruction and
systemic drug administration make severe side effects an inevitable consequence of
these conventional treatments. Cells whose physiological functions require rapid
turnover, like hair follicles, bone marrow, and the lining of the GI tract, sustain the most
damage from the off-target effects. This damage results in the side effects most
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commonly associated with chemotherapy: hair loss, anemia, weakened immune system, 4
nausea, and vomiting. These ailments develop rapidly after treatment is initiated and are
frequently accompanied by fatigue, 5 impaired cognition,6–8 and loss of appetite.9
Cardiovascular10 and reproductive system dysfunction often follow. Thus, conventional
treatment strategies require clinicians to walk a fine line between killing the cancer and
killing the patient.
In addition to posing a direct threat to patients’ health, 11 the indirect effects on patient
quality of life and mental state can prolong recovery. Weight loss in cancer patients is
associated with decreased survival, but lack of appetite and GI distress can make it
difficult to maintain adequate nutrition. 9 Fatigue, weakness, and other physical
impairments interfere with tasks of daily living. Decreases in physical activity contribute
to further immune impairment, increased pain perception, and longer hospitalizations. 5
Cognitive impairments worsen depression and decrease compliance with treatment. 6,8 In
addition, depression is associated with systemic increases in inflammatory mediators,
which can stimulate tumor growth and metastasis. 7
While these off-target effects are not ideal, in fact they are often detrimental,
conventional chemotherapy treatments still represent a substantial improvement in
survival compared to no treatment. The challenges presented by treating fatal diseases
with equally lethal drugs can only be overcome by improving the specificity of the drugs
for the target tissues.

1.0.3 Targeted Cancer Therapies
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Targeted cancer therapies, which fall under the realm of personalized medicine, have
the potential to dramatically improve the response to chemotherapy as well as patient
quality of life during treatment. However, the development of these targeted therapies is
often quite challenging. Ideally these therapies would “target” tumors by homing on a
feature unique to the cancer cells, which would eliminate off-target and systemic effects.
Since cancers originate from healthy tissues it can be difficult to identify drug targets that
are not present elsewhere in healthy tissues, even if malignant cells use the target
molecule or process for a different purpose or in a different amount than healthy tissues.
Even most current successful targeted therapies, which have increased specificity over
systemic chemotherapy, have off-target effects. Future targeted therapies will rely on the
identification of tumor-specific markers and improvements in localized drug delivery.
1.0.3a Pharmaceutical versus Physical Targeting

Drug targeting can be considered in terms of both specificity of drug activity and
specificity of in vivo drug localization.

From a mechanistic perspective, a drug is

“targeted” when it acts specifically on a process of interest (Figure 1A). However, even
a drug whose action is limited may have widespread biological distribution. Increasing
the accumulation of a drug in a specific physical location is, therefore, also a critical
component of drug targeting – particularly for drugs that require high local concentrations
for effect or those with a high likelihood of off-target toxicity (Figure 1B).
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1.0.3b Strategies for Targeting Tumors
Targeted drugs, for conditions other than cancer, are already widely available but not
commonly associated with the personalized medicine movement. Antibiotics, for
example, are formulated to interact with bacteria-specific enzymes, which minimizes their
effects on human cells. The strategies used for targeting bacteria, fungi, and viruses
break down when it comes to fighting cancer because we are now faced with identifying
“bad self” versus “good self” instead of self versus other.
There are many challenges associated with identifying unique markers of cancer cells
when they are located within a body full of normal tissue. Additionally, identifying these
markers in vitro does not always translate well to in vivo, where there are often unintended
consequences. For example, isotype specific COX blockers were designed to specifically
treat pain while minimizing the dose-limiting GI side effects of non-specific COX blockers,
but the unintended cardiovascular effects resulted in the drugs removal from the market. 12
Despite the challenges, some targeted therapies and treatment strategies have been
developed and integrated into clinical practice. Current approaches include the use of
hormone and hormone-receptor antagonists for estrogen or testosterone sensitive
reproductive cancers,13–17 inhibitors targeting mutated growth factor receptors in nonsmall cell lung cancer (NSCLC),18–20 and inhibitors of a cancer-specific tyrosine kinase
fusion protein in chronic myelogenous leukemia (CML). 21–23
Leuprolide and goserelin are gonadotropin hormone releasing hormone (GnRH)
agonists. GnRH stimulates the release of luteinizing hormone (LH) from the
pituitary gland, which in turn simulates increases in testosterone, DHT, or
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estrogen.13–15 Chemical castration, or the complete suppression of estrogen and
progesterone production by the ovaries or testosterone production by the testes,
can be achieved with both GnRH agonists and antagonists. 13 GnRH agonists have
been used to treat metastatic endometrial cancer, while antagonists have been
used to fight ovarian cancer.13 Both agonists and antagonists are used to treat
prostate cancer.14,15
Tamoxifen is an estrogen receptor (ER) antagonist used to treat ER positive
breast cancer in both men and women.16,17 Estrogen acts a growth factor in breast
tissue, and blocking its effects can reduce tumor growth and reoccurrence. In
patients with ER positive tumors, the addition of tamoxifen as an adjuvant therapy
reduced the risk of disease reoccurrence by 47% and the overall risk of death by
26%.17
Imatinib (Gleevec) inhibits the constitutively active BRC-Abl fusion protein. BCRAbl, encoded by the Philadelphia chromosome t(9;22) reciprocal translocation, is
found in over 90 percent of patients with chronic myeloid leukemia (CML) and its
activity results in dysregulated cell growth.21–23 In CML patients who express BCRAbl, imatinib treatment resulted in 95% survival at 18 months, with 89% of patients
showing no disease progression.21 A follow up study reported an 89% 5-year
survival rate.22
Gefitinib and Erlotinib are small molecule inhibitors that target the mutated
epidermal growth factor (EGFR) tyrosine kinase in non-small cell lung cancer
(NSCLC).18–20 In populations with a high predisposition for EGFR mutations,

6

erlotinib20 and gefitinib18,19 treatment are more effective than standard combination
chemotherapy approaches. When patients are stratified by EGFR status, patients
with the target mutation have significantly improved progression-free survival.
Patients without the EGFR mutation, as expected, do not experience these
benefits.

1.0.4 Antisense Oligonucleotides as Cancer Therapeutics
Antisense oligonucleotides (ASO) are powerful tools for regulating cellular protein
expression. They allow the production of specific, target proteins to be temporarily turned
off. Basic ASO are short fragments of single stranded DNA or RNA, typically 20-30 bases
in length, which are complementary to a portion of target protein’s mRNA sequence. 24,25
Structural modification of the bases structure can enhance both the efficiency and
stability. When ASO are present in the cytoplasm, they bind to the target mRNA and
create a small area of double-stranded nucleic acid that stimulates enzymatic degradation
of the mRNA strands as well as physically blocks the translocation of ribosomal
machinery.26–29

1.0.4a Regulation of Protein Expression with Antisense Oligonucleotides

ASO inhibit protein production by binding to their complementary sequence on the
mRNA for the target protein (Figure 2). Once bound, ASO work alter protein production
by (1) stimulating enzymatic degradation of the double-stranded complex26–28 and (2)
physically blocking the translocation of the ribosomal machinery along the mRNA. 29
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Double-stranded (ds) RNA complexes in the cytoplasm are rapidly detected and
enzymatically degraded by RNase H.26–29 While the primary function of RNase H is to
degrade dsRNA, it also recognizes and reacts with the RNA in DNA:RNA hybrids, like
those formed by ASO and mRNA. RNase H interacts non-specifically in the minor groove
of the RNA, where three carboxylates from the enzyme associate with the 2’-O-hydroxyl
of RNA backbone during the cleavage process.30 RNA is then cleaved from the duplex
via hydrolysis, leaving a 5’-phosphate and a 3’-OH at the cleavage site.27 Because the
reaction relies on the enzyme’s interaction with the RNA 2’-O-hydroxyl group, RNase H
will not react with DNA, which does not have the 2’-OH moiety. Theoretically this
specificity would protect the DNA of the DNA:RNA complex from degradation, meaning
that once the bound mRNA was cleaved the DNA could interact with another target
mRNA. However, the ASO will eventually be metabolized by endo or exonucleases within
the target cell.26

1.0.4b Delivery of Antisense Agents in vitro

As nucleic acids are hydrophilic and highly negatively charged, antisense
oligonucleotides are generally not able to penetrate cell membranes on their own. 31
However, they are structurally and functionally similar to siRNA and can be introduced to
cells in the same way (i.e. transfection or electroporation). Transfection packages the
DNA/RNA in a lipid wrapper, while electroporation utilizes an electric shock to help the
oligonucleotide penetrate the cell membrane.
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1.0.4c Delivery of Antisense Agents in vivo

Challenges often arise when translating in vitro techniques to clinical settings and ASO
are no exception. In fact, the in vivo delivery of antisense agents has, to-date, been
largely unsuccessful. However, the potential advantages of antisense agents are great
enough that their in vivo delivery is still an area of active research.

Many of the obstacles to clinical implementation are due to limitations of naked
oligonucleotides and could be overcome with improved “packaging” for in vivo delivery.31–
34

For example, naked oligonucleotides are rapidly degraded by plasma nucleases upon

intravenous injection.33,34 Those that escape degradation are rapidly cleared by the same
immune surveillance mechanisms that detect other foreign DNA (like viruses). 31,34,35
Nucleic acids are generally easily broken down, and unmodified nucleic acids have been
shown to have stability issues in salt solutions and aqueous media. 36 Improved stability
is possible with structural modifications to the nucleic acid backbone, including
phosphorothioate modifications,31,32 locked nucleic acids,31,36 and 2’-O-methyl or 2’fluoro modifications.30,31

Even if ASO remain intact once they enter the bloodstream, reaching the target tissue
requires avoidance of interactions with plasma proteins, clearance by the kidneys, and
extravasation at non-target locations.31 Assuming the ASO extravasates into the target
tissue, naked ASO are not likely to enter cells unassisted. Some plasma protein
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interactions may enhance uptake by stimulating receptor-mediated endocytosis, but
typically delivery systems are required for in vivo purposes.31

1.0.4d Clinically Relevant ASO.
Although ASO have been investigated as treatments for a number of cancer and noncancer diseases, very few ASO are currently available. Currently only 2 ASO therapies
have received full FDA approval. However, according to clinicaltrials.gov, there are 43
open or active trials of antisense therapy in addition to the 80 completed trials.

Mongersen is an oral ASO for the treatment of Crohn’s Disease that is currently
in phase III clinical trials. The 21 base, single-stranded (ss) ASO has a
phosphorothioate-modified backbone to increase in vivo half-life.32,37 Mongersen
targets SMAD7, which is increased in Crohn’s disease resulting in suppression of
normal anti-inflammatory and immune-suppressive mediators. A pH sensitive
capsule is used to ensure the oral formulation is not released until it reaches the
terminal ileum and right colon (the primary sites affected by Crohn’s disease).

Fomivirsen (Vitravene) was the first ASO to receive FDA approval. 38 It is an
injectable, intravitreous ASO for the treatment of cytomegalovirus (CMV) retinitis
in patients with AIDS/HIV.38,39 The ASO targets the major immediate-early
transcriptional unit of CMV, thus interfering with viral replication. 39 Fomiversen is
no longer on the market, as improvements in antiretroviral therapy have reduced
the incidence of opportunistic infections like CMV retinitis in HIV/AIDS, but it served
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as in important proof-of-concept drug for the clinical applications of ASO
technology.38

Mipomersen (Kynamro) received FDA approval in 2013 for use in the treatment
of homozygous familial hypercholesterolemia.40 The ASO inhibits the production
of apopolipoprotein (apo) B-100 in the liver. In healthy patients, mipomersen
results in dose-dependent LDL decreases, with a maximum reported LDL
decrease of 44% of baseline. Structural modifications to the ASO give it a half-life
of 30 days in circulation. Mipomersen does not interfere with other cholesterol
lowering drugs like simvastatin and ezetimibe.

1.0.5 Future Drug Targets

Successfully targeted cancer therapies require the identification of molecules or
cellular processes that are unique to malignancies. Since cancer develops from healthy
tissues, the identification of these unique targets is challenging. Targeted therapies
currently on the market, like imatinib (Gleevec), 21–23 gefitinib,18,19 and erlotinib,20 exploit
structural, and the resulting functional, changes in proteins crucial to cellular regulatory
mechanisms. Another class of targets includes proteins that are highly expressed in
cancer cells but are not present in most or all healthy cells. The regulation of two such
proteins, survivin41–49 and mesothelin,50–54 has been the focus of many in vitro and in vivo
studies in recent years. This work has presented strong evidence that both survivin and
mesothelin, independently, contribute to chemotherapy and radiation resistance, more
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metastases, and overall decreased survival rates.43–48,51,52 As such, clinical trials have
also been pursued for survivin 55–65 and mesothelin regulating agents, 50,51,66 although todate no such agents have proven efficacious in humans. Challenges of delivering gene
regulatory agents in vivo have been exhaustively documented in relation to treating
cancer as well as genetic diseases like muscular dystrophy and cystic fibrosis. As delivery
methods improve, the identification and eventual regulation of over-expressed cancerrelated proteins will continue to be an important avenue for the development of targeted
therapies.

1.0.6 Survivin

Survivin is a cell-cycle dependent inhibitor of apoptosis protein that is heavily
overexpressed in nearly all types of cancer but largely undetectable in most healthy
tissue.41,42 Survivin is overexpressed, to varying degrees, in cancers of the lung,
pancreas, colon, prostate, breast, esophagus, liver, stomach, uterus, bladder, and skin,
as well as in soft tissue sarcoma, osteosarcoma, melanoma and neuroblastoma. 44–48,57,67–
75

Increased tumor survivin has been linked to an increased risk of chemotherapy

resistance, more aggressive tumors, and overall worse outcomes. 41–49,56,76 The
prevalence of survivin across cancer types, combined with its association with more
aggressive and harder to treat malignancies, makes it an attractive therapeutic target, at
least conceptually.49 To date, several clinical trials have been carried out with survivin
targeted therapies.55–60,77–82 Although no survivin-targeted therapies are currently
available, therapeutic regulation of survivin is still being actively pursued.
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Survivin Structure and Function

Survivin is a 16.5 kDa inhibitor of apoptosis (IAP) protein. 83–86 Structurally, survivin is
the smallest member of the IAP family of proteins and contains only one copy of the IAPcharacteristic baculovirus IAP repeat (BIR) domain. In situ, survivin is often found as a
homodimer. IAPs, including survivin, can inhibit apoptosis through a number of
mechanisms, including direct inhibition of caspase activation 87 and inhibition of
mitochondrial cytochrome c release. 88 Survivin also plays a role in stabilizing the
chromosomes and mitotic machinery during cell division. 83–85,89

Under physiologic conditions, survivin plays a critical role in normal fetal and placental
development, where it acts as a cell-cycle dependent inhibitor of apoptosis. 41,42,90
Survivin expression is increased beginning in the G1 phase of the cell cycle, reaching a
max in the G2-M phase. Survivin interacts with polymerized tubulin, including
centrosomes, microtubules, and mitotic spindles, as well as chromosomal kinetochores
in metaphase, to stabilize the cell during division, thus inhibiting apoptosis. 41,42 After cell
division, survivin is degraded through the ubiquitin-proteasome pathway.41 After birth
survivin expression is restricted to the thymus, CD34+ stem cells, and basal colonic
epithelial cells.41 Most other healthy adult tissues, including peripheral blood leukocytes,
lymph nodes, spleen, pancreas, kidney, lung, liver, brain, and heart, have no detectable
survivin.43
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In many human cancers, the cells have again acquired the ability to express
survivin.41,42 Higher levels of survivin are correlated with worse prognosis, increased risk
of recurrence and metastasis, and, for some types of cancer, a decreased response to
chemotherapy.41–44,56,76 Increased survivin is often related to an increased risk of
chemotherapy resistance, more aggressive tumors, and overall worse outcomes. A
correlation between survivin and tumor aggression/ overall patient outcomes has been
reported in colorectal cancer,48 bladder cancer,67 glioblastomas,68 melanoma,69 non-small
cell lung cancer,57 breast cancers,70,71 diffuse large B-cell lymphoma,44 acute myeloid
leukemia,44 pancreatic ductal cell cancer,72 hepatocellular carcinoma, gastric cancer, 73
malignant gliomas,74 soft tissue sarcoma,75 prostate cancer,45 osteosarcoma,46 and renal
cell carcinoma.47

Role of survivin in cancer

Over-expression of survivin has consistently been associated with apoptosis
resistance, reduced sensitivity to chemotherapy, and other markers of tumor
aggressiveness both in vitro and in vivo.41–49,56,76,83,85 The anti-apoptotic role of survivin
allows it to contribute strongly to the development and maintenance of malignant
phenotypes.83,85 By blocking normal cell death pathways, cellular lifespans are
lengthened, which allows mutations to accumulate. The inability of the cells to die
contributes to cellular resistance to cytotoxic stimuli, like chemotherapy and radiation, and
to metastasis, as the cells are able to survive in inappropriate locations. Conversely,
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survivin inhibition induces increases in spontaneous apoptosis, caspase activation, and
sensitivity to cytotoxic stimuli including chemotherapy and radiation. 42,44,45,72,76,91

Survivin’s anti-apoptotic effects are derived, in part, from its role in driving cells
through the G2/M cell cycle checkpoint. 42 Under physiologic conditions, survivin is
expressed in cell cycle-dependent manner, with increased expression during the G2/M
phase.86 In many malignancies, survivin is constitutively expressed but retains the cell
cycle-dependent spike associated with the G2/M transition. 44,83 In this context, survivin
plays an important role in mitotic spindle assembly 83–85,89 and proper chromosome
segregation during mitosis.89 Specifically, survivin associates with microtubules,
polymerized tubulin, centrosomes, and the mitotic spindles as well as Aurora B kinase, a
mitotic regulator.83,84,89,92 Survivin inhibition in cancer cells results in multi-nucleation,
failed cytokinesis, and multipolar mitotic spindles. 83–85,91 Survivin drives cell cycle
progression through interactions with CDK4 accelerate S phase, leading to increased
cdk2/cyclin E activation and Rb phosphorylation. 84,86 Cell-cycle dependent survivin
expression is transcriptionally regulated. 85

While the stabilization of cell replication machinery is an important contributing factor
to survivin-induced apoptosis resistance, the presence of survivin in all tumor cells, not
just the mitotic fraction, was suggestive of additional anti-apoptotic mechanisms.44,83,85 In
vitro, survivin expression inhibits apoptosis induced by chemotherapeutic drugs, like
cisplatin and etoposide, TNF-α, Fas ligand, and caspase 3, 7, and 9. 44,45,93 One
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contributing mechanism is that survivin can directly inhibit the activation of caspase-3 and
7.83–87

A number of factors contribute to cell-cycle-independent survivin expression in cancer
cells. The constitutive expression arises, in part, from alterations in the survivin promotor
region.83 Mutation in the p53 tumor suppressor gene also contribute, as wild-type, but not
mutated, p53 functions as a transcriptional repressor of survivin. 83,86,94 The interaction
between survivin and p53 is complex, as survivin can also regulate p53 expression. 86
Survivin expression can also be induced by dysregulated activation of growth factor
receptors, including EGFR, Her2, and insulin-like growth factor-1 (IGF-1), various
signaling cascades, and inflammatory cytokines. Aberrantly activated Stat3 and PI3/AKT
signaling pathways are known to increase survivin expression, as do IL-11, angopoietin1, and hypoxia inducible factor-1 (HIF-1). Survivin expression can also be induced by
environmental factors. Nicotine can activate survivin expression through an AKT pathway
in A549 and non-malignant human bronchial epithelial cells. The nicotine-induced
increase in survivin expression was noted within 12 hours and persisted for 3 months
post-exposure.95

Prevalence of Survivin in Cancers

Histological examination of human tumors has revealed survivin expression in the vast
majority of samples, across cancer types and degree of disease progression. For many
cancers, tumor survivin expression increases as the disease progresses and higher
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survivin levels are associated with more metastases, chemotherapy and radiation
resistance, and overall reduced survival. A summary of survivin prevalence in human
cancers is provided in Table 1. Survivin expression in sixty cancer cell lines was
previously assessed by Tamm, et al.. 96

Survivin as a Therapeutic Target

The relative localization of survivin to tumor tissue, combined with the dramatic success
of targeting survivin in vitro, makes survivin regulation seem like an ideal cancer
treatment. Decreasing survivin, at least in vitro, results in timely and significant cancer
cell death without affecting non-survivin expressing cells. However, replicating this
success in a clinically-translatable formulation – or even in in vivo studies – has been
challenging.

Regulation of survivin in vitro

In vitro regulation of survivin expression has primarily relied on ASO and siRNA. 83
Several effective ASO sequences have been identified, including one from Olie, et al. that
has been highly referenced.42 Decreases in survivin expression are noted within 24-48
hours of ASO treatment.42,76 Using these methods, survivin expression can be reduced
to 30-70% of controls; this variation can be attributed to differences in the basal survivin
expression of different cell lines and differences in the potency of the tested ASO. In vitro
regulation of survivin with ASO consistently induces apoptosis and increases radiation
and/or chemotherapy sensitivity in a variety of survivin-expressing cancer cells without
17

affecting non-survivin expressing controls.42,44,72,76 The consistent, strong anti-cancer
effects seen with in vitro survivin inhibition make it an attractive target for in vivo therapies.

Regulation of survivin in vivo: clinical trials

Antisense oligonucleotide LY2181308

LY2181308, the second generation of ISIS 23722, is a 2’-O-methyoxymethyl modified
18-mer antisense oligonucleotide that decreases survivin expression by binding to the
initiation codon of survivin mRNA, resulting in cleavage by RNase H and degradation of
the survivin mRNA.55,60,91,97 The resulting decrease in survivin mRNA translates to a
decrease in survivin protein expression, which restores sensitivity to normal apoptotic
pathways.55,91,97

LY2181308: Pre-Clinical Testing

LY2181308 was identified as the most potent inhibitor of survivin following a screening
of 117 2’-MOE phosphorothioate modified oligonucleotides.91 In vitro testing ensured that
survivin was specifically inhibited, without any effect on other IAPs, in all tested cell lines.
It was noted that the decrease in survivin also caused an increase in the activation of
caspase-3, a pro-apoptotic mediator.91 LY2181308 also inhibited survivin expression and
sensitized tumors to gemcitabine, paclitaxel, and docetaxel in human melanoma and
glioblastoma xenograft models.91 In an in vitro human leukemia model, LY2181308
reduced survivin expression in a dose-dependent manner, with a maximum decrease of
18

40% within 24 hours and 60% within 48 hours. 98 The decreases in survivin expression
correlated with decreases in cell proliferation and a G2/M cell cycle block. In an in vivo
model of non-Hodgkin’s lymphoma, the decrease in survivin expression corresponded
with a significant decrease in proliferation, an increase in apoptosis (measured by
caspase-3 activation), and smaller tumors.99

LY2181308: Clinical Trials

A first-in-human phase I clinical trial of the antisense oligonucleotide LY2181308
was carried out to assess the biodistribution, tumor tissue penetration, impact on tumor
mRNA and survivin protein levels, and dose/toxicity in humans. 55 The study included 40
participants across a variety of cancer types (GI, breast, melanoma, lung, sarcoma, ovary,
and head and neck carcinoma). 39 out of 40 participants had received chemotherapy
prior to the study. During the study, the only drug administered was LY2181308. For this
trial, LY2181308 was diluted in 500mL of normal saline and administered IV. It was given
daily for three days as a loading dose, and then weekly as a maintenance dose. Tumor
biopsies were obtained prior to treatment and 48-96 hours after the third loading dose.
While no conclusive results on the in vivo efficacy of LY2181308 were obtained from the
study,
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immunohistochemistry, and a 20% decrease in survivin mRNA was reported.
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primary adverse effects were flu-like symptoms, including fever, nausea, and
musculoskeletal pain, anticoagulation, lymphopenia, thrombocytopenia, hypokalemia,
and anemia.55
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In an additional Phase I trial, the dose tolerability, pharmacokinetics, and anticancer activity of LY2181308 were studied in 14 Japanese patients with solid tumors that
had not responded to standard therapies. 36 Japanese patients were studied chosen
because the Japanese population, at large, possesses a number of genetic variations
that affect the metabolism and safety of anti-cancer drugs, as well as alterations in the
TNF gene that affect their response to inflammation. The drug was administered
intravenously, in the same manner as in the previous Phase I trial. Adverse effects were
in line with those previously reported, including flu-like symptoms during the loading dose
phase, prolonged PT-INR and thrombocytopenia, and fatigue. No disease regression was
noted in the course of this trial; however, the authors also state that disease regression
was not the intention of this trial and that, in the future, this drug would be most likely to
succeed when combined with other apoptosis-inducing agents.

Several Phase II trials, investigating the efficacy of LY2181308 combination
therapies against non-small cell lung cancer, prostate cancer, and acute myelogenous
leukemia, have had similar disappointing results. 58–60 The three trials described below
relied on dosing methodology and schedule from the first-in-human trials of LY2181308.55
None of the combination trials reported disease regression following treatment. Adverse
effects were noted, but for at least two of the three studies the adverse effects were
ultimately linked to the chemotherapy agents that were administered with the LY2181308
rather than the LY2181308 itself.58,60 One major limitation of all three combination studies
was the failure to enroll patients on the basis of their tumor survivin levels. The small
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number of patients enrolled in each study, combined with the known variations in tumor
survivin expression, would make it unlikely that a significant sub-population of drugresponsive patients would emerge. An additional contribution to the lackluster response
is that the dosing regimen used in all three studies was only shown to reduce solid-tumor
survivin by approximately 20%,55 which may not be a strong enough response to restore
apoptosis sensitivity.60

YM155: small molecule transcriptional inhibitor of survivin

YM155

(1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-

1H-naphtho[2,3-d] imidazolium bromide) is an imidazolium-based small molecule inhibitor
of survivin (Figure 3).57,61,65,100,101 It acts on the promotor region of the survivin gene,
through and unknown mechanism, to specifically decrease survivin protein expression
without affecting other IAPs.100 Pre-clinical trials of the agent resulted in strong proapoptotic and tumor suppressive effects both in vitro and in mouse xenograft models.100–
102

Phase I and II clinical trials of YM155 as a monotherapy, however, showed little anti-

tumor activity despite evidence that it accumulated in tumors and decreased intra-tumoral
survivin expression.57,61–65 Future trials of YM155 in combination with other chemotherapy
drugs are expected to demonstrate stronger anti-cancer activity than YM155 alone.

YM155: Pre-Clinical Testing
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During pre-clinical testing, YM155 activity was assessed in a panel of 119 tumor cell
lines, including 5 known treatment-resistant lines, and a variety of xenograft tumor
models.101 YM155 treatment, and the subsequent decrease in survivin expression,
inhibited cell growth in the majority of the cancer cell lines tested the initial screening
panel. Further in vitro studies in hormone-refractory prostate cancer and NSCLC showed
that YM155 treatment alone increased spontaneous apoptosis. 100,102 In vivo, the antitumor effect of YM155 monotherapy was noted in NSCLC, melanoma, bladder, estrogenreceptor-negative

breast,

and

hormone-refractory

prostate

cancer

xenograft

models.100,101 Decreased intra-tumoral survivin and inhibition of tumor growth were found
in all models. One study of NSCLC xenograft tumors found that YM155 inhibited tumor
growth more than cisplatin or paclitaxel without affecting mouse weight, and that the antitumor effects were still present three weeks post-treatment.101 The synergistic effects of
YM155 and radiation were explored with two NSCLC lines, where it was found that
treatment with YM155 and radiation together resulted in greater apoptosis in vitro and
greater tumor suppression in vivo than either treatment alone.102

YM155: Clinical Trials

A phase I, first-in-human dose study of YM155 assessed the safety and efficacy of
the drug in patients with solid tumors and non-Hodgkin’s lymphoma.61 YM155 was well
tolerated and demonstrated a small, but significant, clinical effect. Three of the five nonHodgin’s lymphoma patients responded to the therapy, as did two of nine patients with
hormone refractory prostate cancer. However, the tumor regression that was seen was
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noted to have occurred at a slower rate than expected with other anti-cancer agents. As
a consequence of the slow response rate, the authors urged caution in future trials.

Between a second phase I study62 and four phase II trials, the major conclusion was
that YM155 was well-tolerated, with the clinical effect appearing questionable at best. In
the phase I study, YM155 was administered to 33 patients with various solid tumors and
stable disease was achieved in 9 patients. 62 One phase II study, conducted in patients
with advanced, refractory, NSCLC reported “moderate efficacy” of the agent, although
they go on to note that they were comparing it to current second-line therapies that also
have abysmal response rates.57 Another trial, conducted in patients with refractory diffuse
large B-cell lymphoma, was terminated early due to futility.64 In a third trial, only 2 out of
32 patients with castration-resistant prostate cancer had a clinically measurable
response, and 26 of the initial 32 participants withdrew due to treatment failure. 63 A trial
of YM155 in patients with advanced melanoma also failed. 65

The failure of YM155 to suppress tumors in clinical trials was attributed primarily
to the tests assessing its efficacy as a monotherapy, with the suggestion that it would
likely be more effective as part of a combination treatment. 61–65 Its mechanism involves
sensitizing cells to cytotoxic stimuli or apoptosis from mitotic failures. Thus, without any
additional stimuli, the treatment would only effect cells that were actively dividing. 63
Additionally, there are anti-cancer drugs currently used that are not effective as
monotherapies.
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Survivin Peptide Vaccine

Survivin overexpression in human tumors elicits a T-cell immune response.
Circulating anti-survivin antibodies and survivin-reactive T-cells have been documented
in patients with leukemia, lung, colon, breast, and pancreatic cancers, but not in healthy
control subjects.80,85,91,103 Processed survivin peptide fragments are displayed on human
leukocyte antigen (HLA) class I molecules on the cell surface, where they interact with
cytolytic T-cells. The presence of survivin reactive T-cells has generated interest in the
development of survivin peptide vaccines. 83,85,86,91 To those ends, survivin intracellular
processing was studied and the immune-reactive peptide fragments were enumerated 104
and the identified fragments were used to generate survivin peptide vaccines. 56,77–82
While the survivin peptide fragment that generates the strongest T-cell response will vary
by HLA type and other patient-specific factors, cancer type is not a limiting factor.
Survivin-reactive cytotoxic T-cells isolated from leukemia patients reacted with other
survivin-expressing tumors cells, including breast cancer, renal-cell carcinoma, colon
cancer, melanoma, multiple myeloma, and primary malignant cells from other leukemia
patients.80,105

Survivin peptide vaccines have been tested in a number of late-stage cancers,
including metastatic melanoma, lung cancer, and pancreatic cancer, to demonstrate their
safety and ability to induce a survivin-specific T-cell response.56,77,79,81,82 In a case study
of a HLA-A2 restricted survivin peptide, a single patient with advanced metastatic
pancreatic cancer experienced complete tumor regression after 14 months of weekly
vaccination. He remained disease free for an additional 8 months, at which point new
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metastases were discovered and the patient rapidly declined. 56 In patients with stage IV
metastatic melanoma, HLA-type specific vaccines were developed for HLA-A1, -A2, and
–B3 positive tumors.77 It was found that patients who developed the survivin-specific Tcell response had longer survival times than patients that did develop survivin-specific
reactivity (median survival 19.6 vs 8.6 months). In addition, patients who developed a
post-vaccination inflammatory response, including fevers, had stronger T-cell reactivity
and improved survival than patient who did not develop an inflammatory response.

Although survivin-targeted vaccines appear safe and are able to induce a T-cell
response, the clinical utility of these therapies is still unknown. Trials in heavily pre-treated
patients with metastatic disease could mask the potential of vaccination-based therapies
since many cancer treatments suppress the immune mechanisms required for effective
vaccination. Also, most of the trials so far have utilized single-epitope vaccines, which
were chosen based on patient HLA type. 78 However, even patients with the same HLA
type have dramatic variations in their responses to single survivin epitopes. It has been
suggested that vaccines should contain multiple survivin epitopes to allow for
personalized responses.

1.0.7 Mesothelin

Mesothelin is a cell-surface protein of unknown physiological significance 106 that is
overexpressed

in

approximately

30%

of

all

cancers, 50

including

nearly

all

mesotheliomas50 and many lung,51,52 pancreatic,51,53 and ovarian51,107 carcinomas.
Significant levels of mesothelin are not present in healthy tissues, 53,54 although low levels
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are expressed in normal mesothelial cells & epithelial cells of the fallopian tubes, kidneys,
trachea, and tonsils.107 While the specific function(s) of mesothelin are currently unknown,
its presence in malignancies has been linked to more aggressive tumor behaviors and
chemotherapy resistance.51,52

Structure and Function.

The mesothelin gene encodes a 71 kDa precursor protein that is cleaved in the
cytoplasm to give two functional products: the 40 kDa mature mesothelin cell-surface
protein (MSLN) and a 31 kDa soluble fragment that is released into the blood (SMRP). 51
The mechanisms behind MSLN’s contribution to cancer development and progression
are not yet known; however, MSLN appears to affect a number of critical cell processes
including cell adherence,51 proliferation,51–53 invasion and migration,52,108,109 and
apoptosis resistance.51 The SMRP is clinically detectable in the plasma of patients with
MSLN over-expressing malignancies, and serial measurements of SMRP is under
investigation as a clinical tool for tracking response to treatments and monitoring for
disease reoccurrences in lung adenocarcinoma, mesothelioma, 110 pancreatic cancer,51,53
and ovarian cancer.66

Mesothelin over-expressing cancer cell lines proliferate faster than their mesothelindeficient counterparts, both in vitro and in vivo in mouse xenograft models. In lung cancer
cell lines, mesothelin positive cells proliferated 2-3 times faster than mesothelin negative
cells.51–53 IL-6, an inflammatory chemokine, is thought to be a mediator between
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mesothelin and some of the associated aggressive behaviors. IL-6 promotes cell growth,
chemo-resistance, anchorage-independent cell growth, and invasiveness111,112 and is
over-expressed in MSLN-expressing pancreatic cancer cells.51,112 Cyclin E, a cell cycle
regulator that promotes the G1/S phase transition, is frequently dysregulated in cancer
cells,113 and mesothelin may contribute to increased proliferation rates by inducing cyclin
E overexpression through an IL-6/Stat3 pathway.114

Tumor mesothelin expression has also been linked to increased invasion and
migration in vitro, which translates to increased metastatic ability in vivo. In vitro, induced
overexpression of mesothelin increased invasion and migration in lung and pancreatic
cancer cell lines,51–53 and mesothelin-induced increases in matrix metalloproteinase
(MMP) expression have been linked to increased invasiveness in ovarian cancer cells. 109

Increases in invasion, migration, and metastases may be the result of mesothelinrelated changes in cellular adhesion. 115,116 Interactions of mesothelin with the ovarian
cancer antigen CA-125 have been described, and these interactions are thought to
potentiate the spread of ovarian cancer to the peritoneal lining.51,117 In a mouse model of
kidney tumors, mesothelin expression increased cell adherence to collagen coated
plates, while mesothelin inhibition decreased adherence to collagen. 115,118

In both physiologic conditions and tumor samples, mesothelin expression has been
primarily localized to the apical membrane of the cells.108,117,119–123 In invading tumor
specimens, this can correlate to the leading edge of the tumor. Although the physiologic
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function of mesothelin is not known, the apical localization, taken together with what is
known about mesothelin over-expression, suggests that mesothelin could have a role in
the barrier functionality of mesothelial linings.

Prevalence in Cancer. MSLN is overexpressed in approximately 30% of human cancers;
however, the prevalence varies depending on the cancer type. 50 An excellent summary
of MSLN expression in human cancers is presented in Mesothelin targeted cancer
immunotherapy.124

Lung Adenocarcinoma. MSLN is commonly expressed in lung adenocarcinomas,
including stage 1 patients.52 In an analysis of 1252 patient samples, 69% of patients
had detectable levels of MSLN in tumor, with no MSLN staining in normal lung tissue
or tumor stroma.52 The same study found that MSLN was an independent predictor of
relapse and overall survival, and higher MSLN expression was associated with both
male sex and a positive smoking history.

When patient tumors were analyzed, it was found that lung cancer samples
seemed to have more intracellular MSLN than ovarian cancers, mesotheliomas, and
normal mesothelial cells. The lung cancers were also noted to have more mesothelin
precursor protein than other cancer types.54 Strong cytoplasmic and membranous
staining was also noted by Kachala, et al.52
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Mesothelioma. Mesothelin is highly expressed by nearly all mesotheliomas. 50,51
However, the SMRP is only detectable in 40-70% of patients,50,66 making it of
questionable prognostic value. It has been noted that SMRP levels are higher in
advanced-stage patients than early-stage patients.125,126

Ovarian Cancer. Mesothelin is overexpressed in approximately 70% of ovarian
cancers and contributes to decreased progression-free and overall survival.51,66,107,127
Higher levels of tumor mesothelin expression have also been correlated with
chemotherapy resistance.107 CA-125 is often co-expressed with mesothelin, and coexpression results in worse outcomes than either antigen alone.110

Other Cancers. Mesothelin overexpression has also been documented in uterine
serous carcinoma,51 acute myeloid leukemia,51 cholangiocarcinoma,51 squamous
carcinomas of the esophagus and cervix, 128 pancreatic adenocarcinoma,50,51 and
triple negative breast cancers.50

Mesothelin as Therapeutic Target.

SMRP as Cancer Biomarker.

SMRP is released into systemic circulation when the mesothelin precursor protein is
cleaved to generate mature mesothelin. Since it is easily detectable in patient plasma,
using commercially available ELISA kits, its potential as a clinical cancer biomarker has
been investigated.50,129 Serial SMRP levels could, theoretically, be used as a non-

29

invasive

tracking

tool

to

monitor

for

response

to

treatment

and

disease

relapse.50,51,53,66,110 SMRP has been detected in patients with mesothelioma, 50,110,129
pancreatic cancer,51,53 and ovarian cancer,66 but it is currently of debatable clinical
utility.50,129,130

Therapeutic Targeting: Mesothelin Antibodies and Vaccines

Mesothelin-targeted immunotherapies have been developed using both immunotoxins
and mesothelin vaccines.124,127 Ongoing clinical trials, targeting mesothelin through
immunotherapies, have not resulted in adverse effects and the therapies have not
damaged normal tissues.50

SS1P: Mesothelin Immunotoxin

The anti-mesothelin immunotoxin SS1P utilizes a recombinant anti-mesothelin
antibody linked to a truncated Pseudomonas exotoxin to target cell-surface mesothelin.124
SS1P binds to mesothelin on the cell surface, is internalized via clathrin-coated pits, and
the exotoxin is freed during endosomal processing. The toxin migrates to the endoplasmic
reticulum and inhibits elongation factor-2, leading to inhibition of protein synthesis and
cell death. Initial studies demonstrated the in vitro cytotoxicity of SS1P against tumor cells
from patients with mesothelioma and ovarian cancer. 131–133 In mice, SS1P induced the
complete regression of human epidermoid carcinoma tumor xenografts. 131,134 Additional
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mouse studies demonstrated that SS1P can act synergistically with radiation and
chemotherapy, including paclitaxel, cisplatin, and cyclophosphamide.124,131,135,136

In a phase I dose escalation study, minor tumor responses were noted in 4 patients
while stable disease was achieved in 19 (56%) patients. 124,131 The major adverse effect
was minor, self-limiting pleuritis from SS1P binding to the mesothelin present on normal
mesothelial cells. The limited success of SS1P in clinical trials was attributed to patients
developing antibodies to the immunotoxin. A follow-up study treated patients with
chemotherapy refractory mesothelioma with pentostatin and cyclophosphamide, in
addition to SS1P, to delay the development of anti-SS1P antibodies.137 Of the ten
patients in the study, 3 experienced major tumor regressions and 2 responded to
chemotherapy after treatment with the immunotoxin. This improvement is considered
significant in light of poor prognosis associated with the patients’ disease state. Stronger
anti-tumor activity is possible if SS1P is given intraperitoneally, particularly when treating
ovarian cancer or peritoneal mesothelioma, or given in combination with chemotherapy
or radiation.131

Mesothelin Vaccines

Anti-mesothelin immune responses have been detected in cancer patients, leading to
the hypothesis that an immune response to mesothelin could be induced via
vaccination.124,138 Antibodies against mesothelin are present in many patients with
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mesothelioma and ovarian cancer, while anti-mesothelin T-cell responses have been
noted in patients with pancreatic cancer.66,124

CRS-207, a mesothelin cancer vaccine using live attenuated Listeria monocytogenes
as the vector, is in phase I testing in patients with carcinoma and liver metastases. 124
Vaccination of both mice and monkeys with CRS-207 elicits a human-specific T-cell
response, and anti-tumor activity has been demonstrated in mice.

MORAb-009 is a monoclonal antibody targeting mesothelin that induced a moderate
response against mesothelin-expressing tumors in a phase I clinical trial. 139 Of the 24
patients enrolled, 11 achieved stable disease. In vitro, MORAb-009 was cytotoxic as a
single agent to mesothelin-expressing cancer cells and synergistic cytotoxicity was seen
when it was used in combination with gemcitabine and paclitaxel. 139,140 MORAb-009 also
reduced the adhesion between mesothelin-expressing cells and CA-125.140
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1.1 Evaluating Nanotoxicity
1.1.1 Introduction to Nanoparticles

Nanoparticles (NPs) are 1 to 100 nanometers (nm) in at least one dimension. 141–145
The small size of the NPs confers unique properties when compared to the same material
in bulk, including changes in color, solubility, electrical conductivity, and magnetic
properties.144–146 In addition, NPs have a large surface area to volume ratio, which
increases their surface reactivity.141,144,146 The unique physical and chemical properties
of NPs have resulted in their rapid incorporation into a variety of consumer goods.
Additional industrial, technological, and biomedical applications are the focus of ongoing
research.

NPs used in commercial products include silver NPs in clothing,142 titanium dioxide
(TiO2) in cosmetics, sunscreens, and food packaging, 144 and carbon nanotubes (CNTs)
in

sports

equipment

and

micro-electronics.147

Superparamagnetic

iron

oxide

nanoparticles (SPIONs) received FDA approval for use as MRI contrast agents 148–151 and
for the treatment of anemia in patients with chronic kidney disease. 150,152 The
development of NP-based biosensors, imaging modalities, and targeted and
multifunctional therapeutics is an area of active research. 145,153,154

Despite the widespread incorporation of NPs into consumer goods, their toxicity is
not well understood.141–144,155,156 It has been demonstrated that bare NPs are often more
toxic than equivalent doses of bulk material, perhaps as a result of the increased surface

33

area to volume ratio.141,144,146 For example, nano-sized TiO2 induces more pulmonary
inflammation than larger particles at the same dose. 144 However, coated or functionalized
NPs,

when

appropriately

designed

for

biological

purposes,

are

considered

biocompatible.143,145,154,157–161

These contradictory safety reports have impeded the incorporation of NPs into
additional goods and technologies. The ability to draw conclusions from much of the
existing research into NP biocompatibility is limited because of a lack of standardization
in NP characterization, doses, exposure routes, and toxicity metrics. 141–144 NPs can also
interfere with many of the standard toxicity assays. 142,144,155,156,162,163 Understanding the
relationship of particle NP composition and physical properties to toxicity, biodistribution,
clearance, metabolism, and mechanisms of toxicity will pave the way for clear
occupational safety standards and the introduction of biocompatible engineered NPs for
clinical use. However, overcoming the obstacles associated with achieving this
understanding will require a shift from traditional approaches to toxicity testing.

1.1.2 Nanoparticle Toxicity

Determination of NP toxicity introduces new challenges compared to evaluating the
toxicity of small molecules or larger particles. Although NPs are not a singular class for
toxicity purposes141 - in fact there are dramatic variations in the toxicity of NPs within the
same class when physical properties are altered – the challenges of assessing
nanotoxicity are consistent across all NP types and applications. 141,143 The lack of
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standardization in NP characterization and toxicity assessment has impeded the ability to
compare and parse the often contradictory conclusions reported in the literature. 141–
144,164,165

Additionally, NP toxicity studies are rarely reflective of real world exposure

conditions.141,155,165 Relevant particle size distribution and impurities, doses, exposure
routes, and incubation times are often difficult to discern 141–143,166 and NPs can interfere
with many standard toxicity assays.142,144,155,156,162,163 Although the need for validated
models of NP characterization and toxicity assessment has become apparent, 141,144,162,167
such models do not yet exist.

1.1.3 Role of NP Physical Properties

NP toxicity, and the mechanism of that toxicity, is influenced by particle physical
properties, including particle size, shape, aspect ratio, hardness, composition, surface
area, surface chemistry, coatings and modification, and stability in solution. 141,146,155,162,164
When NPs are engineered for biomedical applications, the final system properties are
chosen to direct in vivo distribution and accumulation while minimizing clearance and
toxicity.153,168 On the other hand, NPs involved in occupational or environmental are
engineered to maximize industrial performance and ease of synthesis, without regard for
biocompatibility. As a result of the relationship between NP physical properties and
toxicity, NPs used in toxicity assessments need to be fully characterized. 141,146 The
relationship of physical parameters to biocompatibility of biomedical NP platforms is
discussed in Section 1.1.3 (Role of NP Physical Properties), while the relationship of CNT
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physical properties to toxicity is discussed in 1.3.3 (Role of CNT Physical Properties in
Toxicity).

1.1.4 In Vitro Toxicity Assessment

Much of the work evaluating the biocompatibility of NPs has been carried out in vitro.
In vitro assessments are used as a first-line screening approach because they can be
carried out faster, and with less expense, than in vivo studies.155 In vitro toxicity is often
quantified by measuring changes in cell proliferation, viability, membrane integrity, and
cell functions that would be impacted by the NPs mechanism of action, like ROS
generation and DNA damage.141,143,155 In vitro studies also allow for quantification of NP
uptake, determination of the mechanism of uptake, and intracellular localization.142,162,169
However, NPs have been noted to interfere with a number of traditional toxicity assays,
including the several widely utilized measures of cell viability and membrane integrity
(Table 2).142,156,162 As a result, it is recommended that multiple assays are used to validate
in vitro results.162

Unfortunately in vitro test conditions are not always reflective of in vivo results or real
world exposures.142,165 For example, unrealistically large NP doses are often used in
single-dose

treatments

to

simulate

long-term

occupational

exposures

and

accumulation.146,155,166 Thus, many of the in vitro screenings are cursory looks at changes
in cell viability, proliferation, or apoptosis after acute, high-dose exposures141,143,155,170,171
When NPs are intended for use as therapeutics these measures might be reflective of
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actual exposures (controlled dose of a well-described material), but for occupational
exposures chronic, low-dose exposures are more likely.171 To overcome some of these
limitations, chronic in vitro exposure models have been developed that account for longer
term, lower dose occupational exposures like those associated with CNTs. 172,173

1.1.5 In Vivo Toxicity Assessment

In vivo exposure models are used to determine NP biodistribution, clearance
mechanisms, and systemic and target organ toxicity. 155 In vivo models overcome the
limitations that arise in vitro from the use of single-cell types, limited exposure times, and
artificially high NP accumulation when NPs settle on cultured cells.142 NP distribution can
be assessed from organ analysis or radiolabeled or fluorescently-tagged NPs can be
used for real-time in vivo tracking.155 However, radio- or fluorescent labels can change
the surface properties of the NPs and affect their distribution and clearance. Systemic
toxicity can be monitored through changes in blood composition, changes in serum
proteins that would signify target organ damage, or changes in inflammatory mediators.

1.1.6 Dosing NPs for Toxicity Evaluations

Determining appropriate NP dosing is problematic in both in vitro and in vivo studies.
Complex, multi-functional NP systems challenge traditional dosing paradigms, as all
components, and their relative amounts, orientations, and effects on the NP systems
physical properties, must be taken into account. Thus, fully elucidating the composition
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of complex NP systems is critical to obtaining meaningful, reproducible, dose-dependent
toxicity data. CNT inhalation exposure is a major concern in industrial settings. 146,174–176
CNTs used in industrial applications are typically mixtures containing a variety of particle
shapes, sizes, agglomeration states, and metal impurities. 141,142,155,163,177 This variety is
difficult to mimic during laboratory testing, but a thorough evaluation of the particles that
are being tested will allow for more informed extrapolation to real world conditions. NP for
use in biological systems as contrast agents, drug delivery vehicles, or biosensors, are
often coated and functionalized to improve biocompatibility, circulation time, and
therapeutic efficacy.143,145,153,154,177,178

The addition of these coatings and functional

ligands creates a complex, multilayer system composed of combinations of surfactants,
amphiphilic polymers, linker molecules, fluorescent dyes, and biomolecules surrounding
the NP core. In this conditions, the relative amounts of the components become
important. Ideally the components will combine in constant ratios, allowing consistency in
dosing across batches regardless of the dosing measure, but such consistency is rare
even in commercially available products.

1.1.7 Dosing Considerations: NP Quantification & Dosing Metrics

Many NPs for biological applications, including SPIONs, contain several organic
layers built around a metal oxide core. While quantification of the various components
within a given sample is possible, there is no way to ensure that each particle is uniformly
coated or functionalized. Although the variation likely averages out over a large enough
dose or sample size, the inherent heterogeneity and complex makeup necessitates
careful consideration of the appropriateness of the chosen dosing measure. Commonly
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used dose measures include concentration of the metal in the core, 179–181 particle
mass,182,183 or molarity.157,159 When therapeutic ligands, such as ASO,184 aptamers,185
antibodies,160 or targeting molecules like folate186–190 are present, their concentration
should also be considered. In many situations, the most appropriate dosing measure will
be a combination of two or more measures, ensuring that all relevant components are
accounted for.

Although mass and molarity are the most obvious dosing methods, particularly from
the viewpoint of conventional toxicity assessments, their use with complex, multifunctional NP systems has a number of disadvantages. The major disadvantage to massbased dosing is that particle coating and functionalization has a significant impact on
mass. As a result, equivalent masses of bare, coated, or differently functionalized NPs
would contain drastically different numbers of particles. In one study dosed by mass, the
bare NPs were 75% core and 25% surfactant by mass, while the coated particles were
15% core and 85% surfactant/coating. 182 Consequently, cells treated with the bare NPs
were exposed to 5 times more particles than cells treated with coated particles. Thus the
use of mass as a dosing metric makes it difficult to determine if any observed differences
are the result of the change in composition or the vastly different number of particles
between the two samples.

Dosing by molarity assumes that the composition of the NP system is consistent,
which it rarely is, and then the mass of a mole must be calculated or defined; however,
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when molarity is used in NP toxicity assessments, it is almost never explained how a mole
of the NP-platform was defined.

When NP doses are calculated by the concentration of the metal in the particles core,
the number of NPs is kept consistent regardless of the coatings. This overcomes one of
the major limitations of dosing by mass. However, inconsistent amounts of coatings or
ligands are not accounted for. In addition, determining the metal concentration of a
sample is destructive and may require an impractically large sample size when NPs are
functionalized in small batches.

If NPs are functionalized with an easily quantifiable therapeutic ligand, like an ASO,
the ligand concentration can be used to keep the expected effect constant. Dosing based
on ligand concentration allows for comparisons to previous studies of the ligand alone,
for example the efficacy and timing of a naked ASO can be compared to a NP-ASO
conjugate. In cases where the ligand does not couple consistently to the NP platform,
dosing in this manner can help normalize data to the actual amount of ligand.

In an ideal scenario, several of these measures would be combined to allow for
consistent, reproducible, and easily explained NP dosing. Consistent relationships
between NP components would allow one measure to be used, while the relative amounts
of the remaining components could be calculated for comparison across studies. For NPs
with inconsistent ratios of components, measuring and reporting the relative amounts of
all components will allow for more meaningful comparisons between studies and will
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contribute to improved understanding of the roles of various components in toxicity and
therapeutic effects. Fully described NP systems will help overcome initial limitations in
interpreting nanotoxicity literature, where incomplete characterization reports 144 and
inconsistent dosing made it nearly impossible to compare experimental results. 141,155,173

1.1.8 Dosing Considerations: Modeling Real World Exposures

For occupational exposures, dosing and exposure routes should be chosen to closely
approximate real world human exposures.141,165 In determining test dosages,
occupational exposure limits, documented human exposures, and the time course of the
exposure should be considered. In addition, conversions from in vitro to in vivo exposures
should account for exposed surface area rather than relying on solution concentrations. 166
When modeling chronic NP exposure in vitro, long-term exposure to low-doses172,173,175
may be more representative than a single large dose.166

1.1.9 Strategies for Evaluating NP Toxicity

It is already impossible to avoid exposure to NPs and their incorporation into everyday
products is rapidly increasing. Developing methods for thorough, reliable evaluation of
NP acute and long-term toxicity is critical to harnessing their full potential for industrial
and biomedical applications. However, evaluating the toxicity of NPs requires critical
evaluation of suitability of standard approaches.
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Quality control during NP synthesis and functionalization is of the utmost importance,
as intra- and inter-batch variation can have a dramatic impact on observed toxicity. In
addition, NPs are often synthesized under non-sterile conditions, resulting in frequent
contamination with bacteria or endotoxin that can cause false positives or increases in
observed toxicity and inflammatory responses. 144,191

Once the NPs are properly

formulated, their stability in storage solutions must be monitored. 145,146 During biological
testing, changes in NP aggregation or solubility can arise from changes in pH or
interactions with biomolecules in culture media. 191 The adsorption of proteins from culture
media can also affect particle uptake or toxicity, meaning that culture conditions need to
closely approximate actual exposure conditions. 145,153,169 The interplay between the
physical properties of the NPs and their storage or treatment conditions necessitates
monitoring for quality control through the NPs entire laboratory lifespan. The optimal
conditions for each NP formulation may vary, meaning a one size fits all approach to
evaluating toxicity will have little relevance.

The generation of meaningful, relevant nanotoxicity data will require approaches that
integrate knowledge of the NP chemical and physical characteristics with the biological
test conditions and the mechanisms behind toxicological assays. The current paradigm
of purchasing a compound and testing it as is, which works for small molecules, needs to
shift to one with improved access to and understanding of quality control measures and
monitoring. The lack of characterization data is most apparent in NPs engineered for
biomedical applications, where there is hand-off from the scientists who prepare the NPs
to those who test them. It seems that there are well-characterized NPs where the
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biological applications are an afterthought, or detailed biological experiments where little
consideration is given to the NP design, properties, or dosing.

Improvements in the determination and reporting of the physical properties of these
complex NPs will require increased collaborations between fields. Continued
communication between the scientists who make the NPs and those who test them can
also help identify or resolve problems with assay interference before miscalculated results
are released. The ongoing communication, full NP characterization, and ensuring
formulation consistency will initially increase the time required for NP toxicity
assessments; however, the improvements will eventually save time and money by
reducing the conflicts and confusion surrounding published toxicity data.

43

1.2 SPION-Based Therapeutics
1.2.1 NP Therapeutics

There has been great interest in the development of NP-based agents for drug
delivery and diagnostics, particularly in fields like oncology where there is an undeniable
need for improved efficacy with reduced side effects. 152,153 Many current therapeutic
agents have low solubility, low stability, and are rapidly cleared from circulation. Rapid
clearance necessitates frequent administration to maintain therapeutic concentrations. 153
Conjugation of these drugs to polymers can improve circulation half-life, reducing the
frequency of administration. Generally, untargeted NPs will accumulate passively in
tumors or areas of inflammation due to leaky vasculature and poor lymph clearance. The
addition of biomolecules or targeting ligands can increase therapeutic efficacy or increase
accumulation in target tissues.150,186,192–196 To those ends, NPs can be functionalized with
DNA or RNA oligonucleotides, peptides, antibodies, fluorescent dyes, polymers, or
drugs.145,150,186,192–196 However, NP functionalization changes particle size, surface
charge, hydrophobicity, and biodistribution, so toxicity assessments will require the final,
fully characterized NPs.

1.2.2 Therapeutic NPs: Design Considerations

NPs for therapeutic applications must be carefully designed to evade normal
clearance mechanisms. Typically hepatic filtration removes large particles, while renal
filtration removes small particles.152,153 In addition, NP interactions with various plasma
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proteins can drive rapid clearance. 142,144,145,162,191 NP coatings, including poly(ethylene
glycol), and surface functionalization can be strategically chosen to minimize undesirable
plasma protein interactions and maximize distribution to target tissues and cellular
internalization.145,150,151,153 Thus careful engineering of particle size, shape, and surface
charge improves biocompatibility and circulation half-life while contributing to increased
therapeutic efficacy.

1.2.2a NP Size

When NPs are engineered for biomedical applications, the final system dimensions
are chosen to direct in vivo distribution and accumulation while minimizing unwanted
clearance.153,197 Ideally NPs for intravenous (IV) administration should be 10-100 nm. NPs
that are less than 10 nm are rapidly filtered by the kidney, while those larger than 100 nm
are cleared via the liver and spleen. When NPs are intended to accumulate in target
tissues, their ability to exit circulation also needs to be considered. Normal blood vessels
are tightly sealed, but the rapid growth and inflammation associated with tumors results
in porous vasculature that allows NPs up to 400 nm to extravasate.

1.2.2b Minimizing Plasma Protein Adsorption

NPs are also rapidly cleared from the circulation by phagocytic cells such as
macrophages. Phagocytic clearance is stimulated by the adsorption of specific plasma
proteins to the NP surface.142,144,145,153,162 The addition of inert, biocompatible surface
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coatings, like poly(ethylene glycol) (PEG), dextrans, or synthetic block co-polymers
increases circulation half-life by reducing plasma protein interactions and, thus,
minimizing clearance by macrophages. 145,150,151,153,154 Without modification, most NP drug
carriers are cleared from circulation within minutes. 154 When neutral, hydrophilic coatings
are employed, half-life can be extended to upwards of 2 hours. 154

1.2.2c NP Surface Charge

NP surface charge also affects particle uptake, internalization mechanism, and
intracellular distribution, even after controlling for NP size and shape. 169 In general,
positively charged particles have a higher rate of cell uptake compared to negative or
neutral surface charges.153,169,198 However, positively charged NPs are also more
cytotoxic than NPs with negative or neutral surface charges. 157 Differences in uptake
mechanism have been noted in vitro, where positively charged NPs accumulate quickly
on cell surfaces, likely due to electrostatic interactions with the negatively charged cell
surface proteins, and are taken up via adsorptive endocytosis in a concentrationdependent manner.169 NPs with a negative surface charge, that were otherwise of similar
size, shape, and composition to the positively charged ones, were taken up at a steady
and constant rate, independent of their membrane concentration, by common
endocytosis. In vivo, NPs with a positive surface charge have higher rates of non-specific
internalization, perhaps due to their electrostatic attraction for the negatively charged cell
membrane proteins, and have a shorter circulation half-life.153 NP surface charge also
indirectly affects in vivo uptake and distribution, as positive and negatively charged NPs
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have different plasma protein interactions. Negatively charged NPs are more likely to
interact with proteins that have specialized cellular uptake mechanisms. 169,191

1.2.3 NP Targeting

When no targeting mechanisms are employed, intravenously administered NPs that
evade clearance will distribute primarily to the liver, spleen, kidneys, and tissues with
leaky vasculature, which includes tumors and areas of inflammation. 152,154,199 This
passive distribution is affected by changes in NP size and surface charge, as the major
driving force in the distribution pattern is size-dependent extravasation through vascular
fenestrations and size-dependent clearance by the liver, spleen, and kidneys. 150,192
Improved control over NP localization can be achieved with surface functionalization.

Conjugation of the NP with ligands targeting tumor specific cell-surface receptors,
proteins, or uptake reduces non-specific uptake and enhances concentration at target
tissues.145,153,192 For example, folate-conjugated NPs were taken up by tumors at a
greater rate than surrounding tissue. 160,186–190,200 The addition of an aptamer targeting
prostate-specific membrane antigen (PSMA) to a doxorubicin-loaded SPION created a
system that was cytotoxic only to PSMA-expressing cells.185 Antibodies are also highly
specific and can significantly increase accumulation within target tissues. 145,201,202
However, antibodies require proper conformation and orientation to recognize their
targets. Conformation and orientation are difficult to maintain or guarantee during the
coupling process. In addition, antibodies are immunogenic and may stimulate an
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undesirable increase in particle clearance. 154 Consequently, whole antibodies are not
typically used; rather, when antibodies are employed, small fragments containing the
variable region are used instead.154

1.2.4 NP Surface Modification Strategies

NP therapeutics are generally complex, with multiple layers surrounding the NP core.
For SPIONs, the NP core is typically coated in a surfactant, like oleic acid, which is then
coated with an amphiphilic polymer to improve aqueous solubility and provide reactive
sites for further functionalization.145,150,176,203,204 Commonly used coatings include
poly(acrylic) acid,205–208 poly(ethylene) glycol (PEG),186,194,195 or dextran,209,210 all of which
are hydrophilic and accepted as biocompatible.145,153,154,158,181,203,211 Targeting or
therapeutic molecules can then be conjugated to the polymer coating. 150,186,192–196
Surface ligands are added to NPs through both covalent and non-covalent attachment
mechanisms.145 Although the type of attachment can influence the biological effects, the
preferred mechanism is highly dependent on the ligand being attached and the system in
which it will be used.145,212,213 Protocols for NP functionalization vary wildly, as many
particle-specific factors need to be considered, including stability of the NP, functional
groups, conjugation catalyst, solvent choice, and the biomolecule being attached. For
multi-functional NPs, hydrophobic drugs can be loaded into the hydrophobic surfactant
layer surrounding the NP core.214,215

Covalent Attachment

48

Covalent ligand attachment is often achieved via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) catalyzed amide bond formation between an amine terminal ligand
and an outward facing carboxylic acid on the NP coating. 145 Carbodiimides activate
carboxylate anions to an O-acylurea intermediate in the condensation reaction between
amines and carboxylic acids. Then the amine can attack the intermediate to form an
amide or another carboxylate can attack to generate an anhydride, which is then attacked
by the amine.216

EDC is a popular choice for NP modification because it is water soluble, the excess
reagent is easy to remove, and the reaction can take place at room temperature. 145,217–
220

However, despite being one of the most common strategies for NP functionalization,

the protocols,221,210,222–225 and success rates, for EDC-mediated attachments vary
significantly.145,218,221,226 Further complicating matters, EDC initially gained wide
acceptance for its ability to form amide bonds on surfaces, and adaptation of the surface
modification protocol for use with NPs in solution requires additional consideration. 218,221
For

example,

in

many

cases

excess

EDC

causes

NP

aggregation

or

precipitation,222,145,208 possibly because the positively charged activated EDC molecules
neutralize the negative charges of the carboxyl groups that are keeping the particles
suspended.145

The use of EDC for both surface and NP modification requires careful consideration of
the reaction conditions. Controlling reaction pH is critical, as only the protonated form of
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EDC participates in reactions. With a pKa of 3.5, EDC is most active in acidic conditions
(pH <4).217 The pKa and ideal reaction pH for the moieties being linked should also be
considered. Once EDC is added to the reaction, timing is also critical as EDC rapidly
hydrolyzes in aqueous solutions.216,217 Given the proclivity of EDC to hydrolyze in the
presence of water, the use of properly stored reagent and freshly prepared EDC solutions
is imperative. This could contribute to the reported inconsistencies in EDC efficiency and
reaction concentrations. EDC is readily available in large quantities, particularly relative
to the amounts needed for small-scale reactions, and the water sensitivity of the reagent
would allow for degradation with time, repeated container opening, or improper storage
conditions. As a result, larger quantities of reagent would be needed the longer the
container is open.

Non-Covalent Attachment

Non-covalent

attachments

include

electrostatic,

hydrophobic,

and

affinity

interactions.145 Although non-covalent interactions can be easier to induce than covalent
linkages, they are less stable and offer less control of binding ratios and ligand orientation.
Even so, hydrophobic interactions are frequently employed to orient polymer coatings on
surfactant-coated NPs. When amphiphilic polymers are used, it is assumed that the
hydrophobic side chains will associate with the NP surfactant, forcing the polymer
backbone to form shell around the NP with the hydrophilic moieties facing outwards.208
The hydrophobic surfactant layer can be loaded with hydrophobic drugs, like
docetaxel.145,215 At the particle surface, the outward facing functional groups of the
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polymer are charged in many aqueous solvents. The reactivity of these groups, typically
carboxylic acids or amines, and thus their affinity for interacting with molecules of the
opposite charge, can be mediated by adjusting the solvent pH. 145 DNA, siRNA, and
proteins can be adsorbed to the charged NP surface through electrostatic interactions.
145,198

1.2.5 SPIONs as Multi-Functional Therapeutics

SPIONs, which are nano-sized maghemite (γ-Fe2O3) or magnetite (Fe3O4),143,145 have
been investigated for a variety of biomedical applications, including many multi-functional
platforms that exploit the magnetic properties of the particles in addition to their
biocompatibility.148,152,154,157,158,227 Because SPIONs are superparamagnetic, they are
magnetic when placed in a magnetic field, like an MRI, but do not retain that
magnetization when the field is removed. 228 Their strong magnetization when in a
magnetic field allows them to function as MRI contrast agents, while the lack of
magnetization in the absence of a magnetic field keeps the SPIONs from agglomerating
during storage or circulation.143,145

SPIONs have been investigated for a variety of biomedical applications, including roles
in drug delivery platforms,152,195,227 MRI contrast agents,148,152,195 and magnetic
hyperthermia.152,197 Ferumoxytol (FeraHeme), a dextran-coated SPION formulation, has
received FDA approval for use a treatment for anemia in patients with chronic kidney
disease.149,150,157,229 While there is some debate surrounding the biocompatibility of bare
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SPIONs,143,154,157,181 coated SPIONs are considered biocompatible and are attractive
platforms for biomedical technologies. 143,150,152,154,181 In addition, SPIONs are considered
easy

to

functionalize,

making

them

an

ideal

base

for

multi-functional

theranostics.152,160,192,195,214

1.2.5a SPION Therapeutics

SPION therapeutics are generally complex, with multiple layers surrounding the SPION
core. Typically the SPION core is coated in a surfactant, like oleic acid, which is then
coated with an amphiphilic polymer to improve aqueous solubility and provide reactive
sites for further functionalization.145,150 The polymer coatings also improve circulation halflife, as bare SPIONs are rapidly cleared, 154 and enhance biocompatibility.33,154,158,181,211
Targeting or therapeutic molecules are then conjugated to the polymer coating. 150,186,192–
196

Hydrophobic drugs can be loaded into the hydrophobic surfactant layer surrounding

the SPION core.160,185,214,215,230–233

Intravenously administered SPIONs, without specific targeting ligands, primarily
accumulate in the liver and spleen but can also be found in the heart, lungs, kidney, brain,
stomach, small intestine, and bone marrow. 152,161,199,234 The distribution of SPIONs
through the body, including into the brain, demonstrates their ability to penetrate a variety
of target tissues when used for drug delivery or diagnostic purposes. SPIONs also
accumulate passively in tumors due to leaky vasculature and poor lymph clearance, and
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the addition of targeting ligands can further enhance accumulation in target
tissues.150,186,192–196

Once SPIONs are taken up by cells, they are metabolized to elemental iron.150,152
SPIONs are degraded within lysosomes to elemental iron, which is released to the
cytoplasm and handled by normal iron regulatory mechanisms. 152,154,235,236 There has
been some concern that the elemental iron could contribute to target organ toxicity via
the generation of ROS through the Fenton reaction or iron accumulation leading to iron
overload.143,152 In reality, however, the amount of iron introduced from SPION
therapeutics is small compared to the normal blood iron stores. 154,235,236 The success of
Ferumoxytol, an FDA-approved SPION-based intravenous treatment for chronic iron
deficiency anemia, demonstrates the effective in vivo metabolism of SPIONs and their
biocompatibility.149,229

1.2.5b SPIONs as MRI Contrast Agents

MRI is a sensitive imaging technique that does not involve radiation or radioactive
tracer dyes, like PET or CT scans. However, MRI does not have cellular level resolution.
Currently gadolinium (Gd) based contrast agents are used to improve resolution, but
gadolinium causes severe complications, including nephrotoxicity, in a subset of
patients.150 SPION-based contrast agents can act as T2-enhancing contrast agents to aid
in the identification of lesions, like tumors and metastases, without the toxicity of
gadolinium.154,160,161
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SPIONs passively accumulate in the liver, spleen, tumors, and areas of inflammation,
and their magnetic properties allow for easy, non-invasive detection of their in vivo
distribution with MRI.154 T2 signal in the liver and spleen is decreased within minutes of
intravenous SPION administration.150,154 As SPIONs leak out of circulation they drain to
the lymphatic system, allowing for lymph node imaging. 154 Dextran-coated SPIONs can
remain in circulation for nearly 2 hours, lending utility as blood-pool contrast agents.154
Conjugation of targeting ligands further increases SPION concentration, and thus contrast
enhancement, in tumors and target tissues. 150,154,192 However, the strong magnetic
response of uncoated SPIONs can be reduced when organic coatings and surface
modifications are present, which should be considered when designing heavily-modified
multi-functional SPION platforms. 158

1.2.5c SPIONs as Drug Delivery Vehicles

Systemic administration of drugs typically requires large drug doses to achieve
therapeutic concentrations in target tissues. The inability of drugs to accumulate
specifically in target tissue is a significant obstacle in cancer treatment because doselimiting systemic adverse effects can occur before therapeutic concentrations are
reached.237 Delivery systems that direct drugs to, or facilitate drug release in, tumors can
improve therapeutic efficacy and reduce off-target effects. SPIONs are biocompatible and
passively distribute to tumors in vivo, making them a popular choice for drug delivery
platforms.150,152,154,186,192–196 SPIONs are also compatible with a variety of coatings and
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functionalization techniques, allowing modifications that can improve targeting,
biocompatibility, or deliver multiple drugs at once. 152,160,192,195,214

Therapeutic agents can be incorporated into SPIONs in a number of ways. 192
Antisense oligonucleotides (ASO), antibodies, or enzymes are often covalently linked to
the outer surface of the particle.150,189,238–240 Lipophilic drugs like paclitaxel 160,215 or
doxorubicin185,230–233 can be loaded into a surfactant layer between the SPION core and
the polymer coating. Drugs can also be attached through links that are readily cleaved in
response to changes in pH230,231,233 or tissue-specific enzymes.237 Additionally,
combinations of drugs can be used to target multiple cancer pathways simultaneously or
one agent can be used to sensitive the cancer cells to the other. 160

SPIONs, and other NPs, functionalized with ASO are able to overcome many of the
obstacles that preclude in vivo use of therapeutic oligonucleotides. When the surface of
polymer coated SPIONs was decorated with covalently linked ssDNA in vitro cell uptake
increased significantly.240 While very few polymer-coated SPIONs were internalized, even
at high doses, the DNA-bearing SPIONs were taken up in a dose-dependent manner.
This is consistent with reports that gold NPs functionalized with ASO are internalized in
significantly larger quantities than non-functionalized or peptide-functionalized controls241
and can decrease target protein expression more efficiently than commercially available
transfection methods.213 ASO loading onto the gold NPs is more easily controlled than
loading onto SPIONs, and this precise control allows for comparison of the uptake and
protein regulatory effects of NPs with varied ASO densities. NPs with more densely
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packed ASO were taken up at higher rates than those with less ASO per NP. 213,241 Similar
ASO-gold NP systems reach glioblastomas in vivo and sensitize the tumor cells to
apoptotic stimulants; this system is now being testing in phase I clinical trials. 242 Although
many of the proof-of-concept studies for ASO-NP systems have been carried out using
gold NP cores, it is believed that the core material is of little significance. 34 Rather, the
dense oligonucleotide packing on the surface of the NP drives the biological effects.

1.2.5d Multi-functional SPION Systems

Although the SPION-based agents currently on the market each serve a single purpose
(iron replacement or providing MRI contrast), many of the research-stage formulations
are multi-functional.192 Carefully engineered systems can serve, simultaneously, as drug
delivery platforms and MRI contrast agents. 150,152,215,227,232,233 Other multi-functional
systems aim to sensitize tumor cells to a drug carried within the platform. 201 When
targeting molecules are used in conjunction with the aforementioned strategies, SPIONs
can be used to label or track tumor cells with specific features. The ability to label specific
cells, combined with the strong magnetic response of SPIONs, allows for identification of
small metastases using MRI instead of radiation-based imaging.150,230,237 Potential for
drug resistance could also be identified without the need for a tumor biopsy, as
characteristic cell surface markers like Her2 or PSMA can be targeted with SPIONantibody conjugates.201,202
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1.3 Carbon Nanotubes
1.3.1 Carbon Nanotubes

Carbon nanotubes (CNTs) are hollow tubes formed from rolled up graphene sheets. 177
Single sheets of graphene form single-wall carbon CNTs (SWCNTs) while multi-wall
CNTs (MWCNTs) have multiple, concentric graphene layers. 142 CNTs of various lengths,
widths, and surface chemistry can be obtained by varying synthesis methods.177 As CNTs
are considered highly amenable to functionalization, further variety can be achieved
through surface modifications. Pristine and functionalized CNTs possess unique physical
and chemical properties that make them of interest to scientists, engineers, and industry.
Specifically, their light weight, high tensile strength, thermal and chemical stability, and
conductivity have led to the incorporation of CNTs into electrodes, lithium ion batteries,
thin film flexible electrodes, and sports equipment.142,143,164,177 The use of CNTs in
biomedical applications, including use in drug and gene delivery,243–245 vaccinations,246
biosensors,164,247 and tissue scaffolding,142,248 has been a popular research endeavor. As
CNTs find their way into an increasing variety of consumer products, concerns have
arisen about their toxicity.171,249–251 In fact, concerns about CNT toxicity are considered a
limiting factor for their use in biomedical applications.147,177

1.3.2 Carbon Nanotube Toxicity

The integration of CNT in an increasing number of consumer goods creates a high
likelihood of industrial exposures. Because CNTs are small, light, and easily aerosolized,
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inhalation exposures are a primary concern. 141,252 The toxicity of CNTs depends heavily
on the particle physical properties, dose, exposure route, and exposure time. However,
there is little standardization of these variables, or their reporting, across studies from
different groups.163,251 Despite conflicting reports, it is generally agreed that CNTs are
toxic/harmful to cells, although the degree of damage depends on physical characteristics
including residual catalysts, aggregation state, surface chemistry, and structural
differences.142,164,171,253

A lack of standardization in NP characterization, dose determination, and toxicity
assessment has contributed to conflicting toxicity reports.164,165 As variations in CNT size,
shape, surface chemistry, aggregation state, synthesis methods, and dispersal
techniques all affect CNT toxicity, inconsistencies in these variables have made it difficult
to compare toxicity studies performed by different groups. 142,143,171,253 However, at this
point it is largely accepted that CNTs are hazardous to human health, and the
conversation has shifted towards determining the specific effects and elucidating the
mechanisms and time course of the damage, as well as the influence of various particle
properties.156,252,254

Many initial toxicity studies were conducted with high-dose, short-term CNT
exposures, which are poor models of real world conditions. 171,250 Low dose, chronic
exposure models are needed to simulate most likely exposure conditions. CNTs are
small, light, and easily aerosolized, making occupational inhalation exposures are
considered the most likely real world exposure route. 165,252 In addition, CNTs have been
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likened to asbestos in terms of their fibrous shape, bio-persistence, and ability to induce
pulmonary inflammation and fibrosis. 164,171,249,250,252 Miscalculation of the long-term risks
of asbestos had devastating human health and financial implications. Unfortunately the
rapid incorporation of CNTs into consumer goods, without a full understanding of the
human health risks, may lead to down the same path. 253 Thus, improved understanding
of CNT toxicity is needed to remediate the introduction of a potential health hazard.

Acutely,

inhaled

CNTs

cause

pulmonary

irritation,

inflammation,

and

fibrosis.170,171,175,251,255 However, CNT bio-persistence allows for accumulation over
time.165,174,256,257 CNT accumulation can cause direct and indirect physical and chemical
damage to bronchial epithelial cells and pulmonary macrophages and the full extent of
the progressive damage, particularly to DNA, can take years, or decades, to
manifest.171,174,175,250 Asbestos-related malignancies are often detected 30-40 years
following exposure.258 Given their physical similarities, it is reasonable to extrapolate that
CNT-related damage could occur over a similar time frame. Despite the likely health risks,
there are currently few studies investigating the long-term effects of chronic, low-dose
CNT exposures, although chronic CNT exposure has been shown to induce malignant
transformation of lung epithelial cells in vitro172,259 and promote carcinogenesis in
vivo.174,252

1.3.3 Role of CNT Physical Properties in Toxicity
CNT structure (length, width, and aspect ratio), functionalization, and aggregation
state are strong determinants of toxicity.248,165 The size of inhaled particulates determines
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how deep into the lung they are able to penetrate.248 Particles <100 nm bypass most of
the lungs defense mechanisms and deposit at the broncho-alveolar junctions and in the
alveoli themselves.141,165,175,174 After CNTs have deposited, normal lung clearance
mechanisms are evoked. However, the high aspect ratio of CNTs impedes phagocytosis
by macrophages.164,260 Consequently, CNTs can persist in the lungs for up to 11
months.141,165,175,174 The persistent presence of foreign material stimulates an ongoing
inflammatory

response

that

can

ultimately lead

to

granulomas,

fibrosis,

or

carcinogenesis.164,260 CNT shape affects the extent of the damage. Longer, thinner CNTs
are better able to penetrate lung cells and induce more granuloma formation and
inflammation than shorter or wider CNTs. 164,248,260 Agglomeration changes the shape,
surface, and stiffness of the particles.143,164 Some studies have found that SWCNT
bundles are less toxic than single SWCNTs,143 but others have reported that the
increased stiffness of CNT aggregates resulted in greater cytotoxicity than dispersed
CNTs.164

CNT surface modifications can affect the size, surface charge, and biological activity
of the particle.164 Pristine (non-functionalized) CNTs, which are primarily graphene
(carbon) are hydrophobic and highly reactive. 248,261 When CNTs are designed for
biomedical applications, functionalization improves biocompatibility by reducing CNT
immunogenicity and surface reactivity while increasing aqueous solubility. 177,143,164,248,178
Solubilized CNTs can be further decorated with therapeutic or targeting ligands, including
antibodies, biomolecules, or nucleic acids. 164,245,246,261
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Reports of functionalized CNTs being biocompatible are carried out in different
conditions than studies looking at toxicity from inadvertent exposures. One major
difference is that functionalized CNTs for therapeutic applications are injected
intravenously, resulting in different distribution, immune reactivity, and clearance
mechanisms than those that drive pulmonary toxicity. 178,183,262 Another difference is that
therapeutic CNTs are more likely to have a narrow size distribution and to be uniformly
suspended with few agglomerates.178,183 Additionally, evaluation of many of the
therapeutic CNT platforms seems to primarily rely on short exposure times and fewer
toxicity endpoints.143,183 These short (4-48 hours) exposure times may be relevant to the
expected delivery to the platform, but the CNTs will likely persist in vivo and can have
effects beyond those time points.

CNT functionalization for therapeutic applications necessitates dosing considerations
similar to those discussed in 1.1.6 Dosing NPs for Toxicity Evaluations. The use of pristine
CNTs, which have markedly different physical and chemical properties than the
functionalized system, as a control introduces additional confounding factors. Particularly
for in vitro testing, where the system is stationary and stagnant, the effects of improved
solubility of the functionalized CNTs alone can contribute heavily to the decrease in
observed toxicity.

For example, improved biocompatibility of glycodendrimer-coated SWCNTs, versus
pristine SWCNTs, has been reported. 183 However, the improvements noted in vitro may
not be as significant as they appear due to differences in the way the particles interact
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with the in vitro system. The coated SWCNTs reportedly stay homogenously suspended
in aqueous solutions for many months, while the pristine SWCNT control precipitates
almost immediately. In an in vitro test system with adherent cells on the bottom of the
culture dish, many more of the rapidly precipitating pristine SWCNTs will be available to
interact with the cells than the stably suspended coated particles. 165

In addition, cells were treated with equivalent masses of the coated and uncoated
CNTs.183 Although the contribution of the coating to the particle mass was not reported,
enough coating to confer stable suspension in aqueous solution would be expected to
have a measureable contribution. Even if the coating was a small percentage of the total
mass, there would inherently be fewer glycodendrimer-coated SWCNTs in a given mass
than there would be in an equivalent mass of pristine SWCNTs. If concentration
dependent effects are expected, adding different absolute numbers of particles negates
the validity of the mass-equivalency dosing. The extreme differences in particle solubility
would also change the dose the cells were ultimately exposed to.

1.3.4 Modeling Real World Exposures
CNTs are small, low-density particles are easily aerosolized. Thus, occupational
inhalation exposures are the most pressing public health concern. 141,252,165 However, the
CNTs used for industrial applications are heterogeneous mixture of particle sizes, shapes,
and agglomeration states.166 Approximating the composition of real world exposures is
often challenging when designing toxicity assessments, and many evaluations instead
utilize more homogeneous mixtures. Modeling the dose of real world CNT exposures for
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in vitro or in vivo studies is also difficult.141,165 Following inhalation, CNTs deposit in small
airways and alveoli, where they can remain for upwards of 11 months. 141,165,175,174 Normal
lung clearance mechanisms are invoked but are largely ineffective at degrading the
CNTs.141,175,174 Consequently, the CNTs accumulate over time despite the low
concentration of each individual exposure. In experimental systems, doses for are often
calculated to (model) a lifetimes worth of exposures. 166 This has led to the use of
extraordinarily high bolus doses in both in vitro and in vivo studies.166 Acute toxicity is
readily apparent when these large doses are applied, which has contributed to the
continued use of unreasonable doses.165 In contrast, lower, more realistic doses induce
much less overt toxicity in acute evaluations. 166 The validity of life-time exposure dosing
for assessing chronic toxicity has been questioned. 165,166 Chronic in vitro CNT exposure
models, in which cells are cultured with sub-acute concentrations of CNTs for 6 months,
have been developed to overcome this limitation. 172,263
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1.3.5 Acute Toxicity of CNTs
Acute exposure to CNTs results in dose- and time-dependent decreases in cell
viability in vitro143,260 and inflammation and fibrosis in in vivo inhalation models.260 CNTs
are internalized within 48 hours of exposure in vitro,260 which induces oxidative stress,
release of IL-8, and overexpression of immune and inflammatory genes. 143 Genotoxicity
following acute CNT exposures, including aneuploidy, centrosome fragmentation,
damage to mitotic spindles, and increased numbers micronuclei, has also been reported.
174,256,264

1.3.6 Chronic Toxicity of CNTs
Health problems stemming from chronic occupational exposure to CNTs could
take years, or decades, to become apparent, similar to asbestos induced mesothelioma,
and short-term, high dose studies do not provide a full picture of the risks. 171,250,175,258 The
long latent period between exposure and disease onset can make it difficult to assess the
potential carcinogenicity and carcinogenic mechanisms. 174,260 Consequently, acute, highdose exposures are more widely studied even though they are not representative of most
real world exposures.171,250 Over time, the particles cause continual inflammation,
irritation, and immune system activation. In addition to the damage inflicted through
physical interactions of the particles with cells, organelles, and genetic material, the
ongoing inflammatory response also triggers changes in cell behavior. 170,255,174,256,264
Chronic inflammation is, by itself, a risk factor for the development of cancer, as
evidenced by the increased risk of malignancy in patients with autoimmune diseases.
174,256

Acutely, CNT genotoxic effects include the induction of aneuploidy, centrosome

fragmentation, damage to mitotic spindles, and increased numbers micronuclei. 174,256,264
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Genetic damage accumulates over time and the impacts become evident long after the
inciting event.250,258 CNT exposure in a mouse inhalation model resulted in K-ras
oncogene mutations.255,256 Despite the evidence for CNT-induced DNA damage, their
status as an oncogenic initiator is still unconfirmed. 175 However, a murine inhalation study,
using an initiator/promotor model, demonstrated that CNTs do act as tumor promotors. 252

In vitro chronic exposure models have been developed to better understand the
effects of long-term, low dose CNT exposures.250,175,172,259,265 Many of these studies have
examined the response of non-cancerous bronchial epithelial cells, which are the first
layer of defense against inhaled CNTs in humans. 172,266 When lung epithelial cells were
exposed to sub-acute doses of CNTs for 6 months, they underwent malignant
transformation, with obvious morphological changes appearing half way through the
exposure period. Following the CNT exposure, the transformed lung epithelial cells
proliferated more rapidly, were more invasive, demonstrated anchorage-independent
growth, and were resistant to apoptosis.175,172,259 CNT-induced cell cycle dysfunction has
been linked to decreases in p53 expression,267 while apoptosis resistance has been
linked to increases in c-FLIP expression.268 Increases in transformed cell invasion and
migration have been related to increases in matrix metalloproteinase (MMP)
expression.259
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1.4. Figures and Tables

1.4.1 Figures

A

FIGURE 1

B

Figure 1. Specificity of NPs, in the form tissue specific effects, can be conferred through
two distinct mechanisms. (A) NPs that target a cell- or tissue specific pathway will be
taken up by all cells but only effect cells that have the target feature. For the purposes of
demonstration, the illustration shows NPs bearing antisense oligonucleotides that target
a cancer specific protein. (B) NPs that recognize surface features of target cells will be
internalized with greater specificity. Antibodies targeting cell surface features can be used
to improve uptake specificity, as can molecules that are readily internalized, including
folate.
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Figure 2

Figure 2. Mechanism of ASO protein synthesis inhibition. Binding of the ASO to the
complementary sequence of the target protein mRNA occurs in the cytoplasm. Ribosomal
translocation along the mRNA is physically blocked by ASO hybridization with its
complementary sequence.
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Figure 3

Figure 3. Structure of YM155 (1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide), a small molecule inhibitor
of survivin.

68

1.4.2 Tables
Table 1. Survivin expression in human tumor samples.
Survivin Positive

Survivin effect on survival, outcomes, tumor behavior,
chemotherapy/radiation sensitivity

Glioblastoma

31/39 (79%)68

Pancreatic cancer

n/a

Non-small cell lung
cancer
Acute myeloid
leukemia

>80%57

CML

n/a

B-Cell Lymphoma

134/222 (60.4%)44

Anaplastic large cell
lymphoma

34/62 (55%)44

Adult T-cell leukemia
Myelodysplastic
syndrome

100% 44

Higher survivin expression noted in more aggressive disease44

11/12 (92%)44

n/a

Melanoma

“almost all”

Reduction in survivin, in vitro results in increased spontaneous apoptosis
and increased sensitivity to radiation and cisplatin. 69

Prostate Cancer

?

Survivin levels increase as disease becomes more aggressive, and
increase in survivin promotes flutamide resistance45

Osteosarcoma

?/22

Higher survivin levels in patients with metastatic disease; high survivin
expression associated with significantly decreased 5 year survival. 46

Renal cell carcinoma

n/a

Retrospective studies linked survivin expression to decreased survival,
more aggressive disease, resistance to therapy, poorly differentiated
variants, and accelerated reoccurrence.47

Head and neck
squamous cell
carcinoma

n/a

Only HNSCC cells that have high cytoplasmic survivin (versus nuclear
survivin) are chemo- and radiation-resistant.260

Colorectal cancer

n/a

High tumor survivin associated with significantly reduced survival and
reduced apoptotic index.48

Gastric carcinoma

n/a

Tumor survivin expression is associated with increased p53 and bcl-2
expression and significantly reduced apoptosis.73

Breast Cancer

n/a

Survivin contributes to tamoxifen70 and trastuzumab261 resistance

Bladder Cancer

n/a

Reduction in survivin sensitized cells to cyototoxic stimuli 262

Neuroblastoma

n/a

Survivin expression is correlated with aggressive tumor behavior and poor
prognosis43

Soft tissue sarcoma

n/a

Survivin is a prognostic marker in soft-tissue sarcomas263

80%44

n/a
siRNA inhibition of survivin decreases radio-resistance and cell
proliferation; increases apoptosis and G0/G1 cell cycle arrest72
Survivin expression correlated with worse prognosis and decreased
survival57
Survivin expression is considered a negative prognostic indicator even
after adjusting for typical prognostic factors44
Survivin is detectable during CML blast crisis but not during chronic
phase44
Survivin expression associated with a significant decrease in survival 44
In tumors positive for anaplastic lymphoma kinase (ALK), the 5 year
failure free survival rate was 34% for survivin positive tumors, and 100%
for survivin negative tumors.
In tumors negative for ALK, the 5 year failure free survival rate was 46%
for survivin positive tumors and 89% for survivin negative tumors.44
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Table 2. Interference of NPs with in vitro assessments of toxicity
Cell
Proliferation
143,155,162,203

Membrane
Integrity

Techniques/Reagents

Assay Mechanism

Usage Considerations

MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium
bromide)
WST-1 (a water soluble
tetrazolium salt)

Colorimetric determination of
mitochondrial viability

Fast, reproducible results155

MTS (3-(4,5-dimethylthia- zol-2yl)-5-(3-carboxymethoxyphenyl)
2-(4-sulfophenyl)- 2Htetrazolium)
Lactate dehydrogenase (LDH)
release 10,14

Conversion of a tetrazolium salt to a
formazan dye, resulting in a color
change proportional to the number of
metabolically active cells

LDH is an intracellular enzyme that
leaks into the culture media when cell
membrane integrity is compromised.

Interference from NPs:

Direct reactions of CNT, porous silica, and carbon black with tetrazolium
salts – falsely increases measured viability142,155,156,264

Adsorption of formazan dye to CNT – measured viability is falsely
low142,155,163

Spontaneous activation of MTT by graphene142,265

NP can physically block light transmission144
LDH has a half-life of 9 hours in media; timing of cell death relative to assay
influences results.156

LDH in media oxidizes lactate to
pyruvate, which triggers the
conversion of a tetrazolium salt to a
formazan dye.

Interference from NPs:

LDH can be inactivated by Cu or silver NPs or adsorb to TiO 2142,266

LDH is deactivated under low pH conditions, while a high pH stabilizes
the substrate144

Metal ions can interfere with LDH assay, although SWCNT do not appear
to interfere144,267

Apoptosis

Caspase activation144,155

Caspase-3 activation leads to cell
death

Caspase-3 is inhibited by trace metal ions, but is mostly unaffected by
changes in pH144

NP
Intracellular
Localization

Transmission electron
microscopy (TEM)142,155

Visualization of electron dense
materials, like metal NPs, and stained
cellular structures allows for
determination of precise intracellular
localization
Quantitative measure of metals, with
sub-ppb limits of detection

Does not show organic coatings on NPs, so can only be used to determine
location of NP core155

Reaction of iron with various reagents
allows for colorimetric quantification of
iron concentration using UV-vis

Not useful for carbon-based NPs because of large carbon background in
biological samples

Quantitative and qualitative
assessment of the uptake and
intracellular localization of
fluorescently-tagged NPs

Fluorescent dyes alter NP surface properties and can affect uptake and
localization

Quantification
of NP Uptake

Inductively Coupled Plasma
(ICP)142,155,162
Colorimetric quantification of iron
(Prussian blue,268,269
ferrozine,187,270 ophenanthroline)271,272
Fluorescence Spectroscopy142,155

Staining biological samples can introduce electron-dense artifacts that are
similar in size to NPs155
Destructive technique requires acid digestion of samples
Detects metal from physiological sources as well as from treatment

No insight into NP localization
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2.1. Abstract
Superparamagnetic iron oxide nanoparticles (SPIONs) can be used to improve the
specificity of cancer drug delivery, thereby reducing the toxicity associated with systemic
administration.

SPIONs can be easily conjugated to therapeutic agents, including

antisense oligonucleotides. Survivin, an anti-apoptotic protein over-expressed in many
types of cancer but undetectable in most healthy adult tissues, is an attractive therapeutic
target. Increases in survivin expression are correlated with more aggressive cancers,
treatment resistance, and greater patient mortality. Antisense agents alone are an
effective means of reducing survivin expression in vivo, where they trigger apoptosis
specifically in survivin expressing cells. In vivo, however, a platform is needed to deliver
antisense agents to tumor cells. SPIONs coated in oleic acid were synthesized by thermal
decomposition and coated with a biocompatible polymer, octylamine modified polyacrylic
acid before conjugation with survivin antisense DNA. SPION physical properties,
including particle size and composition, were characterized at each step of synthesis.
A549 (human lung adenocarcinoma) cells, which have high baseline survivin expression,
were exposed to DNA-coupled SPIONs for 24 or 48 hours. SPION uptake and localization
was followed with confocal and fluorescent microscopy. Survivin expression was
quantified with Western blots, while cytotoxicity was assessed with the colorimetric water
soluble tetrazolium (WST-1) assay. Our results showed that the SPION platform is
biocompatible and capable of delivering functional antisense oligonucleotides to regulate
survivin expression; however, significant refinement of the DNA-to-SPION coupling step
is needed. Applied clinically, antisense survivin coupled SPIONs can reduce the required
dose of, adverse effects from, and resistance to, current cancer chemotherapy regimens.
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2.2. Introduction
Many of the systemic toxicities of current cancer chemotherapeutic agents are the
result of the drugs’ indiscriminate action on all rapidly dividing cells. Drugs that specifically
target cancer cells are difficult to design due to the considerable spatial and functional
overlap between healthy and malignant cells. One target that is ubiquitous in cancer
cells, yet virtually undetectable in healthy cells, is the anti-apoptotic protein survivin.1–3
Survivin overexpression has been identified in nearly all types of cancer, including lung
adenocarcinoma,4 mesothelioma,5 anaplastic large-cell lymphoma, 6 osteosarcoma, 7
glioblastoma multiforme,8 and prostate,9 endometrial,10 bladder, ovarian,11 and
pancreatic12 carcinomas.

Clinically,

high tumor

survivin levels correlate

with

chemotherapy and radiation resistance, increased metastases, and overall greater
mortality.4,7,9,10,13–16 In vitro, antisense oligonucleotides decrease survivin expression and
increase sensitivity to chemotherapy and radiation induced apoptosis without affecting
the survival of non-survivin expressing cells.1,5,9,10,17–22 The specificity of survivin-targeted
therapies and their striking in vitro success spawned a number of clinical trials, including
YM155, a small-molecule inhibitor of survivin,23 a vaccination against a survivin peptide, 24
and LY2181308, a naked antisense survivin agent administered in saline. 25 Although
none of the tested therapies progressed in their initial states due to formulation issues or
practical considerations, they demonstrated the viability of clinically targeting survivin.

Specifically, nucleic acids are challenging to deliver in vivo. Naked nucleic acids are
rapidly hydrolyzed upon entering the bloodstream, rendering them inactive. 26,27 Then,
even if a therapeutically relevant concentration of antisense agent is reached in the target
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tissue, naked nucleic acids require coaxing to cross cell membranes. Their dense
negative charge is repelled by the negative charge on the surface of cell membranes and
in vitro strategies to increase uptake, including liposomes and electric shock, do not
translate well to in vivo settings.28,29 Structural modifications to the nucleic acid bases
have been employed to increase stability in circulation by reducing enzymatic
degradation.26,28–31 Other delivery strategies have included encapsulation of the nucleic
acids in a cationic polymer27–29 or pH sensitive coatings for controlled release. 27,31,32
Considering the strong in vitro response to survivin antisense agents, and the known
limitations to the delivery of naked nucleic acids in vivo,26,28,33 a stable, biocompatible
antisense delivery system is needed before their clinical potential can be realized. 29

Superparamagnetic iron oxide nanoparticles (SPIONs) have been widely investigated
for use as both drug delivery platforms 34,35 and MRI contrast agents36 and, recently,
Ferumoxytol (FeraHeme) has received FDA approval for use a treatment for anemia in
patients with chronic kidney disease.37 SPIONs are readily metabolized to elemental iron
in vivo,35,3737 making them an attractive platform for diagnostics and therapeutics. Ease
of SPION functionalization allow for great versatility and the design of multipurpose
particles.35,38 SPIONs will accumulate passively in tumors due to leaky vasculature and
poor lymph clearance, and active targeting with tumor-specific antibodies or aptamers
can further increase particle concentration in target tissue. 37–43

This work centers on the development of a SPION-based platform for the delivery of
survivin antisense oligonucleotides to cancer cells. We anticipate that this platform will
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result in selective toxicity to malignant, survivin expressing cells, leaving healthy, nonsurvivin expressing cells unscathed.

SPIONs coated in oleic acid were synthesized by thermal decomposition 44 and coated
with a biocompatible polymer, octylamine modified polyacrylic acid (Figure 1),45 to
increase aqueous solubility and provide reactive sites for further functionalization.
Polymer coated SPIONs were coupled to 3’- amine-modified survivin antisense1 or nontargeting control DNA sequences.46 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) was used to catalyze the formation the 3’-amide linkage.46 SPION physical
properties, including particle size and composition, were characterized at each step of
synthesis. A549 (human lung adenocarcinoma) cells, which have high baseline survivin
expression,47 were exposed to DNA-coupled SPIONs for 24 or 48 hours. SPION uptake
and localization was followed with confocal and fluorescent microscopy. Survivin
expression was quantified with Western blots, while cytotoxicity was assessed with the
colorimetric water soluble tetrazolium (WST-1) assay. Our results showed that the SPION
platform is biocompatible and capable of delivering functional antisense oligonucleotides
to regulate survivin expression; however, significant refinement of the DNA-to-SPION
coupling step is needed.

2.3. Results
2.3.1. SPION Synthesis and Characterization.
Oleic acid

coated

SPIONs (SPION-OA)

were

synthesized

using

thermal

decomposition, as previously described.44 After washing, the synthesis consistently
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yielded homogenous particles with 7.07 ± 0.74 nm SPION cores (Figure 2). SPION-OA
readily disperse organic solvents, like hexane and toluene, even at high concentrations,
resulting in opaque black solutions. We have previously described the full characterization
of the elemental composition and magnetic susceptibility of SPION-OA.61

An octylamine modified poly(acrylic) acid (PAA) coating 45 was added to SPION-OA to
allow transfer to aqueous solvents and to serve as a link to additional functionalization.
Hydrophobic interactions are expected to drive the octylamine moieties to intercalate with
the hydrophobic oleic acid tails, resulting in the formation of a hydrophobic layer
encapsulated by the outward-facing carboxylic acids of the PAA backbone. 62 The newly
formed PAA coated SPION-OA (SPION-PAA) were washed, dried, and suspended in
basic water (pH 9) before filtering to remove aggregates; without filtering, SPION-PAA
was difficult to disperse and rapidly settled out of solution. Unfortunately, much of the
SPION-PAA characterization was carried out before we discovered the importance of
filtering the samples.

To verify the addition of the PAA coating, FT-IR was performed on SPION-OA and
SPION-PAA. The SPION core is not expected to contribute greatly to the FT-IR spectra,
but the interactions of the oleic acid with the core allow for differentiation of SPION-OA
from oleic acid alone (Figure 3A). Specifically, oleic acid alone has a strong carboxyl
(C=O) peak at 1750 cm-1. However, the carboxyl (1750 cm-1) peak is very small in SPIONOA, which aligns with the expectation that the oleic acid carboxyl group is binding SPION.
The small remaining carboxyl signal may be the result of oleic acid that is not covalently
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bound.61 After coating SPIONs with PAA, a small carboxylic acid hydroxyl (OH) peak is
present at (3333 cm-1) (Figure 3B). These hydroxyl groups are critical to further
functionalization of the platform. The small size of the peak is expected as the hydroxyl
groups are a small percentage of the total structure.

Thermogravimetric analysis (TGA) was used to quantify the mass contributions of
each coating in SPION-OA and SPION-PAA, while dynamic light scattering (DLS) was
used to determine the contributions of the coatings to the hydrodynamic diameter of the
particles (Figure 4). SPION-OA was found to be 20% oleic acid and 80% iron oxide, a
ratio that remained consistent across samples and synthesis batches (Figure 4, A and
C).61 SPION-PAA was found to be 75% PAA, 5% oleic acid, and 20% iron oxide (Figure
4, B & C). SPION-PAA composition was also consistent across batches; however, this
measurement was made on unfiltered SPION-PAA, and it is not yet known if the filtered,
soluble SPION-PAA will have the same mass composition as the washed but unfiltered
particles.

DLS showed that SPION-OA had a hydrodynamic diameter of 11.27 nm, with a narrow
size distribution indicative of a homogeneous, well-dispersed sample (Figure 4D). SPIONOA hydrodynamic diameter was ~4 nm larger than the diameter determined from TEM,
which was expected since TEM only allowed measurement of the metallic core while DLS
accounted for the iron oxide core and oleic acid coating. SPION-PAA had a hydrodynamic
diameter of 43.12 nm (Figure 4E). Although the DLS histogram shows a narrow size
distribution, this measurement was performed on the poorly soluble, unfiltered SPION-
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PAA. Large aggregates of SPION-PAA, visible to the naked eye, are present in nearly all
suspensions of unfiltered SPION-PAA; however, these aggregates often settle out or
float, which would result in less of an impact on the DLS measurement.

2.3.2. Coupling DNA to SPION-PAA

SPION-PAA forms the base of our delivery platform, with outward-facing carboxylic
acids from the PAA providing covalent attachment sites for amine-terminal ligands like
our survivin antisense (SASO) and non-targeting control (NTC) oligonucleotides. Our
single-stranded DNA was synthesized with a 3’ C7-NH2 to allow for coupling via
carbodiimide

chemistry.

Our

intent

was

to

use

1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC) to drive the reaction, as EDC/carbodiimide
chemistry is widely utilized for the formation of amide bonds, particularly between
biological molecules.45,63,64,50,54 However, our coupling success varied dramatically, often
varying by a factor of ten between reactions performed in parallel from identical starting
materials. While a definitive procedure for this coupling application was not successfully
discerned in the course of this work, a number of variables have been identified as targets
for reaction optimization.

Despite the issues with DNA coupling consistency, some characterization of SPIONDNA was carried out. TEM was used to examine the SPION core of a batch of SASOSPION as well as a sample of the SPION-OA from which they were derived (Figure 5, A
& B). Although the additional coating layers are not expected to change the core size, the
core diameter of SPION-OA (7.07 ± 0.74 nm) was found to be 2 nm smaller than the
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average core diameter of SASO-SPION (9.01 ± 0.72 nm). The difference may be due, at
least in part, to the small sample size for the SASO-SPION. SASO-SPION was prepared
from a very dilute solution and particles were sparse when imaged.

DLS showed that SASO-SPION had a hydrodynamic diameter of 50.58 nm (Figure
5C). Thus, the DNA makes up a small portion of the final SPION diameter (Figure 6). It is
interesting to note that even though the amount of DNA coupling to the SPIONs was not
consistent, the change in particle diameter when DNA was added is in line with what
would be expected if the SASO covalently bound (Table 1). It is not clear at this point is
if the biologically active DNA is the covalently bound portion or is, perhaps, made up of
an additional layer of DNA attached through electrostatic interactions.

2.3.3. SASO-SPION Decrease Survivin Expression and Reduce Survival in A549
Cells, a High Survivin Human Lung Cancer Cell Line.
Although the reaction for coupling DNA to SPIONs is still in need of refinement, our
preliminary in vitro results that suggest our SPION platform is not inherently toxic to cells
and support the viability of this platform as a delivery system for antisense
oligonucleotides.

It is important to note that the following results were obtained by using multiple batches
of SPION-DNA. Although every attempt has been made to standardize the dosing
measures and presentation, the batch-to-batch variation of the current DNA coupling
procedure is such that that results from different batches are not directly comparable.
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Dosing evolution is addressed in the discussion, while dosing explanations are included
in the procedure and results for each experiment. However, the results are, as a whole,
supportive of the hypothesis that this SPION platform has potential as a drug delivery
agent. This data is meant to serve as proof-of concept and will be presented with
appropriate details on the SPIONs used in each study. In the future, once the DNA
coupling/formulation issue has been addressed, in vivo studies will be repeated and
expanded to determine the actual magnitude and time course of the biological effects.

Early in the formulation development process, confocal microscopy was used to verify
that SPION-DNA could enter our target A549 lung adenocarcinoma cells (Figures 7 and
8A). For this study, SPION-PAA was coupled to a fluorescein-labeled antisense survivin
oligonucleotide. Following a 24 hour incubation, cells were thoroughly washed and fixed
before staining with DAPI and FM4-64FX cell membrane stain. 3D renderings confirmed
that SPIONs were internalized and were within the cytoplasmic compartment. Since this
was an early-stage study, the main purpose was to show that the SPIONs could enter
cells, which was accomplished. In addition, the determination that the SPIONs were in
the cytoplasm supports the use of this system in hindering protein production via
antisense oligonucleotide interference with cytoplasmic mRNA.

After determining that the SPIONs were entering the cells, we briefly investigated the
mechanism of entry (Figure 8B). A549 cells were again incubated with fluorescently
labeled SASO-SPION for 24 hours and cells were stained with DAPI and either a cell
membrane stain (Cell Mask Orange) or a lysosome tracking dye (Lysotracker Deep Red).
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Examination of fixed cells with fluorescent microscopy confirmed that SPIONs were
entering the cells. Co-localization of the lysosome/membrane dyes with the SPIONs
fluorescent tag suggests that the SPIONs are within vesicles, with many notable
localization to the peri-nuclear region.

While SPION internalization is likely a necessary step in delivering the therapeutic
DNA to the cells, the lysosomal/vesicular localization of internalized SPIONs was
concerning.27,29 Cytoplasmic localization of the SPIONs, or at least the therapeutic
antisense ligands, is required for the downregulation of protein production through the
intended mechanism.27–29 Since the goal of this specific SPION formulation is induce or
sensitize cells to apoptosis through decreased survivin expression, changes in cell
viability and survivin expression were then assessed.

For assessment of the toxic and/or therapeutic effects of DNA coupled SPIONs,
SPIONs were dosed by DNA concentration. DNA concentration was chosen because it
could be measured using non-destructive, reproducible methods and it allowed for
comparison to previously reported studies on our chosen SASO. Ideally iron
concentration would also be accounted for, perhaps in the form of a consistent
relationship between iron and DNA concentrations. Unfortunately that was not possible
in this study.

To test our hypothesis was that SASO-SPIONs would contribute to cancer cell death
by decreasing survivin expression, A549 cells were exposed to SASO- or NTC-SPION
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(1000 nM) for 24 hours and survivin was detected by Western blot (Figure 9A). Our initial
studies used a high DNA concentration (1000 nM) so that an effect, if present, would be
readily apparent. We found that after 24 hours, SASO-SPIONS significantly reduced
survivin expression to 66.14% (± 15.11%) of the untreated control, while NTC-SPIONs
resulted in survivin expression that was 110.87% (± 9.67%) of the untreated control. Olie,
et al. reported that the same SASO sequence, at 400 and 600 nM, reduced survivin
mRNA to 35% of the untreated control when introduced to A549 cells with lipofectin. 1

While decreases in cell survivin expression have been correlated to increased
sensitivity to chemotherapy drugs and radiation, decreasing an anti-apoptotic mediator
does not inherently trigger apoptosis. Thus, the cytotoxic effects of SASO- and NTCSPIONs on A549 cells were assessed following 24 and 48 hour exposures.

A lactate dehydrogenase (LDH) release assay (results not shown) was used to
quantify cell necrosis and late-stage apoptosis, as LDH is released into the surrounded
media when cells lyse. Metabolic viability of remaining live cells was determined from
using WST-1, a colorimetric assay where functional mitochondria convert a formazan dye
to a water soluble tetrazolium salt and the color change is proportional to the number of
live cells. Since the LDH assay is performed on used cell culture media and WST is
performed on the cells themselves, both assays were performed on the same exposed
cells at the same time.
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Although LDH is frequently used as a measure of cytotoxicity in SPION or
nanoparticle-exposed cells, it is not always an appropriate choice for the quantification of
cell death.65 In our case, many of our LDH results showed that treated cells experienced
much less toxicity (cell lysis) than untreated controls even though the WST results (or
simply viewing the wells through a microscope) indicated the opposite. It turns out that
once LDH is released it has a half-life of 9 hours in solution. As a consequence, it is not
well suited to capture cell death unless it is occurring relatively close the time of the assay.
If the tested agent is causing rapid cell death or growth restriction, the LDH released from
the dying cells will not be picked up by the assay. Since cells have a small level of baseline
LDH release, using LDH as the only measure of cytotoxicity will show a well with no cells
as “healthier” than a control well with a healthy cell population.

Metabolic viability of the cells was assessed after 24 and 48 hour SPION exposures.
After 24 hours, no significant changes in viability were noted at any dose of SASO- or
NTC-SPION (Figure 9B). However, our 48 hour incubation (Figure 9, C & D) revealed
that the effects of the SASO-SPIONs were strongly batch dependent. In comparison, no
changes in viability were noted at any dose, or for any batch, of NTC-SPION, indicating
that they are innocuous. The two coupling batches tested in Figure 9 C & D were prepared
from the same starting materials and prepared and tested in parallel. However, UV-vis
analysis immediately after coupling suggested that batch 1 (Figure 9C) had twice as much
DNA per SPION as batch 2 (Figure 9D). Although the batch-to-batch variation was high,
replicates within each batch were remarkably consistent (± 4%). This SASO sequence,
when introduced to A549 cells by lipofectin, reduced cell viability to 50% (300 nM SASO)
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and 10% (600 nM SASO) after 72 hours.1 Once our SPION-DNA coupling procedure has
been optimized, assessing cell viability at 72 hours will allow us to compare the efficacy
of our delivery platform to the current delivery standard.

While more studies are needed to fully understand the does- and time-dependent
effects of the SASO-SPIONs, this batch dependence does support the biocompatibility of
the SPIONs. Specifically, the less effective batch had less DNA per SPION, meaning that
significantly more poorly-coupled SPIONs were required to achieve each DNA dose.
Additionally, no significant toxicity is noted with NTC-SPIONs at any dose or from any
batch.

2.4. Discussion
In this work, we demonstrated that a biocompatible SPION scaffold can be reliably
synthesized and coated. The functionalization of our SPION platform has been
inconsistent; however, our preliminary data supports the use of this system to deliver
antisense oligonucleotides to alter cell behavior. Specifically we have chosen to target
the anti-apoptotic mediator survivin, which is heavily expressed in cancer cells but
virtually undetectable in healthy tissue.1–4,7,9,10,13–16

The overexpression of survivin in malignant tissue has been well established, as have
the benefits of reducing survivin expression in vitro.1,5,9,10,17 Unfortunately there has been
great difficulty in translating those in vitro successes to clinically useful treatments. One
major obstacle in clinical translation has been the difficulty of delivering therapeutic
oligonucleotides in vivo.26,28–31 Thus we proposed the use of a SPION-based platform to
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chaperone the nucleic acids, in our case an antisense oligonucleotide, to their in vivo
destinations.

The magnetic properties of SPIONs make them particularly appealing for clinical
applications. In addition to delivering therapeutic agents, SPIONs can act as MRI contrast
agents, outlining a tumor or metastasis. Their strong response in magnetic fields means
that a low concentration of SPIONs is needed to detect a lesion. The use of
superparamagnetic particles, whose magnetism disappears when the magnetic field is
removed, reduces the risk of agglomerations forming in small vessels. 66

SPIONs are widely regarded as biocompatible; however, there is still some debate
as to their safety for use in humans. 34,35,66–68 Lack of standardization in the reporting of
nanoparticle characterization, dosing, toxicity measures, etc. makes it difficult to draw
conclusions about the safety of various individual SPION formulations. 39,54 However,
general parameters contributing to nanoparticle biocompatibility have been delineated
and new formulations can be designed within these parameters to enhance both safety
and biological efficacy. For instance, particle diameters between 10 and 100 nm increase
circulation time by minimizing clearance by both the renal and the reticuloendothelial
systems.34,35 Additionally, a diameter of less than 150 nm is needed to extravasate. 34
Since SASO-SPION, our therapeutically active formulation, is 50.28 nm, it is the ideal
size to extravasate easily as well as to maximize its half-life in circulation.

Typically SPIONs in circulation interact with plasma proteins, which reduces their
bioavailability.68–71 However, the negative surface charge of the SASO-SPIONs, resulting
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from the highly-negatively charged DNA backbones, will help to minimize these
interactions. Additionally, negatively charged particles will undergo less renal excretion
since they will be repelled by the similarly negatively charged glomerular basement
membrane.35 Decreased renal filtration will enhance circulation time and lessened SPION
interactions with the glomerular basement membrane will reduce kidney toxicity.

SPION biocompatibility, including toxicity, half-life, and eventual uptake by target
tissues, is heavily influenced by the particles coating. 37 Our freshly synthesized SPIONs
are coated with a layer of oleic acid, which serves as a surfactant to separate the particles
during synthesis.44 A water-soluble coating is needed for the platform to function as a
therapeutic, and this coating often serves as the attachment point for therapeutic and
targeting ligands.

Commonly used coatings include poly(acrylic) acid, 45,72,73

poly(ethylene) glycol (PEG),40,41,43 or dextran,51,74 all of which are hydrophilic and
accepted as biocompatible.37,38 Therapeutic and targeting ligands, including nucleic
acids, antibodies, and aptamers, can the conjugated to the SPION coating. Covalent
attachment of these ligands, in the form of EDC-catalyzed amide bond formation linking
amine-terminal biological molecules to surface carboxylic acid moieties, is common but
the procedures for doing so are not well defined.

Carbodiimides activate carboxylate anions to an O-acylurea intermediate in the
condensation reaction between amines and carboxylic acids. Then the amine can attack
the intermediate to form an amide or another carboxylate can attack to generate an
anhydride, which is then attacked by the amine. 75 EDC is popular for these reactions
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because it is water soluble, the excess reagent is easy to remove, and the reaction can
take place at room temperature.50,54,55 Despite its popularity, the mechanics and
necessary parameters of EDC-driven amide formation are not well understood, 63,54,55,76
leading to dramatic variations in reported procedures 51,53,49,76–78 and, frequently, low
coupling efficiencies.63,54,55,76 Further complicating matters, EDC initially gained wide
acceptance for its ability to form amide bonds on surfaces, and adaptation of the surface
modification protocol for use with nanoparticles in solution requires additional
consideration.55,76 For example, in many cases excess EDC causes nanoparticle
aggregation or precipitation,54,77,79 possibly because the positively charged activated EDC
molecules neutralize the negative charges of the carboxyl groups that are keeping the
particles suspended.54
The use of EDC for both surface and nanoparticle modification requires careful
consideration of the reaction conditions. Controlling reaction pH is critical, as only the
protonated form of EDC participates in reactions. With a pKa of 3.5, EDC is most active
in acidic conditions (pH <4).50 In our SPION-DNA coupling reaction, the pKa of the
carboxylic acid and amine groups to be linked must also be considered. The timing is also
critical, as EDC rapidly hydrolyzes in aqueous solutions. 50,75 Given the proclivity of EDC
to hydrolyze in the presence of water, the use of properly stored reagent and freshly
prepared EDC solutions is imperative. This could contribute to the reported
inconsistencies in EDC efficiency and reaction concentrations. EDC is readily available
in large quantities, particularly relative to the amounts needed for small-scale reactions,
and the water sensitivity of the reagent would allow for degradation with time, repeated
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container opening, or improper storage conditions. As a result, larger quantities of reagent
would be needed the longer the container is open.

Despite the challenges in obtaining SASO-SPIONs with consistent DNA coatings, we
found that our SASO-SPIONs had a measurable effect on cell viability. Although this is
what the platform was designed for, it led to some questions as to the mechanism of
SPION entry into the cell and how the SASO was ending up in the cytoplasm. Our imaging
results suggested that the SASO-SPIONs were internalized via endosomes, which tend
to acidify and degrade their contents. 29 The successful use of SPIONs as an iron source
for patients with iron deficiency anemia would also support the theory that SPIONs are
taken up and degraded.35,37 Although other studies have also visualized SPION 80 and
antisense-loaded gold nanoparticles uptake through endocytosis, 81–83 it is possible that
SPIONs are internalized via multiple routes. Another possibility is that it is not the
covalently bound DNA that is responsible for the changes in cell behavior; rather, a layer
of non-covalently bound DNA may form on the particle surface through electrostatic
interactions. This weakly bound DNA would be freed in response to environmental
changes, like the drop in pH encountered in the endocytic vesicles, and the free DNA
could migrate into the cytoplasm.37,84,85
To fully exploit either the drug delivery or imaging potential of our particles, we first
need to demonstrate selective uptake by the target cells. Our present uptake studies
demonstrated that SPIONs entered a survivin expressing cell line. The current SPION
formulation lacks active targeting ligands and is expected to passively distribute
throughout the body, with a preference for tumors or areas of inflammation due to the
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leaky vasculature in those regions. As such, the potential for high levels of non-specific
SPION accumulation, particularly in hepatic and splenic tissue, remains a concern. To
these ends, a method for actively targeting the SPIONs specifically to survivin-expressing
cells would improve their clinical utility. Although passive targeting may allow SPIONs to
accumulate in some tumors as is, specific targeting will increase their effectiveness.
Active targeting of the SPIONs would also allow us to utilize the oleic acid layer that
exists between the SPION core and the polymer coating as drug reservoir. Lipophilic
drugs, such as doxorubicin, can be loaded into the oleic acid to allow for targeted delivery
of high drug concentrations with decreased risk of systemic toxicity. Many drugs are
known to act synergistically with the sensitization from decreased survivin levels to
combat resistant cancers1,15 and delivering such chemotherapeutic agents with the
SPION:DNA platform could improve outcomes in patients with aggressive or resistant
malignancies.
Although more studies, both in vitro and in vivo, are needed to sufficiently demonstrate
the safety of our SPION platform, these initial studies suggest that low doses of our
SASO-SPIONs decrease survival of survivin expressing cells. If utilized to their full
potential, our SPIONs are capable of dramatically improving cancer diagnostics and
therapeutics. Specifically, their multi-functional nature allows a single well-designed
SPION to be used for cancer diagnostics, treatment, and non-invasive monitoring of
response to therapy.
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2.5. Materials and Methods
2.5.1 SPION Synthesis. Oleic acid coated SPIONs were synthesized following a
previously described thermal decomposition method. 44 Octyl ether (10 ml, 0.033 mmol)
(Sigma-Aldrich, Milwaukee, WI) and oleic acid (1.43 ml, 4.56 mmol) (Santa Cruz, Dallas,
TX) were heated to 100°C. Iron pentacarbonyl (0.2 ml, 1.52 mmol) (Sigma-Aldrich,
Milwaukee, WI) was added and the solution was refluxed for 1 hour (solution turned
black). After cooling to room temperature, trimethyl amine N-oxide (0.34g, 4.56 mmol)
(Sigma-Aldrich, Milwaukee, WI) was added and temperature was increased to 130°C for
2 hours, at which point the solution was brown. The solution was then heated to reflux for
1 hour. The resulting black solution was allowed to cool to room temperature.

To remove excess oleic acid, small aliquots of reaction mixture were transferred to a
beaker over a strong magnet. Ethanol (200 proof) (Sigma-Aldrich, Milwaukee, WI) was
added until the SPIONs precipitated. Liquid was decanted and the oleic acid coated
SPIONs (SPION-OA) were suspended in toluene (500 µl). Each aliquot was washed a
total of three times and the final product was collected in toluene.

2.5.2 Octylamine-modified Polyacrylic Acid (PAA) Synthesis.45 1-Ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) (5.33g, 28 mmol) (Sigma-Aldrich, Milwaukee,
WI) was added to 1800 MW polyacrylic acid (5.0 g, 70 mmol) in DMF (70 ml) (Alfa Aesar,
Ward Hill, MA) and stirred for 30 minutes. Octylamine (4.6 ml, 28 mmol) (Sigma-Aldrich,
Milwaukee, WI) was added and stirred overnight at room temperature. Solvent was
removed under vacuum. Distilled water was added and the resulting precipitate was
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isolated by centrifugation (300g, 3h). Aqueous NaOH (1M) (Fisher Scientific, Pittsburgh,
PA) was added and the mixture shaken overnight. Solution was washed with ethyl
acetate (3 x 20ml). Dilute HCl (10% HCl) (Fisher Scientific, Pittsburgh, PA) was added to
the aqueous layer until the pH was less than 5 to give a white precipitate. Precipitate was
collected following centrifugation (300 g, 3h) and dried. NaOH (0.1M) was used to
neutralize dry product. Final product was dried over P 2O5 and a PerkinElmer Spectrum
One FT-IR spectrometer was used in transmission mode under ambient conditions to
verify the structure of the modified polymer.

Octylamine-modified PAA (50 mg) was added to dry SPIONs (10 mg) in chloroform (5 ml)
(Fisher Scientific, Pittsburgh, PA) and methanol (3 ml) (Fisher Scientific, Pittsburgh, PA).
The mixture was sonicated for 3 hours and dried under vacuum. Basic water (pH 9) was
added and the solution was filtered through 0.2 µM PVDF centrifuge filters (VWR, Radnor,
PA) to remove aggregates. Suspended particles were dialyzed with distilled water in
Amicon Ultra 15 100K molecular weight cutoff (MWCO) filters (Millipore, Billerica, MA).
PAA coated SPIONs (SPION-PAA) were collected and diluted with distilled water. FT-IR
of dried PAA-SPIONs was used to verify that the coupling had occurred.

2.5.3 Oligonucleotide Synthesis and Purification. Oligonucleotides were prepared
using 1 µmol 3'-PT-Amino-Modifier C3 CPG column (Glen Research, Sterling, VA) on an
ABI-394 DNA and RNA Synthesizer (Applied Biosciences Incorporated, Foster City, CA).
Single-stranded survivin antisense (3' – C6-amino link - GTT CCT CGA CCT TCC GAC
CC - 5')1 or non-targeting control (NTC) (3’ – C6-amino link – TTT CCT TTG TGA TCT
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TGC CCT – 5’)48 DNA was prepared with and without a 5’ fluorescein (Glen Research,
Sterling, VA).

Concentrated ammonium hydroxide (28-30%, 1 ml) (Sigma-Aldrich,

Milwaukee, WI) was used to cleave the oligonucleotides from the column. Cleaved
oligonucleotides were incubated at 55°C for 15 hours and then dried under vacuum.
Oligonucleotides were purified with fast protein liquid chromatography using a Waters 510
pump, a Waters 2487 Dual λ absorbance detector, and a Bio-Rad TSK DEAE-5-PW
column and a linear gradient (10-70% B over 60 min, Buffer A: 10 mM NaOH, pH 11.8,
Buffer B: 10 mM NaOH, 1 mM NaCl, pH 11.8, flow rate 6 ml/min, UV detection, 260 nm).
Reverse phase Waters Sep-Pack (C-18) (Waters, Milford, MA) cartridges were used for
desalting following purification. Absorbance of diluted oligonucleotide solutions was
measured on a Beckman DU-600 spectrophotometer (Beckman Coulter Inc., Brea, CA)
at 260 and 280 nm.

2.5.4 Oligonucleotide-SPION Coupling. SPION-DNA coupling was inconsistent and the
procedures were modified throughout this work with the goal of improving coupling
efficiency and reproducibility. No finalized, reproducible coupling parameters were
identified, which has led to the inclusion of results from SPIONs coupled under varying
conditions. While this is not ideal, the ability to obtain optimistic results even with
formulation difficulties supports the potential of this platform. The general procedure for
oligonucleotide-SPION coupling is outlined below, followed by notes on procedural
changes. The reaction, and possible alternatives, are discussed in greater detail in the
results and discussion sections.
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EDC (19 mg, 100 mmol) was added to dry SPION-PAA (1 ml, 1 mg). Dry DNA
(SASO or NTC) (1.5 mg, 40 OD) was dissolved in MilliQ water (500 mL) and added to the
mixture. Additional MilliQ water was added to bring the total volume to 1 ml. Mixture was
heated at 50°C for 3 hours, with vortexing every 15 minutes. Excess DNA was removed
by filtration through a Vivaspin 2 100 kDa Molecular Weight Cut-off Filter (10 min, 250 g)
(Vivaproducts, Littleton, MA) using distilled water to wash three times. Washed
SPION:DNA was collected in distilled water. The absorbance of SPION solutions at 260
and 280 nm was measured on a Beckman DU-600 spectrophotometer (Beckman Coulter
Inc., Brea, CA) to quantify DNA coupled to SPION.
A number of reaction conditions were modified, at various points, to optimize the
reaction. Due to timing and logistical constraints, this analysis was not as thorough or
methodical as was needed. One major challenge was that the freshness of the EDC had
a strong impact on the reaction, primarily in the form of fresh EDC causing rapid particle
precipitation at concentrations similar to, as well as several times less than, those used
with older EDC. The difference was so dramatic that the use of fresh EDC nearly negated
any prior work on this reaction. SPION-PAA concentration was held constant while EDC
concentrations from 0.01 to 19 mM were tried, and DNA concentration was varied from
10 to 100 OD.
Initially, the reaction was performed by adding EDC (powder) to dry DNA, then
adding dry SPION-PAA and MilliQ water. Dry SPION-PAA did not disperse well in the
solution and attempts to improve its solubility included adding SPION-PAA in a wellsonicated solution of MilliQ water and, later, slightly basic milliQ water. While increasing
the pH of the solution did help to keep the SPIONs in solution, it did not enhance the
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overall reaction efficiency, probably due to inactivating the EDC. 49,50 To address the pH
sensitivity of EDC, the reaction was next attempted in MES buffer (25 mM) at pH 6.0. 51–
53,49

However, this reintroduced the SPION-PAA solubility issue.
The reaction time and temperature were also modified throughout this work

because the initial conditions frequently resulted in sample destruction. That is, if SPIONs
settled at all during the 3 hour incubation at 50 °C, they would decompose and stick to
the bottom of the reaction vessel. After consulting additional protocols, the incubation was
carried out at room temperature with constant gentle agitation. 50,52,54–56 As EDC
decomposes within the first 15 minutes of the reaction in an aqueous solvent,50 so the
reaction time was reduced to 1 hour. To encourage SPION suspension throughout the
entirety of the reaction, some trials were conducted in an ice bath to allow for continuous
sonication.

2.5.5 Transmission Electron Microscopy. A drop of dilute SPION solution was placed
on a carbon coated 200-mesh copper grid (Ted Pella Inc, Redding, CA) and allowed to
dry at room temperature.

A JOEL JEM-2100 transmission electron microscope

(Peabody, MA) with an accelerating voltage of 200 kV was used. NIH Image J software
(http://rsbweb.nih.gov/ij/) was used to analyze images for size of iron oxide core.

2.5.6 Dynamic Light Scattering. SPION hydrodynamic diameter was measured in
toluene (SPION-OA) or water (all other SPION solutions) with dynamic light scattering
(DLS) at a scattering angle of 90° at 25 °C using a Malvern Zetasizer Nano (Malvern,
UK).
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2.5.7 Thermogravimetric Analysis. Thermogravimetric analysis (TGA) was carried out
for powder samples (3-10 mg) from 20 to 700 °C with a heating rate of 5 °C/min in flowing
N2 gas using a TA Instruments Model Q50 (New Castle, DE).

2.5.8 Inductively Coupled Plasma (ICP). ICP-OES was used to determine the iron
concentration of SPION solutions. SPION solutions were sonicated in HNO 3 (3 ml, 3.47
M) overnight. Samples were diluted with water to 50 ml final volume prior to analysis.
Analysis was conducted on a Perkin Elmer Optima 7300 V ICP-OES by the West Virginia
University National Research Center for Coal and Energy. All samples were prepared in
replicates of 6, and the mean and standard deviation of the sets were calculated.

2.5.9 General Cell Culture. A549 (human lung adenocarcinoma) cells were maintained
in 5% DMEM (Sigma-Aldrich, Milwaukee, WI) supplemented with 5% heat inactivated
FBS (Sigma-Aldrich, Milwaukee, WI), 1% Penicillin/Streptomycin (Sigma-Aldrich,
Milwaukee, WI), and 5% L-glutamine.

Cells were incubated at 37°C in a 5% CO 2

environment. Cells were washed with DPBS (Thermo Scientific HyClone, Logan, UT),
trypsinized (SAFC Biosciences, Lenexa, KS), and stained with Trypan Blue (Thermo
Scientific HyClone, Logan, UT) prior to counting. Cell viability was measured with Cell
Proliferation Reagent WST-1 (Roche, Indianapolis, Indiana). Cytotoxicity was measured
with Cytotoxicity Detection Kit Plus (LDH) (Promega, Madison, WI). Absorbance
measurements were made with a Biotek Epoch Microplate Spectrophotometer (Winooski,
VT).
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Note on SPION dosing for in vitro experiments: SPION-DNA doses were
initially calculated relative to mass. Later, attempts were made to dose SPION-DNA by
iron concentration to deliver similar numbers of SPIONs to each sample, regardless of
the ligands. Challenges in determining the iron concentration of small sample volumes in
a timely manner led to the use of DNA concentration as the primary dosing measuring.
As the therapeutic ligand, the DNA concentration is the measure that best relates to the
literature. However, an ideal dosing measure would include both iron concentration and
DNA concentration.

2.5.10 Cell Cytotoxicity. For viability studies, SPION-DNA doses were calculated to
deliver specified DNA concentrations, which theoretically would overcome the differences
in DNA coupling efficiencies. A549 were plated at a density 5 x 10 3 cells/well in a 96 well
plate. DMEM (10% FBS) (200 µL) was added to all wells. Cells were allowed to adhere
overnight and media was replaced with 150 ul fresh media plus a total of 50 µl of SPIONDNA in PBS (30, 50, 80, 100, 200, 500, 500, 1000 nM DNA) 1,57 and PBS. As nanoparticle
interference with many toxicity assays is not well understood and particle interference has
been reported under some conditions, 58–60 cell-free substance controls were set up in the
same manner, using the highest dose of SPION-DNA being tested, to ensure SPIONs
were not interfering with the assay. All sample sets were run in at least triplicate. Cells
were incubated with SPIONs for 24 or 48 hours, after which the plate was placed on a
bar magnet for 2 minutes to draw SPIONs to bottom of dish. Supernatant (100 µl) from
each well was transferred to a clean 96 well plate and freshly prepared LDH assay
reaction mixture (100 μL) was added to each well. The plate was incubated for 15 minutes
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at room temperature (20°C). Absorbance was measured at 490 and 620 nm. The
cytotoxicity of cells was calculated relative to unexposed cells (all absorbance values
used

in

calculations

were

𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
))∗𝑠𝑢𝑏𝑠𝑡𝑎𝑛𝑐𝑒
𝑠𝑢𝑏𝑠𝑡𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛

(𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠)− (𝑏𝑙𝑎𝑛𝑘 𝑎𝑏𝑠)− (

at
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠

(𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠 )−(𝑏𝑙𝑎𝑛𝑘 𝑎𝑏𝑠 )

490

nm):

× 100%.

2.5.11 Cell Metabolic Viability. For viability studies, SPION-DNA doses were calculated
to deliver specified DNA concentrations, which theoretically would overcome the
differences in DNA coupling efficiencies. A549 were plated at a density 5 x 10 3 cells/well
in a 96 well plate. DMEM (10% FBS) (200 µL) was added to all wells. Cells were allowed
to adhere overnight and media was replaced with 150 ul fresh media plus a total of 50 µl
of SPION-DNA in PBS (30, 50, 80, 100, 200, 500, 500, 1000 nM DNA) 1,57 and PBS. As
nanoparticle interference with many toxicity assays is not well understood and particle
interference has been reported under some conditions, 58–60 cell-free substance controls
were set up in the same manner, using the highest dose of SPION-DNA being tested, to
ensure SPIONs were not interfering with the assay. All sample sets were run in at least
triplicate. Cells were incubated with SPIONs for 24 or 48 hours, after which media was
removed for use in cell cytotoxicity assays, as described above, and remaining adherent
cells were washed with PBS (x3, 100 uL) to remove unbound SPIONs. Fresh media (10%
FBS, 100 μL) and WST-1 reagent (10 μL) were added to each well. Absorbance at 450
and 630 nm was measured after 90 minute incubation at 37°C. Cell viability was
calculated relative to untreated cells with the following equation (all absorbance values
used in calculations were at 450 nm):

(𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠)− (𝑏𝑙𝑎𝑛𝑘 𝑎𝑏𝑠)

.

(𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠)− (𝑏𝑙𝑎𝑛𝑘 𝑎𝑏𝑠)
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2.5.12 Western Blots. A549 cells were incubated with SASO-SPION or SPION-NTC (0
or 1000 nM DNA) for 24 hours. The media was removed and cells were washed three
times with PBS. Cells were lysed with a lysis buffer (50 mM Tris-HCl , pH 8.0 (SigmaAldrich, Milwaukee, WI), 0.1% wt/vol SDS (Sigma-Aldrich, Milwaukee, WI), 1% wt/vol
glycerol (Sigma-Aldrich, Milwaukee, WI)) and total protein content was measured with
Micro BCA kits (Thermo Scientific, Rockford, IL). A total of 60 µg protein was loaded into
each lane of a tray for SDS-PAGE with 10% wt/vol separating gel and 5% wt/vol stacking
gel. Protein was transferred to a polyvinyliene fluoride (PVDF) membrane (30 mA, 2
hours) (Sigma-Aldrich, Milwaukee, WI), which was blocked for 3 hours with a blocking
solutions (1 % wt/vol bovine serum albumin, 0.05% Tween-20 (Sigma-Aldrich, Milwaukee,
WI), 0.9% NaCl, 0.1 M PBS pH 7.2). Rabbit anti-survivin antibody (1:200, v/v) (SigmaAldrich, Milwaukee, WI) was used to hybridize protein overnight at 4°C. The membrane
was then rinsed with PBS and hybridized with HRP conjugated goat anti-rabbit secondary
antibody (1:1000, v/v) (Sigma-Aldrich, Milwaukee, WI) for 2 hours at 37°C. The signal
was detected using ECL western blotting detection reagents and images were acquired
on an ImageMaster VDS-CL (Amersham Biosciences, Pittsburgh, PA).

2.5.13 Confocal Microscopy. SPIONs doses in this experiment were based on particle
mass, with SPION-PAA used as a control rather than NTC-SPION. A549 cells were plated
at a density of 2 x 105 cells/well in DMEM (10% FBS) (1500 μL) on glass cover slips in a
6 well plate. After 24 h, the media in the wells was replaced with fresh DMEM (1500 μL)
containing 0 µg/ml, 20 µg/ml or 200 µg/ml of SPION-PAA, SASO-SPION or fluoresceinlabeled SASO-SPION. Cells were incubated for 24 hours at 37°C, washed three times
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with PBS (100 μl/wash), and stained with FM4-64FX Lipophilic Styryl Dye (Invitrogen,
Carlsbad, CA) dye before fixing with 3.7% paraformaldehyde. Fixed cells were mounted
onto slides with ProLong Gold Antifade Reagent with Dapi (Invitrogen, Carlsbad, CA).
Cells were viewed with Zeiss LSM 510 laser scanning confocal microscope (Zeiss).
Image processing was done in Zeiss LSM Image Browser Ver. 4.2.0.121.

2.5.14 Fluorescent Microscopy. SPIONs doses in this experiment were based on iron
concentration, as determined by ICP analysis, and SPION-PAA was used as a control
rather than NTC-SPION. A549 cells were plated at 1 x 105 cells/well on glass cover slips
in a 6 well plate. DMEM (10% FBS) (1500 μL) was added to each well and plates were
incubated at 37°C. After 24 hours, the media in the wells was replaced with fresh 10%
FBS media containing SPION-PAA, SASO-SPION or fluorescein-labeled SASO-SPION
(0, 3, or 33 µg Fe/ml). Cells were incubated for an additional 24 hours at 37°C. Media
was removed and cells were washed three times with DPBS. Endosomes were stained
with Lysotracker deep red (250 nM, 20 min, 37 °C) (Invitrogen, Carslbad, CA). Cells
were fixed in 3.7% paraformaldehyde and mounted with ProLong Gold Antifade
Reagent with Dapi (20 µl). Slides were viewed with Leica DMI 6000 inverted fluorescent
microscope with a DFC300FX camera (Leica, Buffalo Grove, IL). All images were
acquired using the same L5 channel settings.
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2.7. Figures and Tables
2.7.1 Figures
Figure 2.1. Schematic of SPION platform.

Figure 2.1. Schematic of SPION platform. (Left) SPION-OA is synthesized via thermal
decomposition synthesis, (center) coated with octylamine modified PAA, and (left) aminemodified DNA is coupled to the outward-facing carboxylic acid groups of the PAA coating.
The hydrophobic layer formed by alkyl tails of the oleic acid and octylamine could be
loaded with lipophilic drugs (red dots).
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Figure 2.2. Diameter of SPION-OA by TEM and DLS.

Figure 2.2. (A) Representative TEM image of SPION-OA. SPIONs are well dispersed
and have uniform iron oxide cores. (B) SPION-OA iron oxide core diameter, measured
across three separately prepared syntheses, is 7.05 ± 0.08 nm.
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Figure 2.3. FT-IR spectra of SPION-OA and SPION-PAA.

Figure 2.3. (A) FT-IR spectra for SPION-OA and (B) SPION-PAA. Analysis was
performed on desiccator-dried powder samples.
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Figure 2..4 TGA of SPION-OA and SPION-PAA.

Figure 2.4. A) Representative TGA of SPION-OA and (B) SPION-PAA. Red line shows
percent of original mass remaining as temperature was increased (5° C/minute). Black
line is the derivative of the red line, showing the rate of change of the mass as temperature
was increased. (C) Graphical representation of the composition of SPION-OA and
SPION-PAA. Composition was determined by TGA and was based on the analysis of
three samples from three separate batches. (D) Hydrodynamic diameter of SPION-OA in
toluene and (E) SPION-PAA in distilled water.
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Figure 2.4. Diameter of SASO-SPION by TEM and DLS.

Figure 2.5. (A) Representative TEM image of SASO-SPION. SASO-SPION is well
dispersed and has uniform iron oxide cores. (B) Graphical comparison of iron oxide core
diameter of a single batch of SPION-OA (7.07 ± 0.74 nm) and SASO-SPION (7.07 ± 0.74
nm) prepared from that batch. (C) Hydrodynamic diameter of SASO-SPION in distilled
water, as determined by DLS, is 50.58 nm.
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Figure 2.6. To-scale diagram of contribution of SPION layers to final particle
diameter.

Figure 2.6. To-scale diagram of contribution of various SPION layers to hydrodynamic
diameter (determined by DLS).
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Figure 2.. SASO-SPION is internalized by A549 cells.

Figure 2.7. SASO-SPION is taken up by A549 cells following 24 hour incubation. Cells
were incubated with SASO-SPION or fluorescein- SASO-SPION (0, 20, 200 µg/mL) for
24 hours, washed to remove free SPIONs, and stained with FM4-64X cell membrane
stain before fixation. Fluorescein- SASO-SPION is visible inside the cells, particularly at
the high (200 µg/mL) dose, as shown in the insets.
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Figure 2,8 SASO-SPION is detectable in endosomes of A549 cells after 24 hour
exposure.

Figure 2.8. (A) Fluorescently-labeled SASO-SPION is taken up by A549 cells following a
24 hour incubation. Cells were incubated with SASO-SPION or fluorescein-SASO-SPION
(200 µg/mL) for 24 hours, washed to remove free SPIONs, and stained with FM4-64X cell
membrane stain before fixation.3D reconstruction from confocal microscopy z-stack
images shows that fluorescein-SASO-SPIONs (green) are inside of the FM4-64X stained
cells (red). (B) Fluorescent microscopy shows co-localization (yellow) of fluoresceintagged SASO-SPION (green) and endosomes (red) after staining with Lysotracker Deep
Red (left) or Cell Mask Orange (right). Cells were incubated with fluorescein-labeled
SASO-SPION (33 µg Fe/mL) for 24 hours, washed to remove free SPIONs, and stained
with either Lysotracker Deep Red or Cell Mask Orange cell membrane stain before
fixation.
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Figure 2.9. SASO-SPION decreases survivin expression in A549 cells.

Figure 2.9. (A) Survivin expression in A549 cells following 24 hour incubation. Results
from 2 trials. (B) Metabolic viability, determined by WST-1 assay, of A549 cells was
assessed after 24 hour incubation with SASO-SPION or NTC-SPION (0, 50, 100, 200,
500, 1000 nM DNA). Results are expressed as a percentage of the untreated control
viability. Results of 4 independent trials. No significance (p < 0.05, by Student’s T-test)
was noted. (C, D) Metabolic viability, determined by WST-1 assay, of A549 cells was
assessed after 48 hour incubation with SASO-SPION or NTC-SPION (0, 50, 100, 200,
500, 1000 nM DNA). Results are expressed as a percentage of the untreated control
viability. (C) and (D) show the variation in biological effects resulting from inconsistencies
in the DNA coupling process, despite treating cells with the same DNA concentration.
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2.7.2 Tables

Table 2.1. Contribution of various SPION layers to total particle diameter.
SPION

SPION-OA

SPION-PAA

SPION:DNA

7.00 nm

11.27 nm

43.12 nm

50.28 nm

-------

4.27 nm

32.05 nm

7.46 nm

Length of 1
addition

-------

OA: 1.97 nm

??

DNA: 3.2 nm
C6NH: 0.5 nm

Expected
change

-------

4 nm

??

7.4 nm

Diameter
(DLS)
Change from
previous
step

Table 2.1. Contribution of various SPION layers to total particle diameter. Particle
diameters were determined using DLS. Expected changes were calculated based on a
single layer of covalently bound coating for both oleic acid and DNA.
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3.1. Abstract
Carbon nanotubes (CNTs) have been likened to asbestos in terms of morphology and
toxicity. CNT exposure can lead to pulmonary fibrosis and promotion of tumorigenesis.
However, the mechanisms underlying CNT-induced carcinogenesis are not well defined.
Mesothelin (MSLN) is over-expressed in many human tumors, including mesotheliomas
and pancreatic and ovarian carcinomas. In this study, the role of MSLN in the
carcinogenic transformation of human bronchial epithelial cells chronically exposed to
single-walled CNT (BSW) was investigated. MSLN overexpression was found in human
lung tumors, lung cancer cell lines, and BSW cells. The functional role of MSLN in the
BSW cells was then investigated using stably-transfected MSLN knockdown (BSW
shMSLN) cells. MSLN knockdown resulted in significantly decreased invasion, migration,
colonies on soft agar, and tumor sphere formation. In vivo, BSW shMSLN cells formed
smaller primary tumors and less metastases. The mechanism by which MSLN contributes
to these more aggressive behaviors was investigated using Ingenuity Pathway Analysis,
which predicted that increased MSLN could induce cyclin E expression. We found that
BSW shMSLN cells had decreased cyclin E, and their proliferation rate was reverted to
nearly that of untransformed cells. Cell cycle analysis showed that the BSW shMSLN cells
had an increased G2 population and a decreased S phase population, which is consistent
with the decreased rate of proliferation. Together, our results indicate a novel role of
MSLN in the malignant transformation of bronchial epithelial cells following CNT
exposure, suggesting its utility as a potential biomarker and drug target for CNT-induced
malignancies.
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3.2. Introduction
Carbon nanotubes (CNTs) have unique physical and chemical properties that make
them suitable for a variety of consumer and biomedical applications. Their electrical
conductivity and strength are exploited with their integration into consumer products,
including electronics and sports equipment. The ease of functionalization make CNTs
ideal candidates for biosensors and drug-delivery platforms (10, 32, 38). CNTs are fibrous
in shape and resistant to chemical and high-temperature degradation. Therefore, CNTs
exhibit asbestos-like properties (44). Due to the rapid growth of production, worker
exposure to CNTs is increasingly likely, creating a potential human health hazard (10,
42).
Pulmonary toxicity following CNT exposure is of particular concern, as CNTs are
small, low density, and easily aerosolized (32). As with other nanoparticles, the toxicity of
CNTs depends heavily on the dose, exposure route, and particle physical properties (38,
42). Variations in these parameters often make it difficult to compare published outcomes.
However, the consensus is that inhalation of CNTs are likely detrimental to human health,
but the full scope and mechanisms of the damage are still unclear (11).
Much of what is known about CNT toxicity comes from acute, high-dose exposures,
which result in transient inflammation and fibrosis (7, 42). In reality, chronic, low-dose
exposures are more likely (42), meaning that chronic exposure models are needed to
determine meaningful occupational exposure limits. Additionally, CNTs are not degraded
in vivo and their persistent presence, even at very low doses, can cause oxidative stress
(42) and DNA damage (7). Over time, this damage could contribute to the development
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of cancer. However, the molecular mechanisms underlying this transformation are
currently unknown.
To better understand the mechanism of CNT-induced carcinogenesis, we previously
generated an in vitro chronic CNT exposure model by culturing human bronchial epithelial
(BEAS-2B) cells with single-wall carbon nanotubes (SWCNTs; 0.02 µg/cm2) for 6 months
(21, 47). These chronic SWCNT-exposed (BSW) cells had greater malignant morphology
and behavior than their passage-matched parental cells, including increased proliferation
rates, increased resistance to apoptosis (30, 47), and increased tumor formation in vivo
(21, 47).
The malignant phenotype noted after chronic exposure to sub-acute doses of
SWCNTs results from the interaction of many factors, including changes in regulation of
a variety of cell processes (apoptosis, invasion/attachment, cell cycle regulation, etc.).
The mechanisms causing these changes have not been fully described, but, given the
similarities between CNTs and asbestos, it is possible that the pathologies could develop
through similar mechanisms.
Mesothelin (MSLN), a 40 kD cell-surface protein of unknown physiological
significance, is found in very few normal tissues. The MSLN gene encodes a 70 kD precursor protein that is cleaved into the 40 kD cell-surface mature MSLN fragment and a 30
kD soluble fragment. Mature MSLN is detectable in nearly all mesotheliomas and
approximately 30% of all cancers (29). Over-expression of MSLN in lung
adenocarcinomas is correlated with decreases in both overall and relapse-free survival
(16). Although neither the normal or pathological role of MSLN is explicitly known, it has
been suggested that MSLN may promote the development of malignancy by affecting cell
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adherence (41), cell survival and proliferation (16, 19, 41), invasion and migration (16),
apoptosis resistance, and chemosensitivity (41). The soluble MSLN fragment is
detectable in the serum of many cancer patients, and its presence has been investigated
as a potential biomarker for lung adenocarcinoma, mesothelioma (37), pancreatic cancer
(19, 41), and ovarian cancer (12).
Since MSLN is thought to play a role in carcinogenesis, this study was designed to
determine the functional role of MSLN in SWCNT-transformed bronchial epithelial cells
(BSW). A stably-transfected MSLN knockdown line (BSW shMSLN) was generated and
used to evaluate the effects of MSLN knockdown on cell migration, invasion, colony
formation, and tumor sphere formation in vitro, as well as tumorigenesis and metastasis
in vivo. A MSLN overexpressing BEAS-2B line, B2B/MSLN, was also generated to
determine if MSLN overexpression alone could induce the same in vitro malignant
phenotypic changes as those previously noted in the BSW cells. The mechanism by
which MSLN could contribute to these behaviors was investigated using Ingenuity
Pathway Analysis, which suggested that MSLN induced cyclin E, leading to cell cycle
dysregulation. The effects of MSLN on cyclin E and cell cycle regulation were verified
experimentally.

3.3. Results

2.3.1. Mesothelin expression is increased in human lung tumors and lung cancer
cell lines. As reports on the pervasiveness of MSLN in human cancers vary widely, we
first verified that MSLN was detectable in human lung tumors lysates. MSLN expression
was assessed in ten human lung tumor samples and corresponding adjacent, healthy
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tissue controls (Fig. 1A). Samples included six large cell carcinomas, three squamous
cell carcinomas, and one adenocarcinoma. None of the control samples had notable
MSLN expression. However, five of the ten tumor samples had increased MSLN
expression, ranging from two to tenfold more MSLN than the corresponding normal
controls (Fig. 1B).
To validate the differential expression of MSLN in malignant versus non-malignant
cell lines, MSLN expression was assessed in non-cancerous BEAS-2B cells, two lung
cancer lines (A549, H460), and BSW cells, the previously generated SWCNTtransformed human bronchial epithelial line (47) (Fig. 1C). BEAS-2B cells had a lower
level of MSLN expression than both the BSW cells and the lung cancer lines, A549
(adenocarcinoma) and H460 (large cell carcinoma) (Fig. 1D). Even though the BSW cells
originated from the non-cancerous BEAS-2B cells, their MSLN expression was on par
with the cancer cell lines.

2.3.2. MSLN knockdown BSW cells are less aggressive than BSW cells in
vitro and in vivo. To determine the functional role of MSLN in the expression of a more
malignant phenotype by BSW cells, BSW cells were stably transfected with either MSLN
short-hairpin (sh)RNA (shMSLN) or a vector control (shC). Western blot analysis (Fig. 2,
A and B) showed that MSLN was decreased substantially in the shMSLN-transfected cells
(BSW shMSLN). MSLN was decreased to nearly undetectable levels in two clones (BSW
shMSLN-1 and BSW shMSLN-5) and these clones were selected for further study.
Colony formation on soft agar is used to assess anchorage-independent cell
growth in vitro, a hallmark of malignant transformation (5). MSLN knockdown cells (BSW
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shMSLN) formed significantly fewer colonies on soft agar than BSW controls (BSW shC)
(23.7 ± 5.1 vs. 53.0 ± 9.9) and the colonies that did form were smaller than those formed
by the BSW controls (Fig. 2, C and E). Although non-cancerous cells are not usually
expected to form colonies on soft agar, it has been noted that BEAS-2B cells form small,
slow-growing colonies despite their non-malignant origins (40, 45). Previously, it was
shown that BSW cells formed eight times more colonies than passage-matched BEAS2B cells (47).
Tumor spheres form from the proliferation of cancer stem cells and the number of
tumor spheres that form is indicative of the relative amount of cancer stem cells in the
culture (2). BSW shMSLN cells formed significantly fewer tumor spheres than BSW shC
(50.2 ± 10.9 vs. 81.0 ± 9.7) and the spheres formed by the BSW shMSLN cells were
overall smaller than those formed by BSW ShC (Fig. 2, D and F).
To determine if the reduction in colony formation was due specifically to the
decrease in MSLN, the experiments were repeated with a MSLN-overexpressing line.
BEAS-2B cells were transiently transfected to overexpress MSLN (B2B/MSLN) (Fig. 2G).
After MSLN overexpression was verified, B2B/MSLN colony formation on soft agar was
assessed. B2B/MSLN formed substantially more colonies than B2B cells (6.5 ± 2.17 vs
0.17 ± 0.51), and the colonies that formed were overall much larger than those seen with
B2B cells (Fig. 2, H and I). Next, the effects of MSLN on cell migration and invasion were
assessed. Migration was quantified using a Transwell® system with 8 µm pores in the
barrier. Cells that crossed the pores in the barrier were stained and counted (Fig. 3, A
and C). The BSW vector control cells (BSW shC) had 2.6 times as many migrated cells
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as the MSLN knockdown cells (BSW shMSLN). Previously, BSW cells were shown to
migrate twice as much as passage-matched BEAS-2B controls (47).
Invasion was quantified in a similar manner to migration, except a thin layer of
extra-cellular matrix was added to form a barrier over the pores in the Transwell® insert.
In order for cells to cross through the barrier, they must first break down the extra-cellular
matrix (18). BSW shMSLN demonstrated significantly (2.8 times) less invasion than BSW
shC (Fig. 3, B and D). Previously, BSW cells were shown to invade three times as much
as passage-matched BEAS-2B controls. Overall, the invasion and migration assays show
that the reduction in MSLN significantly reduces the invasion and migration abilities of the
BSW cells.
Next, the effect of MSLN overexpression on migration and invasion was assessed
using B2B/MSLN cells. B2B/MSLN cells demonstrated significantly increased migration
and invasion relative to B2B controls. Migration was increased 6-fold (Fig. 3, E and G)
relative to B2B controls, while invasion was increased 4-fold (Fig. F and H).
Since decreasing MSLN reduced the aggressiveness of BSW cells in vitro, we next
assessed whether this translated to less severe in vivo behavior. While non-cancerous
cells, including the parental BEAS-2B line, are not expected to form tumors in nude mice
(30), the transformed BSW cells have been shown to form injection-site tumors in vivo
(47). In our study, both BSW shMSLN and BSW shC cells formed injection-site tumors in
mice after 30 days, with the BSW shC cells forming tumors three times larger than those
resulting from BSW shMSLN cells (Fig. 4, A and B).
We also assessed the ability of BSW tumors to metastasize by measuring surface tumor
nodules in the abdominal and thoracic cavities. BSW shMSLN cells formed 15 times fewer
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metastatic nodules (average of 1 per mouse) than BSW shC cells (Fig. 4C). Mice injected
with BSW shC had significantly greater tumor surface area in pulmonary and hepatic
cross sections (56 ± 31.27 vs 2.25 ± 4.5 cm2) (Fig. 4D). Examination of hematoxylin and
eosin stained liver and lung slices confirmed these findings, with tumor nodules present
in the liver and lungs of mice treated with BSW shC cells but not in mice treated with BSW
shMSLN cells (Fig. 4E). Tissue sections were stained with anti-human mitochondrial and
anti-human MSLN antibodies to ensure that the tumors had originated from the injected
human cells (Fig. 4, F and G). Tissue staining results indicate that liver and lung
metastatic lesions were of human origin and high in MSLN expression.

2.3.3. Mesothelin increases cyclin E, which drives more rapid cell
proliferation.

Possible

mechanisms

behind

MSLN-driven

malignancies

were

investigated by using Ingenuity Pathway Analysis (IPA) to determine the overlap between
gene expression changes in BSW cells, as previously determined by whole-genome
mRNA microarray (23), and known relationships with over-expressed MSLN (Fig. 5). The
prediction suggests that activated TNF, and K-ras (Z = 2.03), mediators commonly
increased with lung cancer, coupled with decreased and inhibited cyclin A, cyclin B and
cyclin-dependent kinase 1 (CDK1) expression contribute to the induction of MSLN. Once
MSLN has increased, it may increase the expression of matrix metalloproteinase (MMP)
-7 and MMP-9, contributing to increased invasion, as well as stimulating increases in IL6, Stat3, and cyclin E, which contribute to cell cycle dysfunction. MSLN is predicted to
have an inhibitory effect on both p53 and the pro-apoptotic mediator BAX. Inhibition of
p53 would complement the dysfunctional cell cycle progression resulting from the
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increase in cyclin E. Suppression of the anti-apoptotic mediator BAX may shift the cells
towards a more apoptosis-resistant state.
From the IPA data, it appears that MSLN induces cyclin E, which regulates cell
cycle progression by acting as a gatekeeper at the G1/S phase transition. The IPA
prediction was verified using Western blotting, which confirmed that cyclin E was highly
expressed in BSW shC cells but barely detectable in either BSW shMSLN clone (Fig. 6,
A and B), indicating that MSLN is an upstream regulator of cyclin E in these cells.
Increases in cyclin E, and the subsequent decreases in time spent in G1, can result
in more rapid cell cycle progression and ultimately increased proliferation rates. The
change in proliferation rate can be used to determine the functional significance of the
changes in cyclin E and cell cycle distribution. A colorimetric proliferation assay, which
allows for the determination of the number of metabolically active cells based on their
conversion of the reagents tetrazolium salt to a water-soluble formazan dye, was used to
quantify cell proliferation (Fig. 6C). By day 3, BSW shMSLN cells proliferated at half the
rate of the BSW shC cells. In addition, BSW cells proliferate 2-3 times faster than
passage-matched BEAS-2B controls (47). Thus, knocking down MSLN nearly reverts
cells to their original growth rate.
Flow cytometry was carried out to determine if the change in cyclin E levels
correlated with a change in cell cycle distribution. Compared to the BSW shC cells, the
BSW shMSLN cells had a greater percentage of the population in G2 phase and fewer
cells progress to S phase (Fig. 7). Since cyclin E regulates the G1/S phase transition, the
increased S population in the BSW shC cells serves as supporting evidence that the
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increase in cyclin E translates to a change in behavior. In addition, the decrease in the
G2 population also indicates more rapid cell cycle progression.

3.4. Discussion
Cancer develops from continuous dysregulation of the mechanisms controlling
critical cell behaviors. Chemical and physical stimuli can contribute to both the initial
cellular damage and the propagation of those effects. Assessing the potential
carcinogenicity and carcinogenic mechanisms of new materials is often challenging due
to the long latent periods between exposure and disease onset and the intricate molecular
pathways regulating cell behavior (22). Rapid assessment of toxicity, as is possible with
acute exposure models, does not always capture the full range of toxicological
implications, particularly when used to assess bio-persistent materials like asbestos and
CNTs (42, 48).
CNTs have been likened to asbestos in terms of their fibrous structure and
durability. As their integration into consumer products grows, understanding their toxicity
has become a pressing public health matter (10, 42, 44). Their small, light, easily
aerosolized structure makes inhalation exposures, and thus eventual lung toxicity, a
primary concern (32). Once inhaled, SWCNTs can deposit in the deepest regions of the
lung, the broncho-alveolar junctions and the alveoli themselves, where they persist for up
to several months (22, 48). After an initial inflammatory response and the generation of
reactive oxygen species (ROS), SWCNT persistence in the lung leads to the formation of
granulomas and interstitial fibrosis (7, 35, 42, 48). Prolonged pulmonary inflammation and
fibrosis increase the risk of developing lung cancer (22, 34). Additionally, SWCNTs may
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further increase the risk by damaging DNA and interfering with cell replication (7, 22, 34).
Reported SWCNT genotoxicity, in in vitro and in vivo models, includes aneuploidy,
centrosome fragmentation, damage to mitotic spindles, and increased numbers of
micronuclei (22, 34, 36). Moreover, long term exposure to CNTs induced malignant
transformation of bronchial and small airway epithelial cells (47, 48). SWCNT exposure
in a mouse inhalation model also resulted in K-ras oncogene mutations, which have been
implicated in carcinogenesis (34, 35). Despite the evidence for SWCNT-induced DNA
damage, their status as an oncogenic initiator is still unconfirmed (48). However, a murine
inhalation study, using an initiator/promotor model, demonstrated that MWCNTs,
specifically Mitsui-7 MWCNT, do act as tumor promotors (32).
To better understand the molecular mechanisms contributing to CNT
carcinogenicity, we investigated the role of MSLN in the malignant transformation of lung
epithelial cells chronically exposed to SWCNT. MSLN was historically associated with
mesothelioma (37), which is primarily an asbestos-induced malignancy (48). MSLN has
since identified in nearly 30% of all cancers, including a large number of lung (16),
pancreatic (19, 41) and ovarian carcinomas (12).
The role of MSLN in lung cancer is not well defined, at least in part because its
expression is highly variable even among patients with the same type and grade of tumor.
For lung adenocarcinomas, MSLN has been detected in 39-83% of tumors (13, 16, 25–
27), and tumor MSLN expression may be an independent predictor of relapse-free and
overall survival (16). Increased MSLN expression is thought to be involved in cell
adherence and chemotherapy resistance, as well as increased invasion and migration,
cell proliferation, and anchorage-independent growth (41). However, as neither the
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physiologic role of MSLN nor its pathological mechanism is known, the varied prevalence
of MSLN in tumors has made it difficult to discern whether or not MSLN has a functional
role in the development of cancer.
Our BSW line, generated by exposing BEAS-2B cells to low doses of SWCNTs for
6 months (47), offers a model to study the molecular and behavioral changes associated
with malignant transformation of lung epithelial cells. This exposure model has been used
to study the effects of chronic heavy metal exposures (28, 39) as well as chronic
exposures to single (20, 21, 47, 48) and multiwall CNTs (44, 48). In addition, this model
was used to discern the differences in the toxicological effects of chronic in vitro exposure
of lung epithelial cells to SWCNTs, MWCNTs, and asbestos, all of which are known to
accumulate and trigger inflammation and fibrosis in vivo, versus ultrafine carbon black,
which exhibits lower in vivo toxicity and is not highly fibrogenic (48). Chronic in vitro
exposure to non-toxic levels of SWCNTs, MWCNTs, and asbestos triggered neoplastic
transformation, while cells exposed to ultrafine carbon black maintained a non-neoplastic
phenotype with reduced cell proliferation, fewer colonies on soft agar, and an increase in
genome-wide cell death signaling.
In the case of BSW cells, abnormal cell morphology was noted within the first 4 weeks
of exposure and abnormal cell behavior was characterized after 6 months of exposure
(47). Although the mechanisms behind some aspects of this transformation, including the
acquired apoptosis resistance (30, 47) and stem-like characteristics (21, 23), have been
investigated, they do not account for all of the changes seen in the BSW cells, suggesting
that there are likely additional, currently unidentified, contributing mechanisms. In this
study, we found that BSW cells have greater MSLN expression than the parental BEAS-
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2B cells and this model provided a unique platform to study the role of MSLN in malignant
transformation and subsequent aggressive behavior.
BSW cells are morphologically and behaviorally distinct from the parental BEAS-2B
line. These changes trend towards an overall more aggressive phenotype, including
increased cell proliferation, invasion, migration, colony formation on soft agar, acquired
resistance to apoptosis, induction of angiogenesis, and the ability to form tumors in vivo
(47). These changes are consistent with those seen in other in vitro chronic CNT
exposures (20, 44, 48). Interestingly, many of the changes seen in BSW cells correspond
with previously suggested roles of MSLN.
In the present study, MSLN appears to contribute significantly to the increased
metastatic potential of BSW cells. Metastases are responsible for the overwhelming
majority of cancer deaths, because they are difficult to prevent or treat. After MSLNknockdown, invasion and migration were reduced significantly. Conversely, migration and
invasion were increased when MSLN overexpression was induced in BEAS-2B cells.
Lung cancer cells transduced to overexpress MSLN have previously been shown to have
a two-fold increase in both migration and invasion (16), which is similar to the 2.6 and 2.8
fold increase we noted in the BSW shC cells relative to the BSW shMSLN cells. MSLNrelated increases in invasion and migration have also been reported in pancreatic cancer
(16), ovarian cancer (6), and mesothelioma (24) cell lines.
Anchorage-independent growth, an in vitro hallmark of carcinogenic transformation,
was also affected by changes in MSLN expression. We found that knocking down MSLN
decreased soft agar colony and tumor sphere formation, while MSLN overexpression
increased soft agar colony formation. This is in line with previous reports that MSLN-
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expressing breast cancer cells formed 1.5 times more colonies, and the colonies were
twice the size, compared to non-MSLN expressing controls (43). Similarly, silencing
MSLN in mesothelioma cells result in reductions in both the number and size of colonies
that form on soft agar (24).
A reduction in the aggressiveness of malignant cells in vitro should correlate with
reduced tumor formation, both local and metastatic, in vivo. Our results show that
knockdown of MSLN in our BSW cells did translate to significantly less metastases and
reduced (but not eliminated) primary tumors in vivo. Immunohistochemistry indicated that
metastatic lesions in BSW shC treated mice were of human origin and expressed human
MSLN. A previous study using pancreatic cancer cells that stably overexpressed MSLN
showed that the MSLN overexpressing cells resulted in larger tumors than the parental
line (3). In rats with tuberous sclerosis, knocking out MSLN reduced the formation of
kidney tumors, a change that was partially attributed to the MSLN-knockdown cells being
less able to bind to collagen (50).
Although elucidation of the specific mechanism for the decrease in metastases is
beyond the scope of this study, it is likely that MSLN mediates cell-cell adhesion, and its
overexpression aids the circulating tumor cells in attaching to new locations. This has
been previously described in the context of ovarian cancer metastases attaching to the
peritoneal lining via interactions between MSLN and the ovarian cancer antigen CA-125
(31). Additionally, in a kidney tumor model, MSLN knockout cells were less adherent to
collagen (50). How this translates to other forms of cancer is not yet known, but further
studies of this interaction in other lines, including BSWs, have the potential to enhance
our understanding of the metastatic process.
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The mechanism by which MSLN mediates metastasis may be related to its normal
function. MSLN is typically found on the apical surface of mesothelial linings (27, 31) and
is often (but not exclusively) seen on the apical surface or leading edge of tumors (1, 8,
9, 33). This is similar to the localization and effects of CA-125, the ovarian cancer antigen,
and may explain why the co-expression of MSLN and CA-125 results in worse outcomes
than either alone (31). This might also point towards MSLN having a similar function to
CA-125.
Predictions as to the molecular mechanisms underlying MSLN-driven changes in
BSW cell behavior were investigated using IPA. These predictions were based on
increased MSLN in BSW cells and fit well with our experimental observations as well as
previously reported effects of MSLN in other cancer cell lines. Many of the predictions
correlated with the observed aggressive behaviors, such as increases in MMP-9, which
would contribute to the increased invasiveness of our SWCNT-transformed BSW cells.
MSLN-induced increases in MMP have previously been linked to increased invasiveness
in ovarian cancer cells (6).
One notable relationship is that TNF appears to induce MSLN, which in turn
increases IL-6. IL-6 is known to stimulate TNF, creating a potential positive feedback loop
that could markedly increase both MSLN and IL-6. IL-6 is an inflammatory chemokine
that may serve as an important intermediate between MSLN over-expression and MSLNinduced aggressive behaviors. Specifically, IL-6 promotes cell growth, chemo-resistance,
anchorage-independent cell growth, and invasiveness (4, 17) and is over-expressed in
MSLN-expressing pancreatic cancer cells (4, 41). It appears likely that MSLN does not
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directly induce IL-6; rather, MSLN activates NF-kB, which in turn induces IL-6 production
(3).
Additionally, higher levels of MSLN tend to correlate with signs of inflammatory
responses, including the induction of IL-6 (3), degradation of extracellular matrix by matrix
metalloproteinases (6), and changes in attachment mediators (15, 50). Our IPA analysis
also suggests that MSLN induces TNF-a, a key pro-inflammatory cytokine with an
important role in lung cancer development. Typically an immune or inflammatory
response to tissue damage or foreign particles will resolve as the particles clear and the
environment returns to normal. The bio-persistence of CNTs, however, would trigger a
continuous inflammatory response, which can form a positive feedback loop to further
increase MSLN expression. The similar bio-persistence of CNTs and asbestos could also
explain why MSLN is increased in nearly all mesotheliomas.
Increases in MSLN expression were also predicted, by IPA, to increase cyclin E,
a cell cycle regulator that promotes the G1/S phase transition and is frequently
dysregulated in cancer cells (14). We demonstrated that MSLN induced cyclin E in BSW
cells. Elevated cyclin E has been found in pancreatic cells transformed to over-express
MSLN, where it was suggested that MSLN induces cyclin E through an IL-6/Stat3
pathway (3). This is a plausible mechanism for the increase in cyclin E in the BSW cells
as well, particularly considering that IPA predicted MSLN-induced increases in both IL-6
and cyclin E.
In addition to verifying that MSLN knockdown did exhibit decreased cyclin E
expression, we found that knockdown of MSLN shifted the proportion of cells in G2 and
S phase of the cell cycle. After MSLN and, by extension, cyclin E knockdown, the
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expected decrease in S phase population was coupled with an increase in the G2
population. MSLN knockdown in mesothelioma cells also resulted in a decrease of the S
phase population (24). IPA suggests that decreased cyclins A and B expression coupled
with inhibited CDK1, which promotes G1/S and G2/M transition, found in the BSW line
independent of MSLN expression, potentially contributed to increases in G2 population.
The increased cyclin E in the MSLN overexpressing cells may overcome the inhibitory
effects of decreased cyclins A and B. This effect would be reversed when MSLN, and
consequently cyclin E, expression is reduced.
As cyclin E drives cell cycle progression via G1/S transition, increased cyclin E is
expected to increase cell proliferation. We found that, while BSW cells proliferate three
times faster than BEAS-2B cells, knocking down MSLN in the BSW cells reduced their
proliferation rate 2.5 times, nearly to the rate of the BEAS-2B cells. Similarly, H1299 lung
cancer cells transduced to express MSLN proliferated 1.6 times faster than controls (16).
MSLN overexpression has also been shown to increase the proliferation rate of
pancreatic cancer cells (3, 24).
While we focused primarily on the contribution of cyclin E to the cell cycle
dysregulation seen in BSW cells, our IPA results suggest that MSLN overexpression can
affect additional cell proliferation and survival regulatory mechanisms. Specifically, MSLN
may inhibit both p53 and the pro-apoptotic mediator BAX. Dysregulation of p53, a critical
cell cycle regulator, is common in cancers. Typically p53 regulates G1/S cell cycle
checkpoint, halting entry into the cell cycle when genetic damage is present (46).
Inhibition of p53, such as that induced by MSLN, would allow cell proliferation regardless
of genetic integrity. We have previously found that p53 is dysregulated in BSW cells (21,
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47). The combined loss of p53-mediated damage control and cyclin E-driven increases
in proliferation is amenable to the rapid accumulation of further mutations, which could
manifest in vivo as more aggressive or treatment-resistant disease.
Additionally, inhibition of pro-apoptotic mediators, such as BAX, shifts the cell
towards an anti-apoptotic state. Although our analysis did not indicate changes in
apoptotic regulators other than BAX, studies in pancreatic cancer cells suggest that
MSLN overexpression leads to the decreases in both BAX and Bad (also pro-apoptotic),
as well as increases in the anti-apoptotic mediators Bcl-2 and Mcl-1 (41). BSW cells also
exhibit apoptotic resistance, particularly in response to extrinsic mediators of apoptosis
with BAX playing a potentially important signaling role (30).
Overall, we found that knocking down MSLN in the BSW cells reduced the severity
of the malignant behaviors tested but did not completely eliminate them. This suggests
that MSLN is important in the formation of both primary tumors and metastases but is not
the sole mechanism behind their formation. Even though MSLN may not be the primary
driver of cancerous transformation, it appears to be heavily involved in a number of
processes contributing to the final malignant phenotype and may make an attractive
target for cancer therapeutics.
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3.5. Materials and Methods

3.5.1 Patient tumor samples. Human lung tissue lysates were purchased from Protein
Biotechnologies (Ramona, CA). Samples from lung tumors and adjacent healthy tissue
were provided as pairs. Six large cell carcinomas, two squamous carcinomas, and one
adenocarcinoma were tested.

3.5.2 Cell Culture. Non-tumorigenic human bronchial epithelial BEAS-2B cells were
cultured with SWCNT (0.02 µg/cm2) for 6 months to generate CNT-transformed bronchial
epithelial cells (BSW), as previously described (21, 47). This cell model has been reported
to be an appropriate model for in vitro lung carcinogenesis studies (28, 48). BSW cells
were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 5%
fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 μg/mL
streptomycin (Gibco, Gaithersburg, MA). A549 cells, human lung carcinoma alveolar type
II epithelial cells, were cultured in DMEM supplemented with 5% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 μg/mL streptomycin (Gibco,
Gaithersburg, MA). Non-small cell lung cancer H460 cells were cultured in RPMI 1640
medium supplemented with 5% FBS, 2 mM L-glutamine, and 100 units/mL
penicillin/streptomycin. With the exception of laboratory-generated BSW and passage
control BEAS-2B cells, all cells were purchased from ATCC (Manassas, VA). All cells
were maintained in a humidified atmosphere of 5% CO 2 at 37 °C.
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3.5.3 Generation of stable MSLN knockdown cells. Stable MSLN knockdown BSW
cells and vector-transfected control cells were generated by using shMSLN lentiviral
plasmid vector or scrambled shRNA vector (OriGene Technologies, Inc, Rockville, MD)
and transfected using the Amaxa Nucleofector II electroporation method (Lonza,
Walkersville, MD). Stable transfected single clones were selected with 5 µg/mL of
puromycin. MSLN knockdown was verified by Western blotting.

3.5.4 Transient MSLN overexpression in B2B cells. MSLN overexpression was
transiently induced in BEAS-2B cells using plasmid DNA (pEasy-MSLN-iCre-HA-Flag,
plasmid #31305, Addgene, Cambridge, MA) and FuGENE HD transfection reagent
(Promega, Madison, WI), according to the manufacturers protocol. At 24 h after the
transfection, MSLN protein expression levels were assessed by Western blotting. MSLNoverexpressing BEAS-2B cells (B2B/MSLN) were used in migration, invasion, and colony
formation assays.

3.5.5 Cell proliferation. MSLN knockdown and vector control cells were seeded at a
density of 1.5×104 cells per well in 100 µL of media in a 96-well plate (Fisher, Waltham,
MA). After 24, 48, or 72 hours, 20 μL of CellTiter 96 Aqueous One Solution (Promega,
Madison, WI) were added to each well, and the cells were incubated at 37 °C for an
additional 3 hours. Viable cells cleave the reagent’s tetrazolium salt to a soluble formazan
dye, resulting in a color change proportional to the number of live cells. Absorbance was
measured at 490 nm, with a reference wavelength at 630 nm, using a BioTek Plate
Reader (BioTek, Winooski, VT).
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3.5.6 Soft agar colony formation assay. BSW shMSLN and BSW shC cells (2500 cells)
were suspended in 0.5 mL of culture medium and mixed with equal amount of 0.7% agar
to a final agar concentration of 0.35%. The 1 mL cell/agar suspensions were immediately
plated onto a 6-well plate coated with 0.5% agar in culture medium (1 mL/well). Colonies
were examined under a light microscope after 2 weeks of culture. Colonies were counted
if >50 cells. In order to assess the self-renewing property of cells, colonies were collected
by gentle centrifugation, dissociated into single cell suspensions, filtered and cultured
under conditions described above (second colony formation).

3.5.7 Tumor sphere formation assay. Tumor sphere assay was performed under stemcell selective (non-adherent and serum-free) conditions as previously described (49).
Briefly, 5×103 cells were suspended in 0.8% methylcellulose (MC)-based serum-free
medium (Stem Cell Technologies, Vancouver, Canada) supplemented with 20 ng/mL of
epidermal growth factor (BD Biosciences, San Jose, CA), basic fibroblast growth factor
and 4 mg/mL of insulin (Sigma, St. Louis, MO) in an ultra-low adherent 6-well plate. Cells
were then cultured for two weeks. Tumor spheres were examined under a light
microscope. In order to assess the self-renewing property of cells, spheres were collected
by gentle centrifugation, dissociated into single cell suspensions, filtered and cultured
under conditions described above (second sphere formation).

3.5.8 Cell migration and invasion assays. In vitro cell migration was determined using
a 24-well Transwell® unit with polycarbonate (PVDF) filters (8 μm pore size). In vitro cell
invasion was performed with a BD Matrigel ® invasion chamber (BD Biosciences, San
Jose, CA). Briefly, cells at the density of 1.5×104 cells per well (migration) or 3×10 4 cells
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per well (invasion) were seeded into the upper chamber of the Transwell ® unit in serumfree medium. The lower chamber of the unit was filled with a normal growth medium
containing 5% FBS. Chambers were incubated at 37 °C in a 5% CO 2 atmosphere for 48
hours. The non-migrating or non-invading cells were removed from the inside of the insert
with a cotton swab. Cells that migrated or invaded to the underside of the membrane were
fixed and stained with Diff-Quik (Dade Behring, Newark, DE). Inserts were visualized and
scored under a light microscope (Leica DM, IL). Number of migrating and invading cells
were counted. Results represent the mean ± SD from 10 fields evaluated.

3.5.9 Immunoblotting. Cells were washed twice with ice-cold PBS and lysed on ice with
modified RIPA buffer containing protease and phosphatase inhibitor mixture (Roche
Molecular Biochemicals, Indianapolis, IN) for 30 minutes. The lysate was sonicated briefly
and centrifuged at 14,000g for 20 minutes. Cell lysates (40 μg of protein) were
fractionated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) and transferred onto polyvinylidene difluoride membranes (PVDF) (Bio-Rad
Laboratories, Hercules, CA). The transferred membranes were blocked for 1 hour with
5% nonfat dry milk in TBST (25 mM Tris-HCl, pH 7.4, 125 mM NaCl, 0.05% Tween 20)
followed by MSLN (ab96869, Abcam, Cambridge, MA) or cyclin E (Cell Signaling,
Danvers, MA) primary antibody at 4 °C overnight with gentle shaking. Membranes were
washed three times with TBST for 10 minutes each followed by incubation with a
horseradish peroxidase-

-actin secondary antibody (A5441, Sigma, St.

Louis, MO) for 1 hour at room temperature. Protein bands were visualized using
enhanced chemiluminescence detection reagents from Millipore (Millipore Corporation,
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Billerica, MA). Actin was blotted to ensure equal loading of the samples, and data were
quantified using image J densitometry software.

3.5.10 Flow cytometry. MSLN-knockdown and scrambled shRNA control cells were
seeded overnight in 6 well plates (Fisher, Waltham, MA) at a concentration of 3×10 5
cells/well. The cells were trypsinized, collected, washed twice with PBS, and fixed
overnight in 70% ethanol (Fisher, Waltham, MA) at −20 °C. Subsequently, the cells were
washed and suspended in 0.2% Tween 20 (Sigma, St. Louis, MO) PBS solution for 15
minutes at 37 °C, followed by RNase A (180 µg/mL) for 15 minutes at room time
temperature. The cells were then stained with propidium iodide PBS (50 µg/mL; Sigma)
for 15 minutes at room temperature. Changes in DNA content were determined using a
BD LSR Fortessa Flow cell analyzer (BD Biosciences, San Jose, CA) and BD FACS
express 5 software. The forward scatter (FSC) and side scatter (SSC) were used to gate
the majority of the cell population; 20,000 events were collected for each sample. The
selection of the cells was based on knowing that in the G0/G1 phase (before DNA
synthesis) cells have a defined amount of DNA (i.e., a diploid chromosomal DNA content)
and double that amount in the G2 or M phase (G2/M, i.e., a tetraploid chromosomal DNA
content). During the S phase (DNA synthesis), cells contain between one to two DNA
levels.

3.5.11 Tumor xenograft mouse models. Animal care and experimental procedures
described in this study were performed in accordance with the Guidelines for Animal
Experiments at West Virginia University with the approval of the Institutional Animal Care
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and Use Committee (IACUC # 15-0702). Immunodeficient NOD/SCID gamma mice,
strain NOD Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG; Jackson Laboratory, Bar Harbor, ME) were
maintained under pathogen-free conditions within the institutional animal facility. Food
and tap water were given ad libitum. Mice (6 per group) were subcutaneously injected
with 5×105 cells of BSW with shMSLN or shControl stable knockdown cells suspended in
100 μL of ExtraCel ® hydrogel (Advanced BioMatrix, San Diego, CA). Mice were inspected
daily for any signs of distress such as weight loss, hunching, failure to groom, or red
discharge from the eyes. After 30 days, mice were euthanized and tumors were dissected
and weighted. Metastatic nodules were counted from the surface on the intestine, liver
and lungs. Liver and lung tumor specimens were dissected into 5 μm sections and stained
with hematoxylin and eosin (H&E) to confirm cancer histology and metastasis in organs.
All tissue sectioning and staining were performed at the West Virginia University
Pathology Laboratory for Translational Medicine.

3.5.12 Immunostaining. Lung and liver sections in paraffin were deparaffinized and
rehydrated. Antigens were retrieved with 10 mM sodium citrate solution in the microwave
for 20 minutes. The slides were then blocked with 3% BSA/ 0.1% Tween in 1X PBS
blocking buffer for 1 h and were incubated with anti-human MSLN antibody (Abcam,
Cambridge, MA) at a dilution of 1:500 or anti-human mitochondria antibody (EMD
Millipore Corporation, Temecula, CA ) at a dilution of 1:100 overnight at 4 °C. After
washing with PBS three times, the slides were incubated with biotinylated secondary
antibodies for an hour, followed by avidin-biotin complex (ABC) reagent (Vector
Laboratories, Inc, Burlingame, CA), and detected with DAB kit (Vector Laboratories, Inc,
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Burlingame, CA). After color development, the slides were counterstained with
hematoxylin, dehydrated, and mounted with Permount mounting medium (Fisher
Scientific, Waltham, MA). Images were taken using a light microscope with the SimplePCI
6 software (Compix Inc, Cranberry, PA).

3.5.13 Ingenuity Pathway Analysis. To further understand MSLN’s role in promoting the
observed cancer cell phenotype, we examined the potential signaling pathways within
BSW cells. Whole genome mRNA microarray data from our previous work (NCBI GEO
Accession #GSE56104) was uploaded into Ingenuity Pathway Analysis (Qiagen). All
known mRNA and miRNA signaling associations with MSLN were plotted along with
differential gene expression of BSW vs. passage control BEAS-2B cells (30). Genes and
miRNA were excluded from the network if the relationship with MSLN was not reported in
lung tissue. Due to the complexity of the network and aggressive, metastatic ability of
BSW cells, genes only known to play a role in metastatic and Stage IV lung cancer were
kept in the MSLN network. Lastly, predictive activation/inhibition analysis of both
upstream and downstream genes from MSLN was conducted using Z-scores. Based on
the observed significant MSLN protein over-expression, we evaluated upstream and
downstream targets with a predicted MSLN activation. These predictions were overlaid
on the MSLN signaling network if Z ±2.

3.5.14 Statistics. Results were expressed as means ± SD. All values were derived from
at least three independent experiments. Differences between groups were assessed by
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analysis of variance (ANOVA) followed by Student’s t test. For all analyses, two-sided P
values of ≤ 0.05 were considered statistically significant.
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3.7. Figures and Tables
Figure 3.1

Figure 3.4. MSLN is overexpressed in lung cancer. (A) Western blot for MSLN in pairs
of lung tumor lysates (T) and normal tissue controls (N) from the same patients. Pairs 16 are large cell carcinomas, pairs 7-9 are squamous cell carcinomas, and pair 10 is
adenocarcinoma. (B) Quantification of tumor MSLN expression, relative to actin. (C)
Western blot and (D) quantification of MSLN in non-cancerous bronchial epithelial cells
(BEAS-2B), CNT-transformed BSW cells, and in two established lung cancer cell lines
(A549 and H460). *P < 0.05 vs. BEAS-2B.
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Figure 3.2

Figure 3.5. Knockdown MSLN reduces soft agar colony and tumor sphere
formation. (A) Western blot and (B) quantification of MSLN in several stable knockdown
clones. (C) Representative images showing colony formation on soft agar of BSW shC
and BSW shMSLN cells. (D) Representative images of tumor sphere formation of BSW
shC and BSW shMSLN cells. (E) Quantification of colonies formed by BSW shC and BSW
shMSLN cells. (F) Quantification of tumor spheres formed by BSW shC and BSW
shMSLN cells. *P < 0.05 vs. BSW shC. (G) Western blot of MSLN expression in B2B and
B2B/MSLN cells. (H) Quantification and (I) representative images of colonies formed by
B2B and B2B/MSLN cells. *P < 0.05 vs. B2B.
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Figure 3.3

Figure 3.6. MSLN expression increases migration and invasion in vitro. (A)
Representative images of BSW shC and BSW shMSLN migration and (B) invasion,
stained with Diff-Quik. (C) Quantification of migrating BSW shC and BSW shMSLN cells.
(D) Quantification of invading BSW shC and BSW shMSLN cells. *P < 0.05 vs. BSW shC.
(E) Representative images of B2B and B2B/MSLN migration and (F) invasion, stained
with Diff-Quik. (G) Quantification of migrating B2B and B2B/MSLN cells. (H)
Quantification of invading B2B and B2B/MSLN cells. *P < 0.05 vs. B2B.
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Figure 3.4

Figure 3.7. MSLN regulates tumor growth and metastasis in vivo. (A) Injection site
tumors. (B) Graphical representation of injection-site tumor weights. (C) Number of
thoracic and abdominal surface metastatic nodules. (D) Surface area of hepatic and
pulmonary metastases. (E) Representative pulmonary and hepatic tissues with
hematoxylin and eosin (H&E) staining. Arrows denote metastatic tumor nodules. (F)
Immunostaining of human mitochondria and (G) human MSLN in representative liver and
lung sections of mice injected with BSW shC or BSW shMSLN. Arrows denote metastatic
tumor nodules. *P < 0.05 vs. BSW shC.

195

Figure 3.5

Figure 3.8. Changes in gene expression when MSLN is increased in BSW cells.
Ingenuity Pathway Analysis (IPA) was used to predict differentially expressed genes.
Yellow to orange colors represent up-regulation, while blue represent down-regulation,
compared to BEAS-2B passage-matched controls. Color intensity signifies fold change.
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Figure 3.6

Figure 3.9. MSLN regulates cyclin E and cell proliferation. (A) Western blot and (B)
quantification of cyclin E in BSW shC and two MSLN knockdown clones. (C) Proliferation
of BSW shC and BSW shMSLN cells, determined using Promega Aqueous One-Step
viability assay, which measures mitochondrial metabolic rate, at 24 and 48 hours after
seeding. *P < 0.05 vs. BSW shC.
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Figure 3.7

Figure 3.10. Cell cycle progression is affected by MSLN. (A) Representative flow
cytometry plot for propidium iodide stained BSW shC and (B) BSW shMSLN cells. (C)
Graphical representation of cell cycle distribution, determined from flow cytometry. FACS
Express 5 software was used for analysis and proliferation statistics (green and red
traces). *P < 0.05 vs. BSW shC.
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Chapter 4
Project Insights and Future Directions
4.1 Design and Evaluation of Multi-functional SPION Platform
Well-designed, multi-functional SPION platforms have the potential to improve cancer
diagnostics and treatment.1–3 Initial studies of our therapeutic SPION platform, presented
in Chapter 2, demonstrated the biocompatibility of our formulation and its potential for
delivering ASO. Although these results were in line with previous reports on both
accounts, our inability to consistently functionalize our platform presented a significant
obstacle to biological testing.

Further work is needed to improve the reproducibility of the SPION-ASO coupling
reaction (4.1.1 Optimization of SPION-DNA Coupling Procedure). The current procedures
employ EDC, a carbodiimide coupling reagent that is widely used for biological coupling
reactions. Despite its widespread use, EDC-mediated coupling reactions are notoriously
difficult to optimize.4–9 More recently, other amide-forming biological linking agents have
been developed to help overcome the limitations of EDC. 10–15 Because consistent
coupling methods are needed to move the SPION platform forward, 16 these newer linking
agents should also be considered.

Once the coupling process is consistent, the composition and physical properties of
the conjugated SPIONs need to be fully characterized (4.1.2 Characterization of
Functionalized SPION Platform). Our freshly synthesized SPIONs have been thoroughly
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evaluated,17 as have several batches of PAA-coated SPIONs. However, the final, ASOSPIONs have not been available in large enough quantities to evaluate.

Fully characterized SPIONs can then be introduced to biological systems (4.1.3
Evaluation of Biological Effects of SPION-ASO) and additional targeting mechanisms can
be investigated (4.1.4 Selection of a Targeting Ligand to Improve the Selectivity of SPION
Uptake by Survivin-Expressing Cancer Cells).

4.1.1 Optimization of SPION-DNA Coupling Procedure

There is little tolerance for formulation inconsistencies of therapeutic agents. Toxicity
testing, and eventual clinical use, require careful control and characterization of all drug
parameters.16 The proof-of-concept preliminary data presented in Chapter 2 supports the
biocompatibility and therapeutic potential of our SPION-ASO conjugate. However, the
attachment our amine-terminal ASO to the PAA coated SPION was inefficient and highly
variable. ASO coupling efficiency was also directly related to the therapeutic efficacy of
the SPION-ASO, even when doses were calculated to ensure equivalent ASO
concentrations. The impact of the loading density of similarly arranged nucleic acids on
NP biological effects has been previously described. 25,26 Therefore, it is critically important
that the SPION synthesis, preparation, and ligand loading be highly reproducible.

The development of a consistent, well-characterized SPION system will provide a
platform that can be customized for other biological and research purposes. Although this
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specific SPION formulation was chosen as a cancer therapeutic, and thus targets the
production of a cancer-specific protein, any number of amine-modified ligands can be
conjugated to the PAA-coated SPION using similar methods. Combinations of targeting
and therapeutic ligands would allow for highly specific in vivo delivery of drug-bearing
SPIONs.27,28 Alternatively, ASO-SPIONs could be used for in vitro gene regulation, where
they could serve as a gentler alternative to transfection. 25

Therapeutic SPION platforms typically incorporate a polymer coating around SPION
core to enhance biocompatibility and to provide functional groups for further
functionalization.15,29–35 Our platform incorporates a 40% octylamine modified PAA,
synthesized in-house, to serve this purpose.36 Hydrophobic interactions are expected to
drive an association between the PAA octylamine groups and the oleic acid surfactant
that surrounds freshly synthesized SPIONs. The unmodified carboxylic acids of the PAA,
which are hydrophilic, are expected to face outward and provide reactive sites for further
modification. The SPION-PAA platform is intended to provide a versatile base to which
biomolecules, including nucleic acids, aptamers, and antibodies, can be conjugated. Due
to the role of the PAA coating in SPION functionalization, the first step in optimizing the
coupling reaction will assess SPION-PAA consistency (4.1.1a Ensuring Particle
Homogeneity).

Amide bonds, which are commonly used to covalently attach biomolecules, are
possible when primary-amine containing ligands are introduced to the PAA surface. A
coupling reagent is needed to drive amide bond formation, as direct condensation of the
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amine and carboxylic acid would require destructively high temperatures. 37 Although
there are a variety of coupling reagents available, the majority are not compatible with
biomolecules. Many methods require the use of halogenated reagents, take place in
organic solvents, or result in hazardous byproducts that are difficult to remove.
Carbodiimide reagents, predominantly in the form of EDC, overcome many of the
limitations of other coupling reagents and have become popular for covalent attachment
of biological amines. However, EDC coupling is far from efficient and protocols often
require extensive refinement (4.1.1b EDC-Mediated Amide Bond Formation). Newer
carbodiimide reagents, including DMTMM, have emerged as more efficient and easier to
use alternatives (4.1.1c Alternative Coupling Reagent: DMTMM).

4.1.1a Ensuring Particle Homogeneity

Based on our preliminary results, the inconsistency in our SPION-DNA platform was
largely due to the DNA attachment reaction. The SPION platform is designed so that
amine-terminal ligands, including ASO, can be covalently attached to the reactive
carboxyl moieties on the surface of the PAA coated SPION. Thus, the issues with DNA
attachment have two probable sources: improper orientation of the polymer coating used
to transfer the SPIONs to aqueous solutions and ineffective coupling conditions.

To pinpoint the source of error, freshly synthesized and PAA-coated SPIONs were
characterized determine their homogeneity. Uncoated SPIONs were had homogenous
size distributions, as determined by TEM and DLS, and consistent composition by TGA.
Composition analysis of PAA-coated SPIONs revealed that PAA consistently accounts
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for 75% of the mass of the coated SPIONs. Although the intention was to have the PAA
form a single layer coating around the SPION, the composition analysis suggests that
there are multiple layers of PAA, creating a thick coating. The orientation of this thick,
multi-layer coating may contribute to the difficulty in attaching the DNA ligands as, if the
carboxylic acids of the PAA are not facing outward, they will not be able to participate in
the EDC-mediated covalent attachment of the DNA. However, it is likely that this is not
the entire problem as some portion of the carboxylic acids in the outer layer of the polymer
are facing outward since the PAA-coated SPIONs were dispersed in aqueous solutions,
and alternative PAA orientations would result in exposed hydrophobic alkanes. Although
it is not likely that the PAA coating is completely unable to be functionalized, further
analysis may be required to ensure that it is reactive.

4.1.1b EDC-Mediated Amide Bond Formation

EDC is widely used for the formation of amides between biological molecules because
it is water soluble, the excess reagent is easy to remove, and the reaction can take place
at room temperature.15,38–42 Despite its widespread use, EDC reactivity and ideal
conditions are poorly understood and some of its limitations contradict the major
advantages of its use.42 For example, EDC can be used in aqueous systems, but
interaction with water also leads to rapid hydrolysis of the EDC to inactive byproducts.13,38
In addition, EDC can cause rapid NP precipitation even at concentrations needed for the
reaction to proceed.6,15,36 There is no standard protocol for EDC-mediated amide
formation, and published procedures vary dramatically in terms of reaction time,
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temperature, EDC concentration, and coupling efficiency. 4,10,15,39,42,43 Until recently, a lack
of suitable alternatives contributed to the popularity of EDC in spite of its often poor
coupling efficiency4,15,39,42,43 and the difficulty of optimizing reaction conditions. 4–10

Optimization of the coupling reaction will first require PAA-coated SPIONs with
consistent composition. The PAA-SPIONs should be fully coated, washed, filtered, and
suspended in distilled water, PBS, or the chosen reaction buffer. It is important that
SPIONs remain stably suspended in the reaction solution, both to improve coating
efficiency and to reduce particle aggregation. SPION suspension can be improved initially
by filtering the PAA-SPIONs and, later, by adjusting the reaction pH. 36 However, pH
adjustments should be used with caution to avoid creating unfavorable reaction conditions
for the amine or inactivation of EDC. EDC coupling reactions have been carried out in
distilled water,44 PBS,45 MES buffer,5,7,46–48 and borate buffer,49,50 with the pH maintained
at 4.5-8.0.5,7,46–49,51 The reaction has the best chance of succeeding if the pH is
maintained between 4.5 and 6.5, which balances EDC stability with maintaining the
reactivity of the carboxy groups.51

After identifying a solvent that will complement all of the reaction components, a
systematic evaluation of reaction conditions, including time, temperature, and reactant
concentrations, can be carried out. Ideally this information can be used to graphically
describe the relationship between parameters like EDC, SPION, or DNA concentration
and the coupling efficiency.7 EDC concentrations of 30-50 mM may be required for DNA
coupling5,7,45 although the coupling efficiency will need to be balanced with minimizing
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EDC-induced particle precipitation.36 A sampling of published procedures for similar
coupling setups describe EDC concentrations of 0.04 mM, 47 30 mM,5,45 and 4 M.46 One
optimization study assessed oligonucleotide binding to carboxylic acid functionalized
glass beads using 0-100 mM EDC, which revealed maximum binding at >50 mM EDC.7
Other reports suggest that the ratio of EDC to carboxylic acid and/or amine groups may
be more important than the absolute EDC concentration. 44 Reported reaction times vary
from 20 minutes to 18 hours.5,7,44–47,49 Realistically the reaction has occurred within the
first 20 to 30 minutes, at which point the carboxyl groups have been activated 51 and the
majority of the EDC has hydrolyzed.13,38 Most protocols perform the coupling at room
temperature (25° C),5,7,45–47,49 although temperatures from 0-60° C have been reported.44
For this specific SPION formulation, heat should be approached with caution as it causes
the oleic acid surrounding the SPION to core to melt, destroying the SPIONs.

Reactions performed during the optimization procedures should be performed in at
least triplicate, using SPIONs from the same batch, identical DNA sequences and
concentrations, and EDC from the same container. To reduce variability due to EDC
degradation during storage, EDC should either be purchased in small quantities (>1 gram)
or aliquoted into single-use storage containers when the container is first opened.
Reaction controls with SPIONs and DNA, but no EDC, should be included in the
optimization process to control for DNA binding through non-covalent mechanisms.
Additional controls include SPIONs with EDC, without DNA, and EDC with DNA, without
SPIONs.
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4.1.1c Alternative Coupling Reagent: DMTMM

Considering the issues with EDC-mediated amide bond formation, perhaps the
simplest approach to improving the reproducibility of the SPION-DNA coupling reaction
is to utilize an alternative attachment method. DMTMM (4-(4,6-dimethody-1,3,5-triazin-2yl)-4-methylmorpholinium chloride) is a commercially available, easier to use alternative
that overcomes many of the limitations of EDC while retaining the major advantages. 10–
12

Specifically, DMTMM is stable over a wider pH range than EDC and has higher reaction

yields. DMTMM has been used to conjugate amine-containing ligands to PAA,10,11,13 and
is may be more efficient than EDC for doing so. 14,15 Like EDC, however, high
concentrations of DMTMM can also result in particle precipitation. Reported DMTMM
coupling protocols are less varied than EDC-mediated procedures. DMTMM protocols
are available for coupling amine-terminal ligands to PAA-coated NPs,10,11,13 which should
allow for faster optimization of reaction conditions. However, minor modifications to the
reagent concentrations or buffer pH may still be needed, as the system still needs to allow
the reactants to the dissolve or suspend.10

4.1.2 Characterization of Functionalized SPION platform

The SPION platform is intended to be used as therapeutic, and thus it is required to
have a safety profile compatible with systemic administration. That is, the underlying
SPION platform should be biologically inert and therapeutic effects of the survivin ASO
are expected to be tumor-specific. SPION toxicity is heavily dependent on particle
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composition and surface properties.19,23,52–56 These effects are described in greater detail
in (1.2.2 Therapeutic NPs: Design Considerations). Briefly, the size and surface charge
of the final SPION-ASO conjugate affect particle internalization in vitro and distribution,
clearance, and half-life in vivo.15,23,54,57–62 Choice of ligand or ASO can also impact uptake,
biodistribution, or biological effects.1,16,24,63–67 For ASO specifically, greater surface
density enhances protein regulatory effects. 25 Additionally, coatings can affect the
magnetic properties of the SPION, which would in turn affect their utility as MRI contrast
agents.32 Thus, obtaining reproducible toxicity results requires consistently formulated
SPION conjugates.30,52,55,58,59,68

SPIONs are prepared in a step-wise fashion, and it is important to characterize the
platform at each step of the synthesis. The addition of each layer is expected to change
the overall diameter, surface charge, composition, and, ultimately, biocompatibility.
Thermal decomposition is used to obtain the oleic acid coated SPION core, 69 which is
then coated with octyl-amine modified PAA to impart aqueous solubility 36 before surface
functionalization. Oleic acid coated SPIONs have been thoroughly characterized,
providing a baseline for comparison. 17 The chosen synthesis method consistently yields
SPIONs with a narrow size distribution. Although the SPION core diameter is consistently
homogeneous, modifications to the procedure, like changing the ratio of oleic acid to iron
pentacarbonyl, affect the mean particle size.69 Thus, the uncoated SPIONs should be
regularly assessed. SPION-PAA has also been characterized, as presented in Chapter
2. However, the final, functionalized SPIONs have not yet been analyzed. Because
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SPION physical properties are dependent on the particle’s composition and surface
functionalization, each specific formulation will require independent analysis.

Functionalized SPIONs should be analyzed to ensure consistent formulation, to
ensure that physical properties are optimized for biological use, and to allow for
appropriate, reproducible dosing for further testing. Ideally the physical properties and
composition of functionalized SPIONs will remain consistent within and across batches
of similarly prepared particles; however, previous experience has shown that this is not
always the case. Consequently, all measurements should be made on replicate samples
from independently coupling reactions.

Thorough analysis of particle properties, including composition, size, charge, ligand
density, will allow SPIONs from different batches to be compared (4.1.2a Characterization
of Functionalized SPIONs: Size, Surface Charge, and Composition), while platform
stability can be assessed by monitoring the physical properties over time (4.1.2b
Characterization of Functionalized SPIONs: Environmental Interactions). Understanding
of particle components will contribute to the determination, and reporting, of relevant,
reproducible dose schemes.30 It will also allow for comparison across experiments and
formulations, allowing the effects of various modifications to be teased out. With full
characterization and detailed reporting, platforms can be compared on the basis of
number of particles, iron concentration, ligand concentration, or other measures,
regardless of which parameter is used to determine the platform dose.
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4.1.2a Characterization of Functionalized SPIONs: Size, Surface Charge, and
Composition

Particle Size and Surface Charge
Size and surface charge are limiting factors in the biocompatibility, metabolism, and
biodistribution of NP constructs in vivo.

61

SPION synthesis via thermal decomposition

results in homogeneous particle cores, 17,69 but the addition of subsequent organic layers
is subject to greater variability. Analysis of SPION diameter and surface charge at each
step of synthesis is needed to determine the effects of each additional layer.
Understanding the contribution of each layer will be critical to the presentation of this
formulation as a proof-of-concept platform that can be modified with other ligands or
loaded with drugs. SPION core diameter is easily assessed using transmission electron
microscopy (TEM).19,58 However, TEM does not provide information about the organic
coatings, which are not expected to affect the diameter of the metallic core. To determine
the diameter of the entire coated SPION system, dynamic light scattering (DLS) can be
used.58 DLS measures the hydrodynamic diameter of NPs in solution, which does require
that the SPIONs be stably suspended in solution. Ideally the combination of TEM and
DLS will reveal changes in diameter that are consistent with the expected thickness of
the coatings. Changes that are much greater than are expected may indicate particle
agglomeration or issues with the coating and functionalization protocols. A narrow size
distribution, in the expected diameter range, will be indicative of successful,
homogeneous surface modifications.
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SPION surface charge, or z-potential, can be assessed using the DLS
instrumentation.20,70 PAA-coated SPIONs need a slightly negative surface charge to
remain suspended in aqueous solutions. The negative charge, arising from deprotonation
of the surface carboxylic acid groups, is also required for formation of the amide bond
during the coupling reaction.15 SPION-ASO is expected to have a significantly more
negative surface charge due to the phosphate backbone of the nucleic acids. Under most
conditions, the significant negative surface charge of the particles would be considered a
hindrance to their eventual clinical use; 23,61,62 however, it has been demonstrated the
negative surface charge arising from densely packed ASO on a NP surface actually
enhances particle internalization.25,26

Overall Composition

Platform composition can be analyzed in a variety of ways, all of which provide
information about the composition of the entire sample being analyzed rather than the
individual particles. To overcome this limitation, inter- and intra- batch replicates should
be assessed. Thermogravimetric analysis (TGA) can be used to determine the
contribution of each component to the total mass. 17,32,71,72 We have previously found that
SPION-OA is 20% oleic acid and 80% iron oxide,17 while SPION-PAA is 75% PAA, 5%
oleic acid and 20% iron oxide. Analysis of composition by mass can be used to determine
the number of particles in a given mass and the consistency of the formulation over time.

Iron Quantification
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For SPION platforms, the iron concentration is an important factor in clinical
utility16,29,72,73 and toxicity potential.30,57 While TGA can give an approximation of the iron
content of a sample, as a percentage of the total mass, analytical techniques like
inductively coupled plasma (ICP),19,61,74,75 atomic absorption spectroscopy (AA),76,77 and
colorimetric detection methods allow quantification accurate to parts per million (ppm) or
parts per billion (ppb). Iron concentration can also be determined from magnetic
relaximetry61,72,78,79 or with commercially available assay kits like the Quantichrome iron
assay.80

ICP is the most sensitive iron quantification method, with limits of detection for iron in
the ppb to ppt range.19 ICP also has a detection range over several orders of magnitude,
which is helpful when the solution concentration is entirely unknown. An alternative to ICP
is AA, which is mechanistically similar to ICP but requires slightly higher concentrations
of analyte. AA can only be used to quantify a single element per sample/run while ICP
can quantify a number of elements simultaneously. A third method of quantifying iron,
which can be performed with more commonly available equipment, is the use of an
indicator dye that changes color upon reacting with iron. The resulting color change can
be quantified with UV-vis spectrometers, including the forms commonly found in biological
labs, like a plate reader or Nano Drop. A number of colorimetric iron indicators have been
described, including Prussian blue,81,82 ferrozine,83–85 and o-phenanthroline. The major
limitation of colorimetric methods is that they are expected to have a much more limited
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linear range of detection than ICP or AA, meaning it could require several trials to dilute
the SPION sample of unknown starting concentration to the appropriate range.

One unfortunate limitation of all the iron quantification techniques mentioned is that
they detect soluble iron, which requires acid digestion of the sample to fully dissolve all
particulates. The sample is then diluted for analysis, and the iron concentration of the
final, diluted sample must be within the detection limits of the instrument being employed.
When synthesis and coupling steps are carried out on a small scale, as they are during
optimization studies, iron analysis can destroy most or all of the prepared SPIONs.
However, with consistently formulated SPIONs, iron content could be correlated to a less
intrusive measure, such as ligand concentration, rather than carrying out iron analysis on
each batch.

Ligand (ASO) Quantification

This SPION platform is functionalized with a survivin ASO, 86 a ligand chosen for the
specificity of its therapeutic effects. Quantifying the SPION-bound ASO is a critical step
characterization, as it will allow doses to be calculated based on the therapeutic ligand.
Then, the degree to which a given concentration of ASO alters protein expression when
introduced as SPION-bound, free, and through traditional transfection methods can be
compared. ASO are expected to have time- and concentration dependent effects on
protein expression87 and comparing the efficacy our formulation to existing ASO
technologies will require a measure of equivalent exposure. Additionally, ligand density
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on the SPION surface may impact biological effects, even at the same ASO
concentrations. When gold nanoparticles are similarly loaded with ASO, greater surface
density of the ASO resulted in stronger protein regulatory effects in vitro.25,26 The
concentration of SPION-bound ASO can be determined indirectly by collecting unbound
from the coupling reaction.7 SPION-ASO conjugates can also be directly evaluated via
UV-vis88 or gel electrophoresis.45,89 Incorporation of fluorescently labeled ASO can be
quantified using flow cytometry or a fluorimeter. 90,91

4.1.2b Characterization of Functionalized SPIONs: Environmental Interactions

Interactions with Plasma Proteins

NPs interact with biological molecules and salts in media and storage
solutions.26,58,60,61 Although these interactions are primarily electrostatic, as opposed to
covalent, they can still have a significant impact on the particle size, shape, and surface
charge. Protein adsorption, then, can have a direct and drastic impact on NP uptake in
vitro and distribution and clearance in vivo.21 NP surface chemistry affects particle
interactions with plasma proteins.26,58 Negatively charged NPs are more likely to interact
with proteins that have specialized cellular uptake mechanisms. 60,61 With spherical
nucleic acids, increased ASO density on the particle surface increased interactions with
plasma proteins, resulting in a more positive (but still negative) zeta potential and leading
to increased uptake.26 In vivo, many NPs are rapidly coated with opsinins, or proteins that
recruit macrophages to initiate clearance of the foreign material. 15,23,54,58,59 Inert,
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biocompatible surface coatings like poly(ethylene glycol) (PEG), dextrans, or synthetic
block co-polymers increases circulation half-life by reducing plasma protein interactions
and, thus, minimizing clearance by macrophages. 15,16,23,29,92 However, nucleic acids,
including the ASO used in our platform, have a strong negative charge and are expected
to interact with plasma proteins.26 In addition to directing SPION uptake and clearance,
plasma protein interactions can have the unintended, and often unaccounted for,
consequence of binding to the soluble nutrients in in vitro setups and effectively starving
the cells.20

To account for the interaction of SPIONs with biological media, the physical properties
of SPION-ASO should be re-characterized after incubation with cell culture media or
plasma and these properties should be reported with the properties of the platform prior
to the incubation.58 If further analysis is desired, protein-particle interactions can be
quantified and adsorbed proteins can separated and identified using gel electrophoresis
and mass spectrometry.70 SPIONs can be incubated with cell-free media prior to in vitro
experiments to avoid unintentionally inducing toxicity through nutrient depletion. 20,90

Solution stability

SPION size, surface charge, and composition will be evaluated after several days,
several weeks, and several months in the storage solution. Changes in particle size, due
to particle agglomeration or interaction with solution components, will impact
biocompatibility and cellular uptake. 93 Solution pH can affect surface charge, as can
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interactions with salts in the storage solution that effectively screen surface charges.21,93
Composition will be assessed to ensure that the particle coating, ligand binding, and, if
relevant, drug loading, remain stable.

4.1.3 Evaluation of Biological Effects of SPION-ASO

In order for SPION-ASO to progress towards eventual clinical use, biocompatibility
and therapeutic efficacy of the SPION-ASO platform must be demonstrated both in vitro
and in vivo. The biological effects will first be assessed in vitro (4.1.3a Evaluation of the
Toxicity of SPION-ASO In Vitro), where the specificity of the therapeutic effects can be
validated. The SPION platform is expected to be inherently non-toxic, and
functionalization with the survivin ASO should limit toxicity to survivin expressing cells.
Cells with varied basal survivin expression will be exposed to SPION-ASO and toxicity
will measured through multiple endpoints, including particle uptake, changes in metabolic
viability, apoptosis, and sensitization to chemotherapy drugs. In vivo murine and (rat)
models will then be employed to assess biodistribution, clearance, systemic toxicity, MRI
contrast enhancement, and anti-tumor effects (4.1.3b Evaluation of the Toxicity of SPIONASO In Vivo).

4.1.3a Evaluation of the Toxicity of SPION-ASO In Vitro

Appropriate Cell Lines
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The survivin ASO was chosen to impact survivin expressing cancer cells without
impacting healthy cells. Thus, the aim of the in vitro studies is to demonstrate specificity
of therapeutic action. The first step of the in vitro evaluation involves demonstrating that
SPION-ASO has a measurable effect on a survivin-expressing cell line. Controls for these
studies should include SPIONs conjugated to a non-targeted DNA sequence of equivalent
length (NTC). Preliminary studies were carried out on A549 lung adenocarcinoma cells.
A549 cells have been used for many previous studies on the effects of regulating survivin
expression in vitro,86,94–97 which serves to both validate the choice of cell line and to provide
resources for comparing results.

Once effects therapeutic effects have been demonstrated, the specificity of the effects
can be evaluated in cell lines with varied basal survivin expression. 95 ASO targeting
survivin have previously been found to have little to no effects on cell lines that do not
express survivin;86,98 however, validating this specificity will also provide further evidence
that the SPION-ASO construct is not inherently toxic. Survivin expression has been
quantified in many commonly used cancer cell lines. 94,95 Differences in survivin
expression between parental and modified, including drug resistant or transformed, cells
of the same origin would also provide interesting comparisons on the effects of basal
survivin expression level.

SPION Uptake and Intracellular Localization

225

Monitoring of SPION uptake and intracellular localization will provide insight into the
mechanisms of therapeutic effect and, if relevant, toxicity. SPION uptake can be tracked
both qualitatively and quantitatively. Qualitatively, TEM can be used to visualize the
locations of the SPION cores relative to intracellular structures.19 Detailed intracellular
images can be obtained with TEM, although laborious sample preparation is required for
visualization of biological samples. TEM is most valuable for viewing metals, like the
SPION core, and does not provide information on the state of the particles coatings or
ligands. Thus TEM images of complex SPION platforms should be used in conjunction
with other techniques to draw conclusions about particle intracellular localization.
Alternatively, the ASO can be fluorescently tagged prior to conjugation with the SPION
and uptake can be tracked with fluorescent microscopy. 58 While this technique is
commonly used, there is a possibility that the fluorescent dyes will change the uptake and
distribution patterns by altering particle size, surface charge, and plasma protein
interactions. However, tracking SPION uptake using fluorescent microscopy can
complement TEM localization data. While TEM is reliable for locating the SPION core,
fluorescent microscopy is only able to convey the location of the tracer dye, which in our
setup is covalently linked to the ASO ligand. If fluorescent images conflict with TEM
images, the possibility that the ASO has been cleaved from the SPION core or the dye
has been cleaved from the ASO should be considered.

Particle uptake can be determine quantitatively using measures on intracellular iron.
The analytical techniques are the same as those used to determine the iron concentration
during particle characterization, which is discussed in greater detail in 4.1.2a
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Characterization of Functionalized SPIONs: Size, Surface Charge, and Composition.
However, modifications to the procedures may be needed to remove cellular debris. It is
also important to note that the iron quantification techniques measure all soluble iron,
including iron that was present in the cell before treatment. Thus, untreated controls are
needed to determine the baseline iron concentration the cells. Additionally, these iron
quantification methods require acid digestion of the entire sample prior to analysis. As a
result, they do not provide any information about intracellular particle degradation prior to
analysis.

Changes in Cell Behavior

Changes in cellular behavior and function will give further insight into the
biocompatibility and mechanisms of action of ASO-SPIONs. Viability assays are an
efficient way to rapid assess a range of doses and time points. The results can then be
used to direct the dosing and time points for additional studies. Cell viability can be
quantified colorimetrically by incubating cells with tetrazolium reagents like MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), MTS (Cell Titer 96 Aqueous One
Solution Cell Proliferation Assay from Promega, or WST-1.19,30,58 Mitochondrial enzymes
convert the reagent to a formazan dye, resulting in a color change proportional to the
number of metabolically active cells. SPION-ASO is expected to reduce the viability of
survivin expressing cells but should not alter the viability of non-survivin expressing cells.
SPION-NTC is not expected to affect the viability of any cell line, which will confirm that
the platform is not inherently toxic. In preliminary studies, none of the SPION-NTC doses
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tested decreased cell viability. Changes in viability should be assessed, at a minimum,
after 24, 48, and 72 hour exposures.86 In our preliminary studies, changes in viability were
not apparent following the 24 hour exposure. By 48 hours, however, significant changes
were noted. One measure of the therapeutic efficacy of the SPION-ASO will be the cell
viability following a 72 hour exposure, which can be compared to the effects of our specific
ASO alone.86

Decreased cell membrane integrity, measured by lactate dehydrogenase (LDH)
release, can serve as an indicator of cell death.19,30 LDH is in an intracellular enzyme that
is released when the cell membrane integrity is compromised, as it is in necrosis and the
late stages of apoptosis. Like viability assessments, LDH is a rapid, colorimetric assay
that can be used to screen a variety of conditions. However, LDH has a half-life of 9 hours
once released from the cells and assays must be carefully timed to capture LDH within
this window.99 Improperly timed assays of treatments that cause rapid cell lysis, and thus
fewer viable cells will detect less LDH in the treated cells. 100 Examination of cells prior to
conducting the assay will help validate results, as will comparing the LDH results to the
number of viable cells determined by MTT, MTS, or WST-1.

Cell viability assays function as a rapid indicator of changes in cell proliferation, but
changes in viability alone do not give a complete picture of toxic effects. The combination
of viability assays and an indicator of cell death, like LDH release, allows for comparison
of live, metabolically active versus dead cell populations. Although that is an improvement
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over either measure alone, cells that are in intermediate states, like those that are in the
process of dying, are still not captured.

Apoptosis is the process of orderly cell death. The cell membrane remains intact until
late in the process, meaning that the cell will not contribute LDH during early stages
despite the cells inevitable demise. Induction of cell death through apoptosis, as opposed
to necrosis, is particularly relevant to our SPIONs, as the SPION-ASO platform was
designed for eventual clinical use. In addition, the target protein, survivin, is anti-apoptotic
and decreases in survivin expression, as would be seen with SPION-ASO, are expected
to induce apoptosis. Apoptosis can be assessed by Hoescht staining, flow cytometry
(FACS), or caspase activation assays.19,58,93,101

Survivin ASO Specific Effects

Ligand specific effects should also be monitored. With the SPION-ASO platform,
changes in survivin expression are the intended mechanism of therapeutic benefit.
Downstream effects of the decrease in survivin expression, including changes in cell cycle
distribution, proliferation, and sensitivity to chemotherapeutic drugs and other apoptotic
stimuli, are also quantifiable.
Changes in survivin expression can be directly assessed via Western blots. With ASO
introduced through transfection, changes in survivin expression are notable at 24 hours
and progress until at least 48 hours post-treatment.102 Changes in survivin expression
should not occur when cells are treated with SPION-NTC.
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Changes in cell cycle distribution are expected when survivin is overexpressed or
inhibits. Survivin overexpression is correlated with increased proliferation rates, while
survivin inhibition has been linked with cell cycle disruptions. The increased proliferation
rates were associated with accelerated S phase and resistance to G1 arrest. 101 Survivin
inhibition, and the resulting increase in apoptosis, were associated with G2/M phase
arrest.101,103 Cell cycle distribution can be assessed using flow cytometry. 104,105

Survivin expression is correlated with chemotherapy and radiation resistance in vitro
and in vivo.86,98,103,106–116 When survivin expression is knocked out, with ASO or small
molecule inhibitors, these effects are reversed. The ability of SPION-ASO to sensitize
cancer cells to treatments will contribute to improvements in quality of life during
chemotherapy treatment, as lower systemic doses will be needed to kill sensitized cells.
SPIONs can also be loaded with chemotherapeutic agents, like doxorubicin or cisplatin,
allowing for simultaneous sensitization and treatment. 34,46,117–121 Cell viability, assessed
with WST-1 or MTS, can be used to demonstrate sensitization.

To best demonstrate the tumor sensitization potential, the timing of ASO-induced
survivin downregulation will need to be considered when establishing a treatment
schedule. The strongest sensitization effects are most likely to be noted while survivin
expression is at a minimum, which may require SPIONs to be added 24 to 48 hours before
the cells are treated with the chemotherapy drug. Survivin inhibition has been shown to
increase cell sensitivity to cisplatin,86,106,122 gemcitabine,107 taxols,123 and tamoxifen.124

230

Cisplatin sensitivity would be a good starting measure, as cisplatin resistant A549 cells
are readily available and the results could be easily compared to the initial toxicity studies.
Previous reports show significant differences in cell proliferation between the parental and
cisplatin-resistant lines of both A549 and H460 at cisplatin concentrations from 0.1 µM to
100 µM.125

Mechanisms of Toxicity

SPION-ASO is not expected to be associated with significant toxicity to non-survivin
expressing cells, and the toxicity in survivin expressing cells should be a consequence of
the ASO rather than inherent SPION toxicity. If toxicity is discovered, efforts should be
redirected to reformulating the platform. However, demonstrating an understanding NP
toxicity, and the mechanisms of that toxicity, may be required to move NP-based
therapeutics forward in the regulatory process. A major concern for general NP toxicity,
as well SPIONs specifically, is the generation of reactive oxygen species (ROS). 19,30,58
ROS are most likely to be generated due to the reactivity of the SPION core, 52,53,59 a risk
that is mitigated in this case by the thick polymer coating. 15,29–35 Once present, ROS are
themselves highly reactive and can cause damage to DNA, proteins, lipids, and nucleic
acids. Electron paramagnetic resonance (EPR) and fluorescent assays can be used to
detect ROS. NP-induced genotoxicity, due to ROS or direct interaction of NPs with
genetic material, is also possible. 19,30,58 Flow cytometry and comet assays can be used
to assess physical DNA damage, while microarrays can offer insight into changes in gene
regulation.
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4.1.3b Evaluation of the Toxicity of SPION-ASO In Vivo

After demonstrating the biocompatibility of SPION-ASO in vitro, the safety of the
platform must be evaluated in vivo. SPION-ASO is intended to be safe for systemic
intravenous administration. Systemic administration will theoretically allow the SPIONs to
localize to tumors and metastases due to the enhanced permeability and retention
effect.29,57,126 However, local delivery, like direct injection into a known tumor, is also a
possibility. Initial in vivo studies will focus on monitoring SPION-ASO biodistribution and
systemic adverse reactions. Therapeutic endpoints will include tumor growth inhibition
and tumor survivin expression. SPION-related MRI contrast enhancement will also be
assessed.

Biodistribution will be determined from tumor and organ analysis. Organ and tumor
iron content will be quantified using ICP.19,127 Tissue sections will be stained for iron, using
Prussian blue, to visualize tissue distribution. 19,76,93,128 The contrast-enhancing effects of
SPIONs will also allow their distribution to be visualized with MRI. 76,128 Systemic toxicity
will be evaluated by monitoring changes in organism behavior, weight, appearance, and
blood chemistry. Induction of systemic inflammatory or immune responses would
increase plasma levels of IL-1β, IL-6 and TNF-α cytokines.93 SPION interactions with the
liver and kidneys as a result of clearance and physiologic filtration could cause target
organ damage. Serial blood levels of serum proteins that indicate hepatic or renal

232

damage, including alanine aminotransferase, aspartate aminotransferase, bilirubin,
creatinine, albumin, and total protein will be used to monitor for target organ damage. 19

4.1.4 Selection of a Targeting Ligand to Improve the Selectivity of SPION
Uptake by Survivin-Expressing Cancer Cells

A well-designed SPION system can serve as both a drug delivery vehicle and an MRI
contrast agent. SPION conjugation with an ASO targeting a protein primarily found in
cancer cells, like survivin, allows for specificity of therapeutic action. While specificity of
action will reduce unintended adverse effects, SPION-ASO conjugates have an
intracellular target and thus do not contribute to tumor-specific particle distribution or
uptake. A ligand directing improved specificity of uptake by target cells would allow the
platform to be used as an MRI contrast agent and/or a delivery vector for high
concentrations of cytotoxic drugs. Previously, SPION conjugation with aptamers,27
antibodies,15,27,28,49 and biomolecules like folate34,66,84,129–132 has been shown to increase
the specificity of accumulation in vivo. Thus, identification of a target specific to survivinexpressing malignant cells would enhance the utility of the SPION system described in
Chapter 2.

One potential target is the unique manner in which many cancer cells process survivin.
Survivin in cancer patients, but not healthy people, is digested and select fragments are
then displayed on the cell surface as part of the major histocompatibility type I complex
(MHC), particularly on human leukocyte antigen A (HLA-A), through a pathway that
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typically handles foreign proteins.133 There are several HLA-A subtypes, and there is
evidence that HLA-A subtype is the defining factor in the survivin epitope displayed,
independent of the cancer type.134 The viability of this complex as a therapeutic target
was demonstrated with the development of a vaccine that sensitized patient T-cells to a
survivin epitope.116 Thus, a ligand that could possibly be engineered to be selective for
this survivin-HLA complex, which is unique to cancer cells, could be conjugated to
SPIONs to increase the selectivity of SPION uptake in vivo.

Aptamer selection is a time- and labor-intensive process. Although our intended target
is well described, it is not known if an aptamer can provide the specificity needed to
recognize the survivin nonapeptide bound to HLA. To streamline the selection process,
in silico modeling will be employed as a first step (4.1.4a In Silico selection of an aptamer
targeting survivin-expressing cells). Starting with in silico modeling will provide a better
understanding of the possibilities of targeting peptide bound HLA, and will allow for
prediction of cross-reactivity between the survivin peptide fragments displayed on
different HLA isoforms. The modeling process will, ideally, identify aptamer sequences
that are expected to bind the target with high affinity and specificity. If the aptamer
modeling fails to identify potential aptamer sequences, aptamer selection can be carried
out in vitro using either isolated MHC-survivin epitope complexes134 or whole-cell
SELEX135 (4.1.4b Selection of an aptamer targeting external feature of survivin expressing cells ).

4.1.4a In Silico selection of an aptamer targeting survivin-expressing cells
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The basic approach will be align published peptide sequences (survivin derived) with
the crystal structure of a peptide bound to HLA (here called the reference nonapeptide).
This will provide a composite from which the predicted binding elements involved will be
identified, based on the known binding of the reference nonapeptide. These peptides will
then be docked to a library of aptamers and the result rank-ordered. Selection of the best
peptide-aptamer complexes (best will be defined) will be further examined. In particular,
high scoring complexes that utilize the predicted region for binding to the aptamer will be
selected. The aptamer and peptide comprising this complex will be made and their
binding measured by surface plasmon resonance (SPR). The aptamer yielding the
highest affinity by SPR will then be attached to SPIONs that also bear antisense survivin,
and the resulting SPIONs will be assayed for binding to survivin expressing and nonexpressing cells.

The peptides that will be used come from Bachinsky, et.al. 136 and Reker, et.al.133 The
binding affinity of each peptide to HLA-A is known and combining these two data sets will
provide approximately 100 peptides. Each nonapeptide will be built and energy minimized
using Amber.137 Since nonapeptides are too short for accurate structure prediction, we
will use simulated annealing to generate multiple conformations. Only the conformation
with the lowest root-mean-squared deviation (RMSd) to the reference nonapeptide will be
retained. Once all nonapeptides are aligned with the reference peptide, the predicted
binding regions of each peptide will be determined by comparison to the known binding
regions of the reference nonapeptide. All peptides will then be screen against a library of
aptamer candidates138 using AutoDock.139 Chushak has provided us with this database.
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The resulting set of peptide-aptamer complexes will be rank-ordered based on the
docking score. The top 100 complexes will be examined to determine the binding mode
of the peptide and those that do not use the binding motif predicted from their alignment
with the reference nonapeptide will be discarded. Further, the aptamer component of
these complexes will screened in silico peptides that are known to bind poorly or not at
all to HLA-A and those ranked high will also be removed with this process simulate
negative selection. The peptides that remain from this process will be examined for their
affinity for HLA-A complexes containing common viral peptides.

Surface Plasmon Resonance (SPR) measurements of relative binding affinities will be
made on a Biacore X1000.140 Gold films on glass will be treated in an ethanolic solution
of mercaptoundecanoic acid (MUA) and octane thiol (1:3), placed in the sample holder
and activated with NHS/EDC followed by exposure to the peptide target (purchased from
Peptide 2.0, Chantilly, VA) under examination (one selected from a nonapeptide-aptamer
complex predicted from the in silico studies). This will result in an amide bond between
the N-terminus of the peptide and the MUA. For peptides containing non-terminal lysines,
mecaptoundecanoaimine will be used in place of MUA and the C-terminus of the peptide
will be activated with NHS/EDC and bonded to the SAM. The aptamer partner will then
be flowed over the chip and the binding constants determined by measuring the SPR
response over time (i.e., during association and dissociation phases) as a function of
aptamer concentration.
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4.1.4b Selection of an aptamer targeting external feature of survivin expressing
cells

If potential aptamer characteristics are identified with in silico modeling, sequences
with the identified features will be used as the starting point for our library for in vitro
selection against an isolated recombinant target. E. coli will be modified to produce
human HLA-A, which will then be mixed with survivin peptide fragments to generate the
isolated protein target.134 Negative selection will be carried out against HLA-A bearing
common viral proteins.

Although the survivin peptide – HLA-A complex has been isolated, it is possible that
we will be unable to replicate this procedure. If this becomes a problem, we will proceed
with whole cell SELEX,135 beginning with a library based off our most likely aptamer
sequences from modeling. In the event that whole cell selection is required, HLA-type
would be used to match survivin expressing cell lines with appropriate survivin-deficient
cell lines for negative selection.

After several rounds of both positive and negative aptamer selection, we anticipate
identifying and sequencing an aptamer that binds selectively to our target. Although the
aptamers are expected to be relatively HLA-type specific, an aptamer that binds to more
than one type might actually be advantageous in vivo since even small mutations can
impede aptamer binding and cancer cells are known for their high mutation rates. This
aptamer can then be coupled to the SPION platform to allow for specific targeting of
survivin expressing cancer cells.
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4.2 Role of MSLN in CNT-induced Malignant Transformation

Malignant transformation takes place over a protracted period of time, during which
genetic damage accumulates.141 Although cancer development occurs as more of a
continuum than as a series of discrete steps, it is usually difficult to identify and study the
early stages of the transformation period. Consequently, most cancer studies are
conducted using definitively malignant cells. Even for particle-induced malignancies,
there can be several decades between the inciting exposure and clinical detection.
Methods allowing for the identification and investigation of early genetic and behavioral
changes would offer greater mechanistic insight than can be obtained from the current
binary classification of malignant or non-malignant.

An in vitro chronic exposure model has been developed to study the effects of chronic
(6

month)

exposures

to

sub-acute

doses

of

SWCNT,142–144

MWCNT,142,144

asbestos,142,144 and metals.145 Using this model, the transformative effects of chronic CNT
exposures have been demonstrated in non-cancerous bronchial epithelial cells (BEAS2B143,146,147 and SAEC142) as well as in a mesothelioma line (Met5A).144 So far this
exposure model has been used to study the transformed cells, but, moving forward, this
chronic exposure model could be used to better understand the dynamic transformation
process. Studying cell populations from numerous time points throughout the 6 month
exposure would help map out the order in which changes occur, and would allow for
comparison of the damages from different materials. Obviously studying all possible
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changes would be inefficient. A more streamlined approach would be to look at specific
pathways, mediators, or expected changes.

Specifically, using this chronic transformation model, subtle changes in cellular
morphology, behavior, and function can be assessed over time to better understand the
course of cancer development. Using our previously generated, CNT-transformed
bronchial epithelial cell line (BSW), we have begun to look at the functional role of MSLN
in the malignant phenotype (Chapter 3). After determining that MSLN was overexpressed
in the BSW cells, a stable MSLN knockdown line (BSW shMSLN) was generated. We
found that while BSW cells were more aggressive than their untransformed counterparts,
knocking down MSLN reverted BSW shMSLN to more normal behavior. To better
understand the mechanism by which MSLN was contributing to the malignant behavior,
IPA was used to identify potential upstream mediators and downstream effects of
mesothelin overexpression in CNT-transformed bronchial epithelial cells (BSW). Many
likely relationships were identified, including mediators involved in cell proliferation and
cell cycle regulation, apoptosis, and metastasis. We previously confirmed MSLN-related
changes in cyclin E expression; however, the remaining relationships have not been
validated (4.2.1 MSLN-Related Changes in Gene Expression). A potential relationship
between MSLN and the anti-apoptotic mediator survivin has also been identified (4.2.2
MSLN as a Survivin Regulator).

4.2.1 MSLN-Related Changes in Gene Expression of CNT-transformed Cells
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We demonstrated the functional contribution of MSLN to the development of malignant
phenotypes following chronic CNT exposure (Chapter 3); however, the mechanisms
behind those changes are still largely unaccounted for. The mechanisms by which MSLN
contribute to carcinogenesis and tumor aggression, in general, are not well
understood.148,149 Predictions as to the molecular mechanisms driving the CNT-induced
carcinogenesis were generated to focus our mechanistic studies. Gene expression
changes following chronic CNT-exposure of bronchial epithelial cells were analyzed using
microarrays.143,150 Gene expression in CNT-transformed cells was compared to
unexposed controls to identify the pathways that were most affected. IPA was then used
to predict the effects of knocking out MSLN expression in the transformed BSW cells
(Chapter 3). Although the predicted effects are in line with our observed changes in cell
behavior following MSLN knockdown, the majority of the IPA predictions have not yet
been verified in our transformed cells. MSLN-related changes in gene expression will be
investigated (4.2.1a Validation of Predicted MSLN-induced Changes in Protein
Expression). Upstream changes expected to contribute to MSLN overexpression include
increase in TNF-α, K-ras, and decreases in cyclin A, cyclin B, and CDK1. MSLN
overexpression then induces, directly or indirectly, IL-6, Stat3, cyclin E, MMP-9, and
MMP-7, while inhibiting p53 and the pro-apoptotic mediator BAX. MSLN and other
relevant mediators will then be quantified in cell samples collected from various time
points through the transformation process, with the aim of determining a time line of the
changes (4.2.1b Evolution of Gene Expression During CNT-induced Transformation).
Changes in gene and/or protein expression will be correlated with cell behaviors. At the
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conclusion of these studies, significant insight into the mechanistic role of MSLN in the
development of MSLN-related aggressive behaviors will have been gained.

4.2.1a Validation of Predicted MSLN-induced Changes in Protein Expression

Our previous MSLN studies were carried out with CNT-transformed bronchial
epithelial cells (BSW) and a stably transfected BSW MSLN knockdown line (BSW
shMSLN) has already been generated. IPA predictions of MSLN interactions were
specific to this cell line, although many of the relationships are expected to be
generalizable as they have been shown previously in other cancer cell lines. Western
blots will be used as a first step to identify significant changes in protein expression
between BSW, BSW shMSLN, and passage matched BEAS-2B controls. Expected
changes include increased TNF-α, K-ras IL-6, Stat3, cyclin E, MMP-9, and MMP-7, and
decreased cyclin A, cyclin B, CDK1, p53, and BAX. Changes in protein expression
detected by Western blot will be correlated with the appropriate cell behaviors. The
altered protein expression profile is expected to be readily detectable, as MSLN
overexpression has previously been shown to induce cyclin E, 151 MMP-7,152 MMP-9,152,153
IL-6,149,151,154 and Stat3151 and to inhibit p53155 and BAX.155 Additionally, decreases in p53
are known to have an important role in CNT-induced cell cycle dysfunction.143,156 To give
a more complete picture of MSLN effects, BSW shMSLN gene and protein expression
will be assessed through DNA microarray analysis and an apoptosis protein array,
comparable to the ones used on the BSW cells previously. 150
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The role of MSLN overexpression in the transformations observed in our other chronic
exposure models has not been studied. However, similar post-exposure effects, including
increased proliferation, increased invasion and migration, and apoptosis resistance have
been noted following a variety of chronic in vitro NP exposures.142,144,145 To use these cell
lines, MSLN expression in the transformed and passage matched controls would first
need to be quantified. MSLN overexpression in these lines, including a second variety of
non-cancerous lung epithelial cells,142,144 would allow for further validation of the role of
MSLN in CNT-induced carcinogenic transformation. A mesothelioma line, Met5A, has
also been used to model chronic transformation.144 Mesotheliomas, including Met5A cells,
highly express MSLN at baseline. Comparison of the MSLN- and whole-genome related
changes in transformed Met5A cells versus non-cancerous lung epithelial cells would
offer insight into the role of MSLN in the transformation process. Thorough analysis of the
genomic and protein expression changes in multiple cell lines following exposure to CNT
through the same model can be used to identify recurrent patterns in the molecular
mechanisms of chronic CNT-induced damage.

4.2.1b Evolution of Gene Expression During CNT-induced Transformation

Validation of MSLN-related changes in CNT-transformed cells offers a starting point
for understanding the transformation process. Ultimately, however, the best way to
understand the transformation is to study the cells as they transition from the noncancerous parental line to the aggressive and tumorigenic state. Presumably sample
populations of CNT-exposed and passage-matched controls were frozen down
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throughout the 6 month exposure. These stored cells can be used to document the
changes in cell morphology, behavior, and gene expression, allowing a step-by-step
reconstruction of the transformation process. Cells from the transition period may further
change if they are passaged too many times, so thawed cells should be used quickly and
passage number should be meticulously documented to minimize the impact of these
effects. Limitations on handling these cells may preclude longer experiments but are not
expected to impede short-term studies.

Expression of MSLN and other critical mediators, including those discussed in the
previous section, should be quantified in the transition-phase cells. Based on the IPA
predictions, MLSN overexpression is induced at least in part by increases in TNF-α and
K-ras, and the increases in either or both before MSLN levels rise would lend support to
that prediction. There is also a chance that MSLN is involved in a positive feedback loop
where TNF-α induces MSLN, which induces IL-6, and then IL-6 further induces TNF-α.
Cell proliferation rate can be used as a fast and simple screening to identify the onset of
cell cycle dysfunction. Similar setups can be used to determine apoptosis
resistance.143,147

4.2.2 MSLN as a Survivin Regulator

Tumor overexpression of both MSLN148,149,157,158,152 and survivin86,103,106,109–116 is,
independently, correlated with more aggressive phenotypes and overall worse outcomes.
The presence of either protein is strongly associated with more rapid cell proliferation,
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apoptosis resistance, and increased invasion and migration in vitro and metastases in
vivo. While survivin has been hot topic in cancer research for over a decade, MSLN has
not been as well described. Although on the surface MSLN and survivin seem to have
little in common, there is significant overlap between the consequences and proposed
molecular pathways driving the consequences of their upregulation. Specifically, MSLN
constitutively activates NF-kβ, increasing the production of IL-6, which increases Stat3
expression.149 Stat3 is an upstream regulator of various anti-apoptotic mediators,
including survivin. As Stat3 binds acts as a transcription factor for survivin, by binding
directly to the survivin promoter,159,160 increases/decreases in Stat3 expression have
been linked to increases/decreases, respectively in survivin expression. 161,162 It seems
reasonable, then, that decreasing MSLN expression would indirectly result in decreased
survivin expression. Identification of a relationship between MSLN and survivin would
significantly enhance the understanding of MSLN downstream effects.

Although MSLN is probably not the sole inducer of survivin in real-world settings, it is
very likely that is plays an important role in MSLN-related aggressive behaviors and that
this relationship can be detected in vitro. To determine if MSLN overexpression can
upregulate survivin, appropriate cell lines must first be chosen. To do so, MSLN and
survivin expression of a variety of cell lines will be quantified (4.2.2a Identification of
MSLN and Survivin Co-Expressing Cell Lines). Then stable MSLN knockdowns will be
generated and used to investigate the resultant changes in survivin expression as well as
changes in cell behavior and expression of target genes (4.2.2b MSLN Knockdown is
Expected to Decrease Survivin Expression and Mitigate Malignant Phenotype). Last,
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survivin expression in MSLN-knockdown cells will be induced and changes in cell
behavior and target gene expression will again be assessed (Overexpression of both
survivin and MSLN is known to increase MMPs,152,164,153 cyclin E,101,160,151 and Bcl2.149,165,166 Repression of p53 is also expected.108,143,160,167

4.2.2c Induced Survivin Expression Restores Apoptosis Resistance, Cell Cycle
Dysfunction, and Invasiveness. Restoring survivin expression independent of MSLN
will aid in identifying any survivin-related changes that are induced by MSLN
overexpression.

4.2.2a Identification of MSLN and Survivin Co-Expressing Cell Lines

Cell lines with high levels of both MSLN and survivin are expected to have the greatest
potential for demonstrating MSLN-related changes in survivin expression. MSLN and
survivin co-expression will be quantified in a number of cell lines and human tumor
lysates. The easiest starting point for this step would be to use cell lines that are already
known to have high MSLN expression, including BSW, mesothelioma,163 or pancreatic
cancer154 cell lines. Transformed cell lines generated using our in vitro chronic exposure
model142–145 are also likely to have increased MSLN expression. Analysis of cell
populations from time points throughout the exposure and transformation process would
provide a timeline and progression of the changes. Additionally, analysis of human tumor
lysates will ensure that the studies are providing clinically relevant insight.
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4.2.2b MSLN Knockdown is Expected to Decrease Survivin Expression and
Mitigate Malignant Phenotype

MSLN and survivin co-expressing cell lines, identified in the previous step, will be used
to study the role of MSLN in survivin overexpression. Stable MSLN knockout lines
(shMSLN) will be generated using shRNA. MSLN expression in the knockout lines will be
assessed and lines with the least MSLN will be selected for initial analysis. However, if
MSLN knockdown is found to have an effect on survivin expression than the dosedependence of that effect can be quantified 164 using cell lines with intermediate levels of
MSLN expression. Evaluation of the aggressiveness of the shMSLN lines can then be
assessed in terms of apoptosis resistance, 143 cell cycle dysfunction, and invasion and
migration. The effects of MSLN knockdown, and subsequent changes in survivin
expression, on drug sensitivity and tumor formation in vivo can also be investigated.
Microarrays will be used to identify changes in gene expression. Overexpression of both
survivin and MSLN is known to increase MMPs, 152,164,153 cyclin E,101,160,151 and Bcl2.149,165,166 Repression of p53 is also expected.108,143,160,167

4.2.2c Induced Survivin Expression Restores Apoptosis Resistance, Cell Cycle
Dysfunction, and Invasiveness

Survivin expression will then be rescued in the shMSLN cells. 168 Survivin rescue, while
still inhibiting MSLN, will demonstrate which pathways are downstream of survivin versus
those effects that are unique to MSLN. Cell behaviors and changes in gene expression
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will be assessed as described in the previous section. Strong correlations between
survivin expression and tumor aggressiveness have been documented in across nearly
all types of cancer, so survivin rescue is expected to restore these behaviors. However,
demonstrating that these behaviors can be reduced or eliminated by knocking out MSLN,
and that they are restored when survivin expression is rescued, would significantly
advance the current understanding of the role of MSLN in carcinogenesis.

248

4.3 References
1.

Ai, J. et al. Nanotoxicology and nanoparticle safety in biomedical designs. Int. J.
Nanomedicine 6, 1117–27 (2011).

2.

Faraji, A. H. & Wipf, P. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem.
17, 2950–62 (2009).

3.

Child, H. W. et al. Working together: the combined application of a magnetic field
and penetratin for the delivery of magnetic nanoparticles to cells in 3D. ACS Nano
5, 7910–9 (2011).

4.

Sam, S. et al. Semiquantitative study of the EDC/NHS activation of acid terminal
groups at modified porous silicon surfaces. Langmuir 26, 809–14 (2010).

5.

Thorek, D. L. J., Elias, D. R. & Tsourkas, A. Comparative Analysis of NanoparticleAntibody Conjugations: Carbodiimide versus Click Chemistry. Mol. Imaging 8, 221–
229 (2009).

6.

Wang, T.-H. & Lee, W.-C. Immobilization of proteins on magnetic nanoparticles.
Biotechnol. Bioprocess Eng. 8, 263–267 (2003).

7.

Walsh, M. K., Wang, X. & Weimer, B. C. Optimizing the immobilization of singlestranded DNA onto glass beads. J. Biochem. Biophys. Methods 47, 221–231
(2001).

8.

Christiaens, P. et al. EDC-mediated DNA attachment to nanocrystalline CVD
diamond films. Biosens. Bioelectron. 22, 170–177 (2006).
249

9.

Millan, K. M., Saraullo, a & Mikkelsen, S. R. Voltammetric DNA biosensor for cystic
fibrosis based on a modified carbon paste electrode. Anal. Chem. 66, 2943–2948
(1994).

10.

Pelet, J. M. & Putnam, D. An in-depth analysis of polymer-analogous conjugation
using DMTMM. Bioconjug. Chem. 22, 329–37 (2011).

11.

Smith, A. M. & Nie, S. Compact Quantum Dots for Single-Molecule Imaging. J. Vis.
Exp. August, 1–15 (2012).

12.

Kunishima, M., Kawachi, C., Hioki, K., Terao, K. & Tani, S. Formation of
carboxamides by direct condensation of carboxylic acids and amines in alcohols
using a new alcohol- and water-soluble condensing agent: DMT-MM. Tetrahedron
57, 1551–1558 (2001).

13.

Thompson, K. & Michielsen, S. Novel synthesis of N-substituted polyacrylamides:
Derivatization of poly(acrylic acid) with amines using a triazine-based condensing
reagent. J. Polym. Sci. Part A Polym. Chem. 44, 126–136 (2006).

14.

Zhang, X., Mohandessi, S., Miller, L. W. & Snee, P. T. Efficient functionalization of
aqueous CdSe/ZnS nanocrystals using small-molecule chemical activators. Chem.
Commun. (Camb). 47, 3532–4 (2011).

15.

Conde, J. J. et al. Revisiting 30 years of biofunctionalization and surface chemistry
of inorganic nanoparticles for nanomedicine. Front. Chem. 2, 1–27 (2014).

250

16.

Jin, R., Lin, B., Li, D. & Ai, H. Superparamagnetic iron oxide nanoparticles for MR
imaging and therapy: design considerations and clinical applications. Curr. Opin.
Pharmacol. 18, 18–27 (2014).

17.

Pisane, K., Despeaux, E. & Seehra, M. S. Magnetic relaxation and correlating
effective magnetic moment with particle size distribution in maghemite
nanoparticles. J. Magn. Magn. Mater.

18.

Mahmoudi, M., Hofmann, H., Rothen-Rutishauser, B. & Petri-Fink, A. Assessing
the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles.
Chem. Rev. 112, 2323–38 (2012).

19.

Marquis, B. J., Love, S. a, Braun, K. L. & Haynes, C. L. Analytical methods to
assess nanoparticle toxicity. Analyst 134, 425–39 (2009).

20.

Laurent, S., Burtea, C., Thirifays, C., Häfeli, U. O. & Mahmoudi, M. Crucial ignored
parameters on nanotoxicology: the importance of toxicity assay modifications and
“cell vision.” PLoS One 7, e29997 (2012).

21.

Fadeel, B. & Garcia-Bennett, A. E. Better safe than sorry: Understanding the
toxicological properties of inorganic nanoparticles manufactured for biomedical
applications. Adv. Drug Deliv. Rev. 62, 362–74 (2010).

22.

Gupta, A. K. & Gupta, M. Cytotoxicity suppression and cellular uptake
enhancement of surface modified magnetic nanoparticles. Biomaterials 26, 1565–
73 (2005).

251

23.

Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors Affecting the
Clearance and Biodistribution of Polymeric Nanoparticles. Mol. Pharm. 5, 505–515
(2008).

24.

Laurent, S. & Mahmoudi, M. Superparamagnetic iron oxide nanoparticles: promises
for diagnosis and treatment of cancer. Int. J. Mol. Epidemiol. Genet. 2, 367–90
(2011).

25.

Cutler, J. I., Auyeung, E. & Mirkin, C. a. Spherical nucleic acids. J. Am. Chem. Soc.
134, 1376–91 (2012).

26.

Giljohann, D. a et al. Oligonucleotide loading determines cellular uptake of DNAmodified gold nanoparticles. Nano Lett. 7, 3818–21 (2007).

27.

Hrkach, J. et al. Preclinical development and clinical translation of a PSMA-targeted
docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl.
Med. 4, 128ra39 (2012).

28.

Zhang, K., Hao, L., Hurst, S. J. & Mirkin, C. a. Antibody-linked spherical nucleic
acids for cellular targeting. J. Am. Chem. Soc. 134, 16488–91 (2012).

29.

Mornet, S., Vasseur, S., Grasset, F. & Duguet, E. Magnetic nanoparticle design for
medical diagnosis and therapy. J. Mater. Chem. 14, 2161 (2004).

30.

Lewinski, N., Colvin, V. & Drezek, R. Cytotoxicity of nanoparticles. Small 4, 26–49
(2008).

252

31.

Mahmoudi, M., Laurent, S., Shokrgozar, M. a & Hosseinkhani, M. Toxicity
evaluations of superparamagnetic iron oxide nanoparticles: cell “vision” versus
physicochemical properties of nanoparticles. ACS Nano 5, 7263–76 (2011).

32.

Mikhaylova,

M.

et

al.

Superparamagnetism of

magnetite

nanoparticles:

dependence on surface modification. Langmuir 20, 2472–7 (2004).

33.

Yu, W. W., Chang, E., Sayes, C. M., Drezek, R. & Colvin, V. L. Aqueous dispersion
of monodisperse magnetic iron oxide nanocrystals through phase transfer.
Nanotechnology 17, 4483–4487 (2006).

34.

Tassa, C., Shaw, S. Y. & Weissleder, R. Dextran-Coated Iron Oxide Nanoparticles:
a Versatile Platform for Targeted Molecular Imaging, Molecular Diagnostics and
Therapy. Acc Chem Res 44, 842–852 (2011).

35.

Muldoon, L. L., S??ndor, M., Pinkston, K. E. & Neuwelt, E. a. Imaging, Distribution,
and Toxicity of Superparamagnetic Iron Oxide Magnetic Resonance Nanoparticles
in the Rat Brain and Intracerebral Tumor. Neurosurgery 57, 785–796 (2005).

36.

Shen, H., Jawaid, A. M. & Snee, P. T. Poly (ethylene glycol) Carbodiimide Coupling
Reagents for the Biological and Chemical Functionalization of Water- Soluble
Nanoparticles. ACS Nano 3, 915–23 (2009).

37.

Montalbetti, C. a. G. N. & Falque, V. Amide bond formation and peptide coupling.
Tetrahedron 61, 10827–10852 (2005).

253

38.

Wrobel, N., Schinkinger, M. & Mirsky, V. M. A novel ultraviolet assay for testing side
reactions of carbodiimides. Anal. Biochem. 305, 135–8 (2002).

39.

Palazon, F. et al. Carbodiimide/NHS Derivatization of COOH-Terminated SAMs:
Activation or Byproduct Formation? Langmuir 30, 4545–4550 (2014).

40.

Kocbek, P., Obermajer, N., Cegnar, M., Kos, J. & Kristl, J. Targeting cancer cells
using PLGA nanoparticles surface modified with monoclonal antibody. J. Control.
release 120, 18–26 (2007).

41.

Natarajan, A. et al. NanoFerrite Particle Based Radioimmunonanoparticles: Binding
affinity and in vivo pharmacokinetics. Bioconjug. Chem. 19, 1211–1218 (2008).

42.

Booth, M. A., Kannappan, K., Hosseini, A. & Partridge, A. In-Depth Electrochemical
Investigation of Surface Attachment Chemistry via Carbodiimide Coupling.
Langmuir 31, 8033–41 (2015).

43.

Banerjee, A. et al. Fast, Efficient, and Stable Conjugation of Multiple DNA Strands
on Colloidal Quantum Dots. Bioconjug. Chem. 26, 1582–9 (2015).

44.

Tobiesen, F. A. & Michielsen, S. Method for grafting poly(acrylic acid) onto nylon
6,6 using amine end groups on nylon surface. J. Polym. Sci. Part A Polym. Chem.
40, 719–728 (2002).

45.

Wagner,

K.

et

al.

Synthesis

of

oligonucleotide-functionalized

magnetic

nanoparticles and study on their in vitro cell uptake. Appl. Organomet. Chem. 18,
514–519 (2004).
254

46.

Santra, S., Kaittanis, C., Grimm, J. & Perez, J. M. Drug/dye-Loaded, Multifunctional
Iron Oxide Nanoparticles for Combined Targeted Cancer Therapy and Dual
Optical/MR-Imaging. Small 5, 1862–8 (2009).

47.

Abdollah, M. R. a et al. Prolonging the circulatory retention of SPIONs using dextran
sulfate: in vivo tracking achieved by functionalisation with near-infrared dyes.
Faraday Discuss. 175, 41–58 (2014).

48.

Schneider, U. V et al. Increasing the analytical sensitivity by oligonucleotides
modified with para- and ortho-twisted intercalating nucleic acids--TINA. PLoS One
6, e20565 (2011).

49.

Wu, X. et al. Immunofluorescent labeling of cancer marker Her2 and other cellular
targets with semiconductor quantum dots. Nat. Biotechnol. 21, 41–6 (2003).

50.

Bi, X. et al. Gene Detection in Complex Biological Media Using Semiconductor
Nanorods within an Integrated Microfluidic Device. Anal. Chem. 87, 10292–8
(2015).

51.

Liu, L. et al. Activity analysis of the carbodiimide-mediated amine coupling reaction
on self-assembled monolayers by cyclic voltammetry. Electrochim. Acta 89, 616–
622 (2013).

52.

Holsapple, M. P. et al. Research strategies for safety evaluation of nanomaterials,
part II: toxicological and safety evaluation of nanomaterials, current challenges and
data needs. Toxicol. Sci. 88, 12–7 (2005).

255

53.

Warheit, D. B. How Meaningful are the Results of Nanotoxicity Studies in the
Absence of Adequate Material Characterization? Toxicol. Sci. 101, 183–185
(2008).

54.

Soenen, S. J., De Cuyper, M., De Smedt, S. C. & Braeckmans, K. Investigating the
toxic effects of iron oxide nanoparticles. Methods Enzymol. 509, 195–224 (Elsevier
Inc., 2012).

55.

Liu, Y., Zhao, Y., Sun, B. & Chen, C. Understanding the Toxicity of Carbon
Nanotubes. Acc. Chem. Res. 46, 702–713 (2013).

56.

Heyder, J. Deposition of inhaled particles in the human respiratory tract and
consequences for regional targeting in respiratory drug delivery. Proc. Am. Thorac.
Soc. 1, 315–20 (2004).

57.

Wahajuddin & Arora, S. Superparamagnetic iron oxide nanoparticles: magnetic
nanoplatforms as drug carriers. Int. J. Nanomedicine 7, 3445–71 (2012).

58.

Love, S. a, Maurer-Jones, M. a, Thompson, J. W., Lin, Y.-S. & Haynes, C. L.
Assessing nanoparticle toxicity. Annu. Rev. Anal. Chem. (Palo Alto. Calif). 5, 181–
205 (2012).

59.

Kroll, A., Pillukat, M. H., Hahn, D. & Schnekenburger, J. Current in vitro methods in
nanoparticle risk assessment: limitations and challenges. Eur. J. Pharm. Biopharm.
72, 370–7 (2009).

256

60.

Schulze, C. et al. Not ready to use – overcoming pitfalls when dispersing
nanoparticles in physiological media. Nanotoxicology 2, 51–61 (2009).

61.

Schweiger,

C.

et

superparamagnetic

al.
iron

Quantification
oxide

of

the

nanoparticles

internalization
with

opposite

patterns

of

charge.

J.

Nanobiotechnology 10, 28 (2012).

62.

Safi, M., Sarrouj, H., Sandre, O., Mignet, N. & Berret, J.-F. Interactions between
sub-10-nm iron and cerium oxide nanoparticles and 3T3 fibroblasts: the role of the
coating and aggregation state. Nanotechnology 21, 145103 (2010).

63.

Li, S.-D. & Huang, L. Targeted delivery of antisense oligodeoxynucleotide and small
interference RNA into lung cancer cells. Mol. Pharm. 3, 579–88 (2006).

64.

Kaaki, K. et al. Magnetic nanocarriers of doxorubicin coated with poly(ethylene
glycol) and folic acid: relation between coating structure, surface properties,
colloidal stability, and cancer cell targeting. Langmuir 28, 1496–505 (2012).

65.

Omidirad, R., Rajabi Hosseinpour, F. & Farahani, B. Preparation and in vitro drug
delivery response of doxorubicin loaded PAA coated magnetite nanoparticles. J.
Serbian Chem. Soc. 78, 1609–1616 (2013).

66.

Mahajan, S., Koul, V., Choudhary, V., Shishodia, G. & Bharti, A. C. Preparation and
in vitro evaluation of folate-receptor-targeted SPION-polymer micelle hybrids for
MRI contrast enhancement in cancer imaging. Nanotechnology 24, 015603 (2013).

257

67.

Shi, J., Xiao, Z., Kamaly, N. & Farokhzad, O. C. Self-assembled targeted
nanoparticles: evolution of technologies and bench to bedside translation. Acc.
Chem. Res. 44, 1123–34 (2011).

68.

Gangwal, S. et al. Informing Selection of Nanomaterial Concentrations for ToxCast
in Vitro Testing Based on Occupational Exposure Potential. Environ. Health
Perspect. 119, 1539–1547 (2011).

69.

Hyeon, T., Lee, S. S., Park, J., Chung, Y. & Na, H. B. Synthesis of highly crystalline
and monodisperse maghemite nanocrystallites without a size-selection process. J.
Am. Chem. Soc. 123, 12798–801 (2001).

70.

Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein
corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S.
A. 105, 14265–70 (2008).

71.

Troutier, A.-L., Véron, L., Delair, T., Pichot, C. & Ladavière, C. New insights into
self-organization of a model lipid mixture and quantification of its adsorption on
spherical polymer particles. Langmuir 21, 9901–10 (2005).

72.

Qin, J. et al. A High-Performance Magnetic Resonance ImagingT2 Contrast Agent.
Adv. Mater. 19, 1874–1878 (2007).

73.

Petri-Fink, A., Steitz, B., Finka, A., Salaklang, J. & Hofmann, H. Effect of cell media
on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal

258

stability, cytotoxicity, and cellular uptake studies. Eur. J. Pharm. Biopharm. 68,
129–37 (2008).

74.

Gonzales, M., Misumori, L. M., Kushleika, J. V., Rosenfeld, M. E. & Krishnan, K. M.
Cytotoxicity of iron oxide nanoparticles made from the thermal decomposition of
organometallics and aqueous phase transfer with Pluronic F127. Contrast Media
Mol. Imaging 5, 286–293 (2011).

75.

Thode, K., Luck, M., Semmler, W., Muller, R. H. & Kresse, M. Determination of
Plasma Protein Adsorption on Magnetic Iron Oxide_Sample Preparation.pdf.
Pharm. Res. 14, 905–910 (1997).

76.

Kumar, M. et al. Cellular interaction of folic acid conjugated superparamagnetic iron
oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of
tumor cells. Int. J. Nanomedicine 7, 3503–16 (2012).

77.

Chang, S. Y. et al. Analysis of peptides and proteins affinity-bound to iron oxide
nanoparticles by MALDI MS. J. Am. Soc. Mass Spectrom. 18, 910–8 (2007).

78.

Kotek, G. et al. Cell quantification: evolution of compartmentalization and
distribution of iron-oxide particles and labeled cells. Contrast Media Mol. Imaging
7, 195–203 (2012).

79.

Huang, J., Zhong, X., Wang, L., Yang, L. & Mao, H. Improving the magnetic
resonance imaging contrast and detection methods with engineered magnetic
nanoparticles. Theranostics 2, 86–102 (2012).

259

80.

Wu, Y. J. et al. In vivo leukocyte labeling with intravenous ferumoxides / protamine
sulfate complex and in vitro characterization for cellular magnetic resonance
imaging. Am. J. Physiol. Cell Physiol. 293, C1698–C1708 (2007).

81.

Boutry, S. et al. How to quantify iron in an aqueous or biological matrix: a technical
note. Contrast Media Mol. Imaging 4, 299–304 (2009).

82.

Boutry, S. et al. Magnetic labeling of non-phagocytic adherent cells with iron oxide
nanoparticles: a comprehensive study. Contrast Media Mol. Imaging 3, 223–32
(2008).

83.

Riemer, J., Hoepken, H. H., Czerwinska, H., Robinson, S. R. & Dringen, R.
Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal.
Biochem. 331, 370–5 (2004).

84.

Fan, C. et al. Tumor selectivity of stealth multi-functionalized superparamagnetic
iron oxide nanoparticles. Int. J. Pharm. 404, 180–90 (2011).

85.

Kalambur, V. S., Longmire, E. K. & Bischof, J. C. Cellular level loading and heating
of superparamagnetic iron oxide nanoparticles. Langmuir 23, 12329–36 (2007).

86.

Olie, R. A., Simões-wüst, A. P., Baumann, B. & Simo, A. P. A Novel Antisense
Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes
Lung Cancer Cells to Chemotherapy. Cancer Res. 60, 2805–2809 (2000).

87.

Dias, N. & Stein, C. A. Antisense Oligonucleotides: Basic Concepts and
Mechanisms. Mol. Cancer Ther. 1, 347–355 (2002).
260

88.

Carter, J. D. & Labean, T. H. Organization of Inorganic Nanomaterials via
Programmable DNA Self-Assembly and Peptide Molecular Recognition. ACS Nano
5, 2200–2205 (2012).

89.

Shukoor, M. I. et al. dsRNA-functionalized multifunctional gamma-Fe2O3
nanocrystals: a tool for targeting cell surface receptors. Angew. Chem. Int. Ed. Engl.
47, 4748–52 (2008).

90.

Patel, P. C. et al. Scavenger Receptors Mediate Cellular Uptake of Polyvalent
Oligonucleotide-Functionalized Gold Nanoparticles. Bioconjug. Chem. 21, 2250–
2256 (2010).

91.

Farokhzad, O. C. et al. Nanoparticle-aptamer bioconjugates: a new approach for
targeting prostate cancer cells. Cancer Res. 64, 7668–72 (2004).

92.

Reddy, L. H., Arias, J. L., Nicolas, J. & Couvreur, P. Magnetic nanoparticles: design
and characterization, toxicity and biocompatibility, pharmaceutical and biomedical
applications. Chem. Rev. 112, 5818–78 (2012).

93.

Caballero-Díaz, E. & Valcárcel Cases, M. Analytical methodologies for nanotoxicity
assessment. Trends Anal. Chem. (2016). doi:10.1016/j.trac.2016.03.007

94.

Tamm, I. et al. IAP-Family Protein Survivin Inhibits Caspase Activity and Apoptosis
Induced by Fas (CD95), Bax , Caspases , and Anticancer Drugs. Cancer Res. 58,
5315–5320 (1998).

261

95.

Nakahara, T. et al. Broad spectrum and potent antitumor activities of YM155, a
novel small-molecule survivin suppressant, in a wide variety of human cancer cell
lines and xenograft models. Cancer Sci. 102, 614–21 (2011).

96.

Jarzynka, M. J., Guo, P., Bar-Joseph, I., Hu, B. & Cheng, S.-Y. Estradiol and
nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth
in mice through the stimulation of angiogenesis. Int. J. Oncol. 28, 337–44 (2006).

97.

Wang, W. et al. Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.
Lung Cancer 65, 306–11 (2009).

98.

Altieri, D. C. The molecular basis and potential role of survivin in cancer diagnosis
and therapy. Trends Mol. Med. 7, 542–7 (2001).

99.

Monteiro-Riviere, N. a, Inman, a O. & Zhang, L. W. Limitations and relative utility of
screening assays to assess engineered nanoparticle toxicity in a human cell line.
Toxicol. Appl. Pharmacol. 234, 222–35 (2009).

100. Smith, S. M., Wunder, M. B., Norris, D. a & Shellman, Y. G. A simple protocol for
using a LDH-based cytotoxicity assay to assess the effects of death and growth
inhibition at the same time. PLoS One 6, e26908 (2011).

101. Li, F. Survivin study: what is the next wave? J. Cell. Physiol. 197, 8–29 (2003).

102. Carter, B. Z., Wang, R., Schober, W. D., Milella, M. & Andreeff, M. Targeting
Survivin Expression Induces Cell Proliferation Defect and Subsequent Cell Death

262

Involving Mitochondrial Pathway in Myeloid Leukemic Cell. Cell Cycle 2, 488–493
(2003).
103. Cong, X. L. & Han, Z. C. Survivin and Leukemia. Int. J. Hematol. 80, 232–238
(2004).

104. Carrasco, R. a et al. Antisense inhibition of survivin expression as a cancer
therapeutic. Mol. Cancer Ther. 10, 221–32 (2011).

105. Rivadeneira, D. B. et al. Survivin promotes oxidative phosphorylation, subcellular
mitochondrial repositioning, and tumor cell invasion. Sci. Signal. 8, ra80 (2015).

106. Li, H., Niederkorn, J. Y., Neelam, S. & Alizadeh, H. Downregulation of survivin
expression enhances sensitivity of cultured uveal melanoma cells to cisplatin
treatment. Exp. Eye Res. 83, 176–82 (2006).

107. Liu, W.-S. et al. siRNA directed against survivin enhances pancreatic cancer cell
gemcitabine chemosensitivity. Dig. Dis. Sci. 54, 89–96 (2009).

108. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3,
46–54 (2003).

109. Mita, A. C., Mita, M. M., Nawrocki, S. T. & Giles, F. J. Survivin: key regulator of
mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res.
14, 5000–5 (2008).

263

110. Sasaki, T., Lopes, M. B. S., Hankins, G. R. & Helm, G. a. Expression of survivin,
an inhibitor of apoptosis protein, in tumors of the nervous system. Acta
Neuropathol. 104, 105–9 (2002).

111. Zhang, M., Latham, D. E., Delaney, M. a & Chakravarti, A. Survivin mediates
resistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474–82
(2005).

112. Osaka, E. et al. Survivin as a prognostic factor for osteosarcoma patients. Acta
Histochem. Cytochem. 39, 95–100 (2006).

113. Zamparese, R. et al. Survivin expression in renal cell carcinoma. Cancer Invest. 26,
929–35 (2008).

114. Kawasaki, H., Altieri, D. C. & Lu, C. Inhibition of Apoptosis by Survivin Predicts
Shorter Survival Rates in Colorectal Cancer. Cancer Res. 58, 5071–5074 (1998).

115. Hansen, J. B. et al. SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther.
7, 2736–45 (2008).

116. Wobser, M. et al. Complete remission of liver metastasis of pancreatic cancer under
vaccination with a HLA-A2 restricted peptide derived from the universal tumor
antigen survivin. Cancer Immunol. Immunother. 55, 1294–8 (2006).

117. Yu, M. K. et al. Drug-loaded superparamagnetic iron oxide nanoparticles for
combined cancer imaging and therapy in vivo. Angew. Chem. Int. Ed. Engl. 47,
5362–5 (2008).
264

118. Zhu, L. et al. Multifunctional pH-sensitive superparamagnetic iron-oxide
nanocomposites for targeted drug delivery and MR imaging. J. Control. Release
169, 228–38 (2013).

119. Akbarzadeh, A. et al. Preparation and in vitro evaluation of doxorubicin-loaded
Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers. Int. J.
Nanomedicine 7, 511–26 (2012).

120. Wilson, M. W. et al. Hepatocellular carcinoma: regional therapy with a magnetic
targeted carrier bound to doxorubicin in a dual MR imaging/ conventional
angiography suite--initial experience with four patients. Radiology 230, 287–93
(2004).

121. Munnier, E. et al. Novel method of doxorubicin-SPION reversible association for
magnetic drug targeting. Int. J. Pharm. 363, 170–6 (2008).

122. Fuessel, S. et al. Chemosensitization of bladder cancer cells by survivin-directed
antisense oligodeoxynucleotides and siRNA. Cancer Lett. 232, 243–54 (2006).

123. Zaffaroni, N. et al. Expression of the anti-apoptotic gene survivin correlates with
taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 59, 1406–12 (2002).

124. Moriai, R., Tsuji, N., Moriai, M., Kobayashi, D. & Watanabe, N. Survivin plays as a
resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Breast Cancer Res. Treat. 117, 261–71 (2009).

265

125. Barr, M. P. et al. Generation and characterisation of cisplatin-resistant non-small
cell lung cancer cell lines displaying a stem-like signature. PLoS One 8, e54193
(2013).

126. Jain, T. K., Reddy, M. K., Morales, M. A., Leslie-pelecky, D. L. & Labhasetwar, V.
Biodistribution,

Clearance,

and

Biocompatibility

of

Iron

Oxide

Magnetic

Nanoparticles in Rats. Mol. Pharm. 5, 316–327 (2008).

127. Maurizi, L., Sakulkhu, U., Gramoun, A., Vallee, J.-P. & Hofmann, H. A fast and
reproducible method to quantify magnetic nanoparticle biodistribution. Analyst 139,
1184–91 (2014).

128. Schlachter, E. K. et al. Metabolic pathway and distribution of superparamagnetic
iron oxide nanoparticles: in vivo study. Int. J. Nanomedicine 6, 1793–800 (2011).

129. Hoebeke, J. et al. Design of Folic Acid-Conjugated Nanoparticles for Drug
Targeting. J. Pharm. Sci. 89, 1452–1464 (2000).

130. Kim, S. H., Jeong, J. H., Chun, K. W. & Park, T. G. Target-specific cellular uptake
of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate
conjugate. Langmuir 21, 8852–7 (2005).

131. Dey, S. & Maiti, T. K. Superparamagnetic Nanoparticles and RNAi-Mediated Gene
Silencing: Evolving Class of Cancer Diagnostics and Therapeutics. J. Nanomater.
2012, 1–15 (2012).

266

132. Mahmoudi, M., Sant, S., Wang, B., Laurent, S. & Sen, T. Superparamagnetic iron
oxide nanoparticles (SPIONs): development, surface modification and applications
in chemotherapy. Adv. Drug Deliv. Rev. 63, 24–46 (2011).

133. Reker, S. et al. Identification of Novel Survivin-Derived CTL Epitopes. Cancer Biol.
Ther. 3, 173–179 (2004).

134. Andersen, M. H. et al. Spontaneous Cytotoxic T-Cell Responses against Survivinderived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer
Patients Advances in Brief As Well As ex Vivo in Cancer Patients 1. Cancer Res.
61, 5964–5968 (2001).

135. Shamah, S. M., Healy, J. M. & Cload, S. T. Complex target SELEX. Acc. Chem.
Res. 41, 130–8 (2008).

136. Bachinsky, M. M. et al. Mapping and binding analysis of peptides derived from the
tumor-associated antigen survivin for eight HLA alleles. Cancer Immun. 5, 6–15
(2005).

137. Case, D. A. et al. Amber 12. (2012).

138. Chushak, Y. & Stone, M. O. In silico selection of RNA aptamers. Nucleic Acids Res.
37, e87 (2009).
139. Morris, G. M. et al. AutoDock4 and AutoDockTools4 : Automated Docking with
Selective Receptor Flexibility. J. Comput. Chem. 30, 2785–2791 (2009).

267

140. Di Primo, C. & Lebars, I. Determination of refractive index increment ratios for
protein-nucleic acid complexes by surface plasmon resonance. Anal. Biochem.
368, 148–55 (2007).

141. Shukla, A., Vacek, P. & Mossman, B. T. Dose-Response Relationships in
Expression of Biomarkers of Cell Proliferation in In Vitro Assays and Inhalation
Experiments. Nonlinearity Biol. Toxicol. Med. 2, 117–28 (2004).

142. Wang, L. et al. Neoplastic-like transformation effect of single-walled and multiwalled carbon nanotubes compared to asbestos on human lung small airway
epithelial cells. Nanotoxicology 8, 485–507 (2014).

143. Wang, L. et al. Carbon Nanotubes Induce Malignant Transformation and
Tumorigenesis of Human Lung Epithelial Cells. Nano Lett. 11, 2796–2803 (2011).

144. Lohcharoenkal, W. et al. Chronic exposure to carbon nanotubes induces invasion
of human mesothelial cells through matrix metalloproteinase-2. ACS Nano 7, 7711–
23 (2013).

145. Stueckle, T. a et al. Chronic occupational exposure to arsenic induces carcinogenic
gene signaling networks and neoplastic transformation in human lung epithelial
cells. Toxicol. Appl. Pharmacol. 261, 204–16 (2012).

146. Luanpitpong, S., Wang, L., Castranova, V. & Rojanasakul, Y. Induction of stem-like
cells with malignant properties by chronic exposure of human lung epithelial cells
to single-walled carbon nanotubes. Part. Fibre Toxicol. 11, 22 (2014).

268

147. Pongrakhananon, V. et al. Carbon nanotubes induce apoptosis resistance of
human lung epithelial cells through FLICE-inhibitory protein. Toxicol. Sci. 143, 499–
511 (2015).

148. Kachala, S. S. et al. Mesothelin overexpression is a marker of tumor
aggressiveness and is associated with reduced recurrence-free and overall survival
in early-stage lung adenocarcinoma. Clin. cancer Res. 20, 1020–8 (2014).

149. Tang, Z., Qian, M. & Ho, M. The role of mesothelin in tumor progression and
targeted therapy. Anticancer Agents Med Chem 13, 276–280 (2013).

150. Chen, D. et al. Gene expression profile of human lung epithelial cells chronically
exposed to single-walled carbon nanotubes. Nanoscale Res. Lett. 10, (2015).

151. Bharadwaj, U., Li, M., Chen, C. & Yao, Q. Mesothelin-induced pancreatic cancer
cell proliferation involves alteration of cyclin E via activation of signal transducer
and activator of transcription protein 3. Mol. Cancer Res. 6, 1755–65 (2008).

152. Chang, M.-C. et al. Mesothelin enhances invasion of ovarian cancer by inducing
MMP-7 through MAPK/ERK and JNK pathways. Biochem. J. 442, 293–302 (2012).

153. Servais, E. L. et al. Mesothelin overexpression promotes mesothelioma cell
invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid
pleural mesothelioma patients. Clin. cancer Res. 18, 2478–89 (2012).

269

154. Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C. & Yao, Q. Mesothelin
overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate
pancreatic cancer cell proliferation. Carcinogenesis 32, 1013–24 (2011).

155. Zheng, C. et al. Mesothelin regulates growth and apoptosis in pancreatic cancer
cells through p53-dependent and -independent signal pathway. J. Exp. Clin. Cancer
Res. 31, 84–98 (2012).

156. Luanpitpong, S. et al. Caveolin-1 regulates lung cancer stem-like cell induction and
p53 inactivation in carbon nanotube-driven tumorigenesis. Oncotarget 5, 3541–
3554 (2014).

157. Alvarez, H. et al. Mesothelin is a specific biomarker of invasive cancer in the Barrettassociated adenocarcinoma progression model: translational implications for
diagnosis and therapy. Nanomedicine 4, 295–301 (2008).

158. Li, M. et al. Mesothelin is a malignant factor and therapeutic vaccine target for
pancreatic cancer. Mol. Cancer Ther. 7, 286–96 (2008).

159. Gritsko, T. et al. Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast cancer cells. Clin.
cancer Res. 12, 11–9 (2006).

160. Chen, X., Duan, N., Zhang, C. & Zhang, W. Survivin and Tumorigenesis: Molecular
Mechanisms and Therapeutic Strategies. J. Cancer 7, 314–23 (2016).

270

161. Aoki, Y., Feldman, G. M. & Tosato, G. Inhibition of STAT3 signaling induces
apoptosis and decreases survivin expression in primary effusion lymphoma. Blood
101, 1535–1542 (2003).

162. Diaz, N. et al. Activation of stat3 in primary tumors from high-risk breast cancer
patients is associated with elevated levels of activated SRC and survivin
expression. Clin. cancer Res. 12, 20–8 (2006).

163. Melaiu, O. et al. MSLN gene silencing has an anti-malignant effect on cell lines
overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS
One 9, e85935 (2014).

164. Gao, F. et al. Survivin promotes the invasion of human colon carcinoma cells by
regulating the expression of MMP-7. Mol. Med. Rep. 9, 825–30 (2014).

165. Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C. & Yao, Q. Mesothelin confers
pancreatic

cancer

cell

resistance

to

TNF-α-induced

apoptosis

through

Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol. Cancer 10, 106
(2011).

166. Kanwar, J. R., Kamalapuram, S. K. & Kanwar, R. K. Survivin Signaling in Clinical
Oncology:

A

Multifaceted

Dragon.

Med.

Res.

Rev.

765–789

(2012).

doi:10.1002/med

271

167. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. & Murphy, M. Transcriptional
repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277,
3247–57 (2002).

168. Kanda, N. et al. STAT3 is constitutively activated and supports cell survival in
association with survivin expression in gastric cancer cells. Oncogene 23, 4921–9
(2004).

272

